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ABSTRACT 
 
MODELING AND PREDICTION OF AMORPHOUS SOLID DISPERSION 
FORMATION USING A MOLECULAR DESCRIPTOR 
 
 
 
By 
Kevin DeBoyace 
May 2019 
 
Dissertation supervised by: Peter L.D. Wildfong, Ph.D. 
 Poor aqueous solubility of an active pharmaceutical ingredient (API) is a significant 
hurdle during drug development. Delivering a drug in its amorphous solid-state is a 
potential method to overcome this issue, since the amorphous form has increased apparent 
aqueous solubility. However, the amorphous state is only metastable, and is 
thermodynamically driven to recrystallize. As a result, pure amorphous drugs are seldom 
used in marketed products. Intimately mixing a drug in its amorphous form with a polymer, 
known as an amorphous solid dispersion (ASD), has the potential to significantly extend 
the physical stability of the amorphous form, while maintaining the benefit of increased 
apparent solubility. However, ASDs remain poorly understood. As a result, ASDs are 
primarily developed using a trial and error approach, resulting in increased costs and 
extended time to market. A method for predicting the probability of successful formation 
  v 
of intimate mixtures of drug and polymer without recrystallization (a.k.a. dispersability) 
has the potential to reduce costs, shorten development time, and advance scientific 
understanding of ASDs.  
 The central hypothesis of this work is that there exists a combination of materials 
properties that correlates with the probability that an ASD will form in PVPva. Since 
molecular descriptors are mathematical representations of properties of a molecule, it is 
hypothesized that they can be successfully applied to predict the formation of amorphous 
solid dispersions. Specifically, the molecular descriptor R3m was investigated as a tool for 
the prediction of ASD formation. The work presented herein addresses 3 primary aims: (1) 
investigating the statistical validity of the model by expanding the model to include 2 
preparation methods and 2 concentrations, (2) advancing the understanding of the 
physicochemical meaning of the R3m descriptor to improve the interpretability of the 
descriptor, and (3) investigating the relationship between R3m and solubility.  
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Chapter 1. Introduction 
1.1. Statement of Problem 
Overcoming limitations associated with the poor aqueous solubility of an active 
pharmaceutical ingredient (API) is a significant hurdle during drug development. Poor 
aqueous solubility will result in drug dissolution limitations and, therefore, limitations to 
bioavailability. Delivering a drug in its amorphous solid-state is a potential method to 
ameliorate this issue, since the amorphous form increases the apparent aqueous solubility 
of the drug. However, amorphous solids are metastable and thermodynamically driven to 
recrystallize. As a result, pure amorphous drugs are seldom used in marketed products. 
Intimately mixing a drug in its amorphous form with a polymer, known as an amorphous 
solid dispersion (ASD), has the potential to significantly extend the physical stability of 
the amorphous form, while maintaining the benefit of increased apparent solubility.  
ASDs represent an important formulation strategy for addressing poor aqueous 
solubility of API. It is estimated that approximately 40% of highly potent compounds fail 
to reach clinical trials owing to their inability to dissolve well in aqueous media,1 and 
approximately 50% of new drug candidates require formulation help to improve solubility 
and delivery.2 ASDs have the potential to increase the apparent solubility of a drug, while 
also increasing the physical stability relative to the pure component amorphous drug 
substance.  
Although ASDs were introduced to pharmaceutical drug delivery more than 50 years 
ago,3 their formation and physical stability remains poorly understood,4 with only a few 
specific exceptions. Proposed stabilizing mechanisms include API crystallization 
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inhibition5 and anti-plasticization effects that reduce molecular mobility,6 while 
dispersions are generally thought to form as the result of specific non-covalent bonding 
interactions between drug and polymer carrier, such as hydrogen-bonds.7, 8 Presently, 
reliable prediction of ASD formation and persistence is not possible, and, therefore, 
requires experimental confirmation. As a result, ASD formulation development must often 
be performed using trial-and-error, which can result in significantly increased development 
costs and delays to market. The challenges imposed by this formulation strategy are evident 
from the relatively few commercially available ASDs.9 Models that can assist with rational 
selection of excipients for ASD formulations are desirable for improvement of formulation 
development, reduction of costs, and reduced time to market.  
 
1.2. Literature Review 
1.2.1. Methods for Improving Aqueous Solubility 
A large portion of newly developed drug candidates have poor aqueous solubility, and 
several formulation strategies (both chemical and physical) have been developed in an 
attempt to increase solubility. These include the use of salt forms, particle size reduction, 
higher energy polymorphs,10 co-crystallization,11 and amorphous solid molecular 
dispersions. However, there is no universally applicable method for increasing solubility, 
and each of these strategies has potential pitfalls.  
Formulation of salt forms is not always practical, and if they are synthesized, they may 
undergo reconversion to their acid or base forms, resulting in no significant benefit in 
dissolution rate.12 Additionally, potassium and sodium salts may react with atmospheric 
  3 
carbon dioxide and water to precipitate out as their original parent compounds, especially 
in the outer layer of a dosage form, resulting in reduced rates of dissolution.13 Particle size 
reduction will increase API solubility due to the increased surface area of the drug crystals. 
However, improvement in apparent solubility via reducing particle size has practical 
limitations, not the least of which is the minimum size to which a particle can be reduced 
relative to the energy input from comminution equipment.14 Also, small particles can have 
a negative impact on downstream unit operations (owing to their poor flow, poor 
wettability, etc.). Additionally, mechanical force may induce solid state phase 
transformations such as polymorphism (e.g., as seen in chlorpropamide15) or 
amorphization,16 which may result in poor control over the final solid form of the API, and 
subsequent undesirable batch-to-batch variability in dissolution rate and/or bioavailability.  
High energy polymorphs of the API of interest will also yield solubility benefits due 
to a reduction in the number of non-bonded interactions. However, the application of 
metastable polymorphs is limited to those that are sufficiently kinetically stable over a 
pharmaceutically relevant timescale.  
Co-crystallization has the potential to yield increases in solubility while maintaining 
thermodynamic stability and potentially avoiding issues associated with polymorphic 
transformations. But, co-crystallization can also lead to deteriorated pharmaceutical 
properties in some cases (e.g., further decrease in solubility) and may exhibit its own 
polymorphism.11  
Formulations that use the amorphous form of a drug have many challenges, but there 
has been increased interest in this approach owing to the approval of several formulations 
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by the FDA.17 In addition, solid dispersions may be beneficial over some other techniques 
due to lower manufacturing costs and smaller pill burden.4 
 
1.2.2. Amorphous Solid Dispersions 
1.2.2.1. Brief History 
Amorphous solid dispersions are intimate mixtures of polymer and API that increase 
apparent aqueous solubility via inhibition of crystallization. The historical background of 
solid dispersions is laid out well in the review article by Chiou and Riegelman.13 Briefly, 
a unique technique for preparation of dispersions of small particles in an inert matrix was 
demonstrated by Sekiguchi and Obi in 1961. They prepared eutectic mixtures by melting 
and rapidly cooling binary mixtures.3 This resulted in a significant increase in drug delivery 
from this mixture as compared to the crystalline form of the API alone. This premise was 
later extended to the preparation of glasses due to the even greater increase in solubility 
offered by the amorphous form.18    
 
1.2.2.2. Manufacturing Methods 
Methods for preparation of amorphous solid dispersions include melting, solvent 
evaporation, and the melting-solvent method.13 The melting-solvent method involves 
dissolving the API in a suitable solvent followed by mixing with a molten polymer. This 
method is less popular in the literature due to limitations in drug loading and concerns 
about the inclusion of solvent in the final formulation. This approach will, therefore, not 
be discussed further in this document.  
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The melting method is performed by co-melting the polymer and API at a temperature 
above the API melting temperature and above the polymer glass transition temperature 
and/or melting temperature (if applicable). After melting, the liquid mixture is rapidly 
cooled so that the API is kinetically unable to nucleate and grow in its crystal form. In 
contrast, the solvent method requires dissolution of the API and polymer in a common 
solvent followed by rapid evaporation of that solvent. As with the melt quench method, 
rapid evaporation and subsequent solidification reduces the likelihood of nucleation and 
subsequent growth of crystals.  
It is important to note that while both the solvent and melting methods may be used to 
formulate an amorphous dispersion, there is evidence to suggest that the resulting 
formulations are not completely molecularly similar. It has been proposed that thermal 
history is an important determinant of the physical properties of the resulting amorphous 
dispersion.19 Differences in experienced stresses are thought to result in different enthalpic 
states. Additionally, it is reasonable to expect dissimilarity between preparation methods 
due to the introduction of a ternary component in solvent evaporation. A change in the 
number of molecular interactions occurring as a result of the presence of a solvent could 
result in differences in the final state of the dispersion.  
It has been shown that preparation method can have a significant impact on the 
resulting solid.20-23 In addition to these concerns, certain small molecules may be more 
amenable to certain manufacturing methods. For example, if the compound is thermally 
labile, a solvent evaporation method would be more suitable. Conversely, if the compound 
is not sufficiently soluble in preferred organic solvents, a melt method may be preferable. 
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1.2.2.3. Miscibility, Solubility, and Dispersability 
Dispersability is defined herein as the successful formation of an ASD by intimate 
mixing of API and polymer followed by co-solidification without crystallization. 
Miscibility is defined as a mixture of drug and polymer “consisting of a single chemically 
homogeneous phase where all of the components are intimately mixed at the molecular 
level, and the properties of the blend are different from the properties of the pure 
components.” 9 The important distinction between dispersability and miscibility is a 
consequence of: (1) the analytical limitations inherent to the detection of phase separation 
and (2) the thermodynamics of the system (miscibility) versus the kinetics (dispersability).   
The current analytical limitations make it difficult to definitively identify the presence 
of a homogeneous system.  For example, differential scanning calorimetry (DSC) is 
commonly used to assess miscibility, but Utracki et al. point out that “a single Tg is not a 
measure of miscibility, but only of the state of dispersion.”24 Phase separation may still 
occur over time. Additionally, it may not be possible to detect phase separation for domains 
<30 nm, or when the glass transitions of the pure components are within 10°C of each 
other.25 Even heating the sample during DSC can result in changes to miscibility that may 
be misinterpreted as representing the initial physical state of the sample (see Chapter 3).  
Another example of an analytical limitation can be seen in powder x-ray diffraction 
(PXRD). This method can be used to detect the lack of an ordered crystalline phase, but 
will not be able to determine if a system is phase separated without more advanced data 
analysis. One such advanced method is pair distribution function (PDF) analysis, which 
can be applied to assess changes in the fingerprint of interatomic distances for co-solidified 
mixtures compared to the amorphous pure components.26 However, this method will be 
  7 
more sensitive as higher energy x-rays are employed, such as a synchrotron source, which 
is not routinely available to research labs. Copper anodes, which are most popular for 
laboratory x-ray diffractometers, may not always generate PDF data that contain enough 
information to be definitive.27 The application of a suite of analytical techniques will 
increase the certainty of conclusions.28 However, there is currently no analytical method 
which can definitively detect phase separation in every case.  
The distinction between solubility and miscibility has been reviewed by Qian et al,4 
and is illustrated in Figure 1 which is adapted from the same. The solid red line represents 
the crystalline API solubility in the polymer, whereas the dashed blue line indicates the 
amorphous API-polymer miscibility.   
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Figure 1: Theoretical figure illustrating both drug-polymer solubility and miscibility. 
(Adapted from the Journal of Pharmaceutical Sciences, Vol 99(7), F. Qian, J. Huang, M. 
A. Hussain., Drug–Polymer Solubility and Miscibility: Stability Consideration and 
Practical Challenges in Amorphous Solid Dispersion Development, Pages No. 2941-2947, 
Copyright 2010, with permission from Elsevier).4 Zones I and II indicate 
thermodynamically stable mixtures, Zones III and IV indicate meta-stable zones, and 
Zones V and VI are unstable zones where recrystallization is certain within a timeframe 
dictated by the molecular mobility of mixtures.  
 
Solubility is defined as the analytical composition of a saturated solution, where the solid 
and solubilized form of a molecule are in equilibrium.29 Solubility is perhaps most 
commonly applied in pharmaceutical science to assess the amount of drug that will dissolve 
in a particular volume of a solvent such as water. It is also possible for a polymer to dissolve 
a drug to some extent when in the liquid state. The API is often considered the ‘solvent’ in 
this case, merely because of its smaller size.  This API-polymer solubility is indicated by 
the red solid line in Figure 1. This line indicates a boundary between a thermodynamically 
stable state and a thermodynamically metastable state.   
  9 
The equilibrium associated with miscibility is given by Equation (1), and the 
IUPAC definition for miscibility is given in Equation (2).29 Miscibility describes the 
successful formation of a homogenous phase through liquid-liquid mixing;30 specifically 
in this document the liquid-liquid mixing of polymer and amorphous API. 
(1) APIamorphous + Polymeramorphous ⇌ API/Polymeramorphous,homogenous phase 
(2)             (
∂2ΔGmix
∂ϕ2
)
T,p
> 0 
The blue dashed line boundary corresponding to the amorphous API-polymer miscibility 
is a boundary between a thermodynamically metastable state and an unstable state, where 
eventual recrystallization is certain.4 This boundary also represents conditions where 
Equation (2) is equal to zero.  
The application of miscibility in this context comes from polymer physics, where 
the individual components are generally stable in the amorphous state. The application of 
the concept to systems in which the thermodynamically stable state is crystalline (i.e., API), 
results in added complexity.4 A thermodynamically stable state will be achieved in Zones 
I and II shown in the figure, a meta-stable state occurs in Zones III and IV, and an unstable 
or crystallized co-solidified mixture in Zones V and VI. It is important to note that this 
figure is theoretical, and measurements of solubility and miscibility at temperatures below 
the Tg cannot be obtained experimentally, and, therefore, can only be estimated through 
extrapolation.4 Methods for such extrapolations will be discussed in more detail in Chapter 
7.  
As stated above, dispersability is defined here as the successful formation of an 
amorphous solid dispersion by intimate mixing with a carrier polymer, followed by co-
solidification without recrystallization. Both miscibility and solubility lack a clear physical 
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meaning below the glass transition temperature of the system because increasing viscosity 
prohibits the system from reaching equilibrium.4 Also noted above, the extrapolation of 
miscibility to lower temperatures is only theoretical. Dispersability differs from these 
equilibrium states because it is expected to also encapsulate kinetic factors. While 
miscibility and solubility refer to equilibrium states, dispersability may also capture 
important factors that occur during formation of the solid binary mixtures. For example, a 
system that is expected to phase separate and/or crystallize based on inferences about the 
equilibrium state could remain dispersed due to rapid solidification.  
 
1.2.2.4. Predicting dispersability 
Currently there is no proven, rapid, and cost-effective way to assess the dispersability 
of API in polymers. As a result, determinations of dispersability have been primarily 
performed by trial-and-error.  
Some current research has been focused on streamlining component screening for 
amorphous solid dispersions. Shanbhag et al. developed an automated screening method 
using 96-well plates to screen an API against 6 polymers and 8 surfactants to identify leads 
for solid dispersion formulations.31 However, screening was performed using the solvent 
method while melt extrusion was the unit operation of interest for manufacturing at large 
scale. As noted previously, potential differences in molecular interaction between these 
methods would suggest that the solvent method may be inappropriate for predicting 
performance of the melt method. Verma and Rudraraju developed a systematic four-phase 
approach to formulation design of amorphous solid dispersions.32 They detail a stepwise 
method for assessment of API, screening against polymers, prediction of miscibility, and 
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confirmation of predictions. While their method is thorough and useful for development of 
amorphous solid dispersions, it is time consuming and requires a significant amount of 
drug for testing. Typically during early pre-formulation studies gram quantities of API are 
often scarce, presenting a limitation to industrial application of this work.  
Predictions related to what is defined herein as dispersability have been relatively 
infrequent in the literature. Existing research tends to be more focused on the development 
of models to assess and predict miscibility or solubility in amorphous solid dispersions, 
with the goal of predicting the physical stability of dispersed mixtures. For example, 
Marsac et al. used the Flory-Huggins theory (a lattice based solution model they applied to 
amorphous solid dispersions) and interaction parameters to predict drug-polymer 
miscibility.30 A thermodynamic model was developed to estimate solubility of API in 
polymer. In a separate study, Vasanthavada et al. studied solid dispersions of trehalose-
dextran and trehalose-PVP. They used modulated DSC to observe the phase separation of 
components over time until equilibrium was reached, based on the consistent glass 
transition value. This equilibrium point was believed to indicate the extent of molecular 
miscibility.33 Additional detail about the above methods, as well as other methods for 
predicting dispersability, are discussed in more detail in Chapter 2. 
These papers also focus mainly on the thermodynamic stability of amorphous 
dispersions and, in general, do not consider kinetic stability. Kinetics may inhibit phase 
separation and crystallization, since the molecular mobility in the solid state is greatly 
reduced. As a result, it may be possible to maintain a homogeneous phase over 
pharmaceutically relevant time scales without the need for a thermodynamically stable 
system. As a result, predictions of the ability of drugs to disperse in polymer systems, 
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regardless of solubility of API in polymer, may be more useful for formulation 
development.  
 The research detailed in this dissertation describes the expansion of a previously 
identified model for the prediction of dispersability in a specific polymer using a molecular 
descriptor, including a detailed investigation into the meaning of that descriptor. This work 
builds toward a broader research goal of building a formulation development tool for 
ASDs. Such a tool is envisioned in Figure 2, where an appropriate polymer could be rapidly 
identified for a new chemical entity (NCE), with material-sparing experimentation. 
Additional molecular descriptors could be identified in the future that predict dispersability 
in other polymers. Such a formulation development tool could aid ASD development by 
reducing experimental burden, time to market, and development costs. 
 
Figure 2: Envisioned formulation tool to speed development of ASDs. Future work could 
also focus on applying molecular descriptors to create models for predicting long-term 
physical stability of ASDs. 
 
1.3. Molecular Descriptors 
Molecular descriptors were developed as a tool enabling indirect association of 
molecular structure with properties of interest,34 and are the basic means for transforming 
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chemical information into a numerical code for application in quantitative structure-
property relationship (QSPR) modeling.35 A fundamental assumption of QSPR is that the 
structure of a molecule is responsible for the physical, chemical, and biological properties 
of that molecule.35 Since chemical and physical properties have been shown to be important 
for the formation and stability of ASDs, it is herein posited that molecular descriptors may 
be useful for prediction of dispersability. The potential usefulness of molecular descriptors 
is supported by their application in other areas of pharmaceutical research, including drug 
discovery,36-38 formulation screening,39-43 and amorphous systems.16, 44-47 These 
applications are discussed in more detail in Chapter 2.  
The application of molecular descriptors to aid formulation development of ASDs 
was proposed in 2011, where Moore and Wildfong48 showed that a single molecular 
descriptor (R3m) was predictive of dispersability for a 15-member API library in poly(1-
vinylpyrrolidone-co-vinyl acetate) (also known as PVPva or copovidone49) prepared by 
melt-quenching (M/Q) at a fixed drug loading (75% w/w). While these initial results were 
promising (see Figure 3), there remained uncertainty with respect to the general 
applicability and limitations of the model. The original model was built by screening over 
1400 molecular descriptors using a relatively small dataset, potentially leading to a type 1 
error owing to multiple comparisons.50 Further model testing was necessary to strengthen 
the statistical power. Additionally, specific questions related to how changes in API 
concentration and changes in manufacturing method could impact the model led to the 
experiments proposed in this dissertation. For example, decreasing the API concentration 
in a co-solidified mixture may result in a reduction in the degree of supersaturation, or 
perhaps even result in a miscible system. This would decrease the thermodynamic driving 
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force of the API to recrystallize, and thereby increase the likelihood that it would be 
dispersable in PVPva. These changes have the potential to impact the model, and therefore, 
are of interest.  
 
 
Figure 3: Logistic regression model showing that R3m is predictive of API (75%w/w) 
dispersability in PVPva.48 Red triangles indicate data used to build the model, while yellow 
squares indicate 3 compounds used to test the model.  
 
R3m is a member of the GETAWAY (GEometry Topology and Atom Weights 
AssemblY) class of descriptors, whose calculation utilizes three-dimensional molecular 
geometry, topology, and chemical information.51 Equation (3), below, describes the 
calculation of R3m, where A is the number of atoms in the molecule of interest, i and j 
refer to two atoms in the molecule, h is the leverage, m is the atomic mass, r is the geometric 
distance between atoms, and δ(3;dij) is a Dirac-delta function. For this descriptor, the Dirac-
delta function results in the consideration of only pairs of atoms where the topological 
distance is equal to 3. The descriptor is explained in more detail in Chapter 5.  
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(3)         R3m =  ∑ ∑
√hii∙hjj
rij
j>i ∙ mi ∙ mj ∙ δ(3: dij)
A−1
i=1  
 
Moore & Wildfong noted that increases in R3m corresponded with an increasing 
number of electronegative atoms, larger atoms more distant from the geometric center, 
and/or intramolecular interactions between atoms having a topological distance equal to 
three.48 However, a clear physicochemical relationship between the R3m descriptor and 
dispersability was not readily apparent from the 2011 work. Uncertainty about the 
physicochemical meaning of the R3m descriptor is, therefore, also a primary driving force 
for the experiments proposed herein.  
 
1.4. Hypothesis & Research Objectives 
The central hypothesis of this research is that there exists a combination of materials 
properties that correlates with the probability that an amorphous dispersion will 
form in PVPva. Molecular descriptors, which are mathematical representations of 
properties of a molecule, can be used to predict the formation of amorphous solid 
dispersions. 
 The following specific aims are proposed to investigate this hypothesis: 
1. Confirm the usefulness of the R3m descriptor.  
While the results of the study described by Moore and Wildfong48 were promising, 
there remained uncertainty with respect to the model’s general applicability and 
limitations. The original model was built by screening over 1400 molecular descriptors 
using a relatively small dataset, potentially leading to a type 1 error due to multiple 
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comparisons.50 Further testing is necessary to strengthen the model’s statistical power. 
Additionally, specific questions related to how changes in API concentration and changes 
in manufacturing method could impact the model led to the experiments proposed herein. 
The goal of specific aim I is to confirm or refute the general applicability of this molecular 
descriptor toward the prediction of ASD formation. This specific aim will be primarily 
covered in Chapter 4. 
 
2. Improve the interpretability of the model. 
It has been argued that the usefulness of molecular descriptors is not limited to cases 
for which they are easily interpretable.35 However, a model which is both interpretable and 
effective is preferable. The goal of this specific aim was to confirm that no simpler, more 
interpretable model predicting dispersability of API in PVPva exists, and to advance the 
understanding of why the R3m descriptor does predict dispersability.  
Molecular descriptors are derived from a representation of a molecule, where it is 
assumed that similar molecular structures have similar physical and chemical properties. 
Therefore, molecular descriptors that can successfully predict dispersability may point 
toward a physical and/or chemical property that is of importance for dispersability. While 
a molecular descriptor may allow for rapid assessment of dispersability potential of an API 
with a particular polymer, identification of a specific physical and/or chemical property 
that is important for dispersability will advance scientific understanding of useful API-
polymer interactions. Data analysis and results associated with this specific aim will be 
covered in Chapter 5 and Chapter 6.  
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3. Investigate the relationship between R3m and the experimentally determined solubility 
of select API in PVPva.  
Ultimately, the formation of ASDs can be attributed to the thermodynamic stability 
and/or the kinetic stability of the mixture. For a soluble system, the API and polymer can 
form a solid solution that will remain stable indefinitely. Likewise, a miscible system can 
remain stable barring nucleation, or changes in temperature or pressure. 
However, it is also possible that the mixture may remain stable for pharmaceutically 
relevant timescales owing to kinetic effects such as anti-plasticization and/or physical 
barriers to API nucleation and crystallization due to the presence of polymer. The goal of 
specific aim III is to experimentally determine if the usefulness of the R3m descriptor is 
specifically associated with the solubility of the API in PVPva. This specific aim will be 
discussed in Chapter 7. 
As briefly discussed earlier in this chapter, there has been much interest in predicting 
the solubility and/or miscibility of ASD systems to aid drug development. Before 
investigating a new method for predicting dispersability, it is necessary to review the 
literature to understand the strengths and weaknesses of existing methods. The existing 
methods for modeling and prediction of the formation of ASDs will be discussed in more 
detail in the next chapter (Chapter 2).  
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Chapter 2. Review: The Application of Modeling 
& Prediction to the Formation of Amorphous 
Solid Dispersions 
As discussed in Chapter 1, the goal of the research described in this dissertation is 
to further develop and refine the understanding of a model that predicts ASD formation in 
PVPva. It is, therefore, important to review the scientific literature for existing methods of 
prediction. This chapter will review the existing methods for modeling and prediction of 
ASD formation, describe and discuss literature important to the field, and convey the 
limitations of each method of prediction.  
 
2.1.  Introduction 
Amorphous solid dispersion (ASD) formulation development is frequently difficult 
owing to the inherent physical instability of the amorphous form, and limited understanding 
of the specific physical and chemical interactions that enable the initial formation of 
dispersions, setting up their long-term physical stability. ASD formulation development 
has been historically accomplished through trial-and-error or experience with extant 
systems; however, rational selection of appropriate excipients is preferred to reduce time 
to market and decrease costs associated with development. Current efforts to develop 
thermodynamic and computational models attempt to rationally direct formulation and 
show promise. This chapter describes and evaluates important methods used to predict 
ASD formation and physical stability, which include recent applications of solubility 
parameters (SP) and the Flory-Huggins interaction parameter (FHIP) to amorphous and 
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ASD formulations. Additionally, newly emerging computational techniques and their 
applications to ASD formulation development are examined.  Recent literature in which 
these methods are applied is also reviewed, and limitations of each method are discussed. 
 
2.2.  Solubility Parameter 
2.2.1.  Theory 
2.2.1.1.  Hildebrand Solubility Parameter 
The solubility of components in a mixture is favorable if the thermodynamic free 
energy of mixing (Δ𝐺𝑚𝑖𝑥) is negative.
52 
 
(4)             ΔGmix = ΔHmix − TΔSmix 
 
In liquid mixtures, the entropy of mixing (Δ𝑆𝑚𝑖𝑥) is generally positive due to increasing 
system disorder brought about by the increased numbers of available interactions. The 
system enthalpy can have the greatest impact on solubility, since a large positive value 
makes mixing unfavorable. In an ideal solution, the enthalpy of mixing (Δ𝐻𝑚𝑖𝑥) is zero 
since the adhesive interactions equal the cohesive interactions. This assumption requires 
that the solvent and solute molecules have essentially the same size, shape and chemical 
nature,53 and can be mathematically represented by the geometric mean assumption: 
 
(5)                   U12 = √U11U22 
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where 𝑈 is the potential energy of the cohesive (𝑈11, 𝑈22) and adhesive forces (𝑈12). 
Cohesive forces are required for a condensed phase, and the presence of interactions such 
as London dispersion forces, polar interactions, and hydrogen-bonds results in a decrease 
in the potential energy of molecules relative to the vapor phase.54 Enthalpic deviations from 
ideality are captured by the solubility parameter, the detailed derivation of which is found 
elsewhere.54-56  
The solubility parameter was defined by Hildebrand57 as the square root of the 
cohesive energy density (CED), often referred to as the ‘Hildebrand solubility parameter’ 
or ‘total solubility parameter.’ The enthalpy of mixing is related to the solubility parameter 
using the equation proposed by Hildebrand and Scott,58 
 
(6)                δ = √CED =  √
ΔEv
Mv
=  √
ΔHv−RT
Mv
 
 
(7)                 
ΔHmix
Mv
= ϕ1ϕ2(δ1 − δ2)
2 
 
where subscripts 1 and 2 refer to the components of the mixture, ϕ is the volume fraction, 
R is the gas constant, T is the absolute temperature, δ is the solubility parameter, Ev and 
Hv are respectively the free energy and enthalpy of vaporization, and Mv is the molar 
volume. A slightly positive or negative Δ𝐻𝑚𝑖𝑥 is required for solubility, where an upper 
limit is imposed by a positive Δ𝑆𝑚𝑖𝑥. Equation (7) suggests that two liquids having similar 
δ will have a low Δ𝐻𝑚𝑖𝑥, and therefore, form a miscible system. Several assumptions 
regarding the relationship between Δ𝐻𝑚𝑖𝑥 and the Hildebrand solubility parameters are 
required, and discussed in detail elsewhere.52, 54, 58 Perhaps most deleterious for application 
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to pharmaceutically relevant materials is the geometric mean assumption, in which polar 
and specific interactions are neglected,54 limiting the usefulness of the Hildebrand 
solubility parameter to nonpolar systems. Nevertheless, extension of solubility parameter 
theory has received considerable interest in pharmaceutical development, and applications 
specific to ASDs are reviewed herein.  
 
2.2.1.2.  Hansen Solubility Parameters 
Three-dimensional solubility parameters (also known as Hansen or partial 
solubility parameters) separate the total solubility parameter into parts that describe 
dispersion forces (𝛿𝑑), polar forces (𝛿𝑝), and hydrogen-bonding forces (𝛿ℎ).
59 
 
(8)                       δt
2 = δd
2 + δp
2 + δh
2  
 
The Hansen solubility parameter more practically estimates solvent miscibility because of 
its explicit inclusion of different interactions. These values can be visualized as a point in 
three-dimensional space enclosed by a sphere containing miscible solvents, where each 
axis corresponds to one of the partial solubility parameters (𝛿𝑑 , 𝛿𝑝, 𝛿ℎ).
60  As the balanced 
values of the partial solubility parameters of two liquids approach each other in this three-
dimensional space, their miscibility is expected to increase because of their increasing 
similarity. However, since this sphere is obtained from experimental data, and not 
thermodynamic considerations, there is no rule-of-thumb for a radius having a particular 
magnitude that universally identifies liquids that will be miscible and those which will 
not.56, 60  
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A common two-dimensional visualization plots the hydrogen-bonding term against 
the polar term, owing to the relatively low significance of the term describing dispersion 
forces.60 A combination of dispersion and polar terms has also been proposed based on 
their similarity, and is known as the volume dependent solubility parameter (𝛿𝑣).
61  
 
(9)                    δv = √δd
2 + δp2  
 
A two-dimensional Bagley plot considers 𝛿ℎ versus 𝛿𝑣, which approximately delimits 
miscible solvents by a circle52 rather than a sphere. Additional extensions or expansions of 
both the Hildebrand and Hansen SPs have been proposed,62-64 but are less often applied in 
pharmaceutical systems, and therefore, beyond the scope of this chapter.  
 
2.2.1.3.  Group Contribution Methods 
Miscibility assessment based on the chemical structures of the compounds of interest 
avoids time consuming, and potentially imprecise experimental determination of the SP.56, 
61, 65, 66 Group contribution (GC) methods for estimating 𝛿 were first proposed by Small,67 
and allow estimations of the solubility parameter by summing molar attraction constants 
based on an atomic or constitutive basis. GC methods used to calculate solubility parameter 
values are relatively easy to use, and a number of approaches have been developed. The 
most frequently used are those by Fedors,66 which either predicts the total solubility 
parameter or the molar volume, and those by Hoy68 and Hoftyzer and Van Krevelen52, 69 to 
predict either the Hansen or total solubility parameters.  
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2.2.2.  Application to Amorphous Solid Dispersions 
The application of solubility parameters in the pharmaceutical industry was reviewed 
nearly two decades ago by Hancock et al.,65 and described their use in aiding dosage form 
design via the prediction of relevant properties. Since 1997, the application of solubility 
parameters to identify a thermodynamically stable mixture of drug and polymer has 
continued.  
In a study by Greenhalgh et al.,70 GC methods were applied to determine Hildebrand 
solubility parameters, and miscibility predictions were compared with experimental results 
compiled from several other studies. The authors noted a strong link between larger 
differences in solubility parameters and incompatibility of API and carriers,70 and 
suggested categorizations to aid miscibility predictions. A Δ𝛿 ≤ 7√𝑀𝑃𝑎 was identified as 
a cutoff for miscibility, while Δ𝛿 > 10√𝑀𝑃𝑎 was expected to indicate immiscibility. 
These conclusions were supported by Mohammad et al.71 when applied to co-crystal 
formation, wherein it was observed that the value of Δ𝛿 for compounds that formed co-
crystals with piroxicam and carbamazepine was generally below 7 √𝑀𝑃𝑎.71 Greenhalgh 
and colleagues did note that Hildebrand parameters do not inform specific types of 
interactions between mixture components.70 In particular, the exclusion of hydrogen-
bonding from Hildebrand parameters may limit the applicability of proposed 
categorizations for pharmaceutically relevant systems. The authors also identified the lack 
of a clear relationship between phase diagrams and Δ𝛿,70 suggesting that the method fails 
to be predictive of solubility over all concentrations.  
Although it was noted that Hansen parameters may be better for ASD predictions, 
Greenhalgh et al. suggested that their practical application may be constrained by limited 
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data for many pharmaceutically relevant structural groups.70 Expanding interest in ASDs 
has resulted in some further development of GC tables, including prediction of Hansen 
parameters for pharmaceutically relevant compounds.72 Because of current limitations, 
however, Greenhalgh et al. used different GC methods to calculate the total solubility 
parameters. In some instances, there were insufficient data for specific functional groups 
using the Fedors GC method (e.g., amide and sulfone groups70), so the authors applied the 
method of Hoftyzer and Van Krevelen,69 and in some cases Martin.73 While this was 
necessary to complete the calculations using available data, this combination of methods 
may yield inconsistent results, since values from different sources can vary significantly.54, 
74 Specifically, the group contributions published by Fedors have been reported as being 
less accurate for the prediction of the cohesive energy.52, 70 Such variation in the calculation 
of the solubility parameter could potentially increase the uncertainty in the boundaries 
proposed in their work. Nonetheless, this study showed the potential usefulness of the 
solubility parameter as a rapid screening method for the selection of carriers in solid 
dispersions.70 Although there may be uncertainty in predictions at the boundaries between 
miscible and immiscible, solubility parameters could be applied to narrow potential 
formulation by rapidly identifying API:polymer combinations having largely different 
solubility parameter values.  
 Forster et al.75 used solubility parameters to predict particular excipient-drug 
mixtures suitable for hot melt extrusion (HME), and found that the calculated Δ𝛿 values 
could be predictive of miscibility, but recommended a different categorization than 
Greenhalgh et al. (see Figure 4).  In their work, Forster et al. used the Hoy and 
Hoftyzer/Van Krevelen method to determine the total solubility parameter, but did not 
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analyze the Hansen partial solubility parameters (i.e., Δ𝛿𝑑, Δ𝛿𝑝, Δ𝛿ℎ). These individual 
differences could potentially be more informative than their total Euclidean distance, since 
a one-dimensional comparison is inherently less descriptive than a three-dimensional 
comparison. Mohammad et al. applied the Hansen solubility parameters in this way in an 
attempt to predict the formation of co-crystals.71 These authors generated a three-
dimensional plot as well as a Bagley plot, to allow for the independent consideration of the 
relative contributions of various types of forces.71 The location of compounds relative to 
the reference API (indomethacin) correlated well with experimentally determined 
miscibility. A more complete description of the various types of forces may give an 
improved description of component similarity, and therefore, improved miscibility 
predictions. 
 
 
Figure 4: Categorizations of miscibility based on differences in Hildebrand solubility 
parameter between components, as proposed by Hoftyzer and Van Krevelen,52 Greenhalgh 
et al.,70 and Forster et al.75 
 
2.2.3.  Limitations of the Solubility Parameter 
Approach 
While the solubility parameter can be a useful screening tool for potential carrier 
polymers, there are limitations, perhaps the most significant of which is the purely 
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thermodynamic foundation of the theory. Solid dispersions are not limited to 
thermodynamically stable API:polymer mixtures, as kinetically stable mixtures can be 
equally useful for the improvement of apparent aqueous solubility. As such, other attributes 
of the dispersion may be important, which may not be captured in a solubility parameter.  
For example, the impact of polyvinylpyrrolidone viscosity was shown to reduce the 
diffusion of ketoconazole molecules, resulting in increased kinetic stability, even in the 
absence of strong specific interactions between the drug and the carrier polymer.6 Failure 
to consider such kinetically stable mixtures when making drug development decisions may 
inadvertently exclude potentially viable formulations. Likewise, overlooking interactions 
not considered by the solubility parameter, such as ionic interactions,9 can also exclude 
important excipients.  
Despite the original thermodynamic basis of the solubility parameter, few studies 
have investigated it as a predictor for long-term physical stability of ASDs. Since a binary 
mixture with low Δ𝛿 indicates a favorable free energy of mixing, it is reasonable to expect 
that such a mixture would remain stable owing to a reduced thermodynamic drive toward 
recrystallization. Yoo et al.76 evaluated the Hildebrand solubility parameter, among other 
properties, as a predictor for physical stability of ASDs. While Δ𝛿 correlated well with 
initial observations of miscibility, it was not successful for predicting which compounds 
remained amorphous after 50 days of storage at 25°C/ 60%RH.76 It is, however, important 
to note that the presence of moisture during storage will likely complicate interpretation 
owing to the impact of water content on molecular mobility. An assessment of stability in 
the absence of moisture may prove to be an important future study to determine if the 
solubility parameter can predict the long-term stability of ASDs.   
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The solubility parameter method also neglects the entropy of mixing term, which 
becomes more important with more complex molecules such as polymers.61 Hansen noted 
that entropy factors could affect visualized data in an undetermined manner,60 likely 
changing the radius of miscibility, depending on the compounds under consideration. The 
impact of temperature is also generally neglected, the importance of which increases as the 
melting point of drugs increases, if for example, molten mixtures are created to prepare 
ASDs. These terms should be included for a truly ab initio thermodynamic model for the 
prediction of API-polymer miscibility.  
Hydrogen-bonding forces associated with the Hansen solubility parameter have been 
of great interest to the pharmaceutical industry. Alhalaweh et al.77 found a high correlation 
between the total solubility parameter and the difference in hydrogen-bonding partial 
solubility parameters when comparing indomethacin with 33 other compounds. Likewise, 
Albers et al.78 observed that Δ𝛿 was mainly influenced by the difference in hydrogen-
bonding forces for a set of 15 drug-carrier pairs. However, Hansen solubility parameters 
are only semi-empirical,79 having no thermodynamic justification for the separation of the 
total solubility parameter into Δ𝛿𝑑, Δ𝛿𝑝, and Δ𝛿ℎ. For example, hydrogen-bonding between 
API and carrier requires the presence of both hydrogen-bond donors and acceptors, 
indicating a requirement for different structural moieties. This is not captured by the Δ𝛿ℎ 
term, and was first addressed by Karger et al.,62 where the hydrogen-bonding term was 
split into acidic (𝛿𝑎) and basic (𝛿𝑏) terms based on Lewis acid-base theory, and further 
pursued by Beerbower et al.80 and Martin et al.64, 73, 81 Unfortunately, this method is less 
often applied due to limited data for relevant functional groups.78  
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It appears that the largest hurdle to the broader application of the solubility parameter 
in understanding ASD formulation is the lack of available data for GC methods. 
Experimental data is difficult to obtain,52, 54 and performing such experiments for each new 
API and excipient is impractical. Nevertheless, the application of solubility parameters to 
ASDs has continued. For example, Verma et al.32 more recently recommended using 
solubility parameters as part of a systematic approach to ASD formulation design. While 
solubility parameters can be useful for the rapid screening of potential excipients for ASD 
formulations, inadequacies in the theory often require additional experimental work to 
confirm inferences. These shortcomings have led to the development of more complex 
models. 
 
2.3.  Flory-Huggins Interaction Parameter 
2.3.1.  Theory 
The Flory-Huggins interaction parameter (FHIP) was developed independently by 
Flory82 and Huggins83 for polymer applications, and considers deviations of polymer 
solutions from ideality thought to result from the underlying assumptions of entropy in the 
ideal case. In a mixture of small molecules, the environment can be approximated by a 
lattice, where it is assumed the molecules are interchangeable (i.e., molecules are identical 
in size, spatial configuration, and external force field84). As shown in Figure 5, the 
connectedness of polymer long-chain molecules invalidates this assumption.84 
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Figure 5: Visualization of the liquid lattice theory. (a) Solute and solvent molecules are 
assumed virtually identical in size, spatial configuration, and external force field. (b) A 
chain polymer occupies the liquid lattice, resulting in changes to configuration entropy. 
Adapted from Principles of Polymer Chemistry, by Paul J. Flory. Copyright 1953. Cornell 
University and Copyright 1981 Paul J. Flory. Used by permission of the publisher, Cornell 
University Press.84 
 
Flory and Huggins adjusted the entropy equation, using the volume fraction in place 
of mole fraction to account for the significant size discrepancy between molecules.85 
Additionally, the probability that a given lattice point was occupied by a polymer segment 
was adjusted (via the enthalpy equation) to account for the connectivity of the chain.86 The 
first two terms on the right side of the resulting equation (Equation (10)) are the entropic 
component, while the final term is the enthalpic component. 
 
(10)                 
ΔGmix
RT
= n1 ln ϕ1 + n2 ln ϕ2 + n1ϕ2χ 
 
Above, subscript 1 is the solvent, subscript 2 is the solute, ϕ is the volume fraction, n is 
the number of moles, R is the gas constant, T is the absolute temperature, and χ is the FHIP. 
The interaction parameter is dimensionless, and characterizes the interaction between 
polymer segments and solvent molecules.84 The entropic portion of Equation (10) is 
relatively fixed due to the high molecular weight of the polymer,85 and thus the FHIP can 
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be used to estimate the miscibility. The critical value for 𝜒 is 0.5 when the ratio of polymer 
to API volume is large due to the high molar mass of the polymer.56 Miscibility is expected 
at values of 𝜒 lower than 0.5, whereas immiscibility is expected above this value.  
The FHIP has been experimentally determined using a number of methods including 
freezing point depression, boiling point elevation, viscosity, and polymer equilibrium 
swelling,56 however, these methods are often difficult to apply for pharmaceutical 
materials. As a result, the FHIP method was not widely applied to ASDs until a new method 
was proposed by Marsac et al.30 
 
2.3.2.  Application to Amorphous Solid Dispersions 
The Flory-Huggins lattice theory is important to ASD systems since it specifically 
considers the entropic effect of the polymer. The FHIP also reflects the relative strength of 
the cohesive and adhesive interactions of the system, thereby capturing the enthalpic 
interactions.30 Although the application of the Flory-Huggins lattice theory to ASDs had 
been limited due to experimental challenges, recent advances have aided in the 
determination of FHIP, and are discussed below. 
 
2.3.2.1.  Solubility Parameters to Calculate the Flory-Huggins Interaction 
Parameter 
Approximation of the FHIP using solubility parameters results in Equation (11), 
when the previously described geometric mean assumption is applied,56 where Vi is the 
volume of the hypothetical lattice site: 
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(11)    Using Hildebrand 𝛿:              χ =
Vi
RT
(δi − δj)
2
 
              Using Hansen 𝛿:              χ =
Vi
RT
[(δdi − δdj)
2
+ (δpi − δpj)
2
+ (δhi − δhj)
2
] 
 
This method for determining 𝜒 is limited, as described in section 2.3. , but benefits relative 
to the solubility parameter alone by including assessment of the entropic contribution and 
the effect of temperature on miscibility.  
Thakral and Thakral87 investigated a screening tool for ASD formulation 
development by determining the Hansen solubility parameter-based FHIP for 83 drugs with 
polyethylene glycol (PEG) 6000 and using values of 𝜒 to predict the free energy phase 
diagrams for each API. Generally, completely miscible API could not be experimentally 
distinguished by thermal analysis from those that were partially miscible,87 however, 
immiscible API were differentiable, indicating that the method could be used to rapidly 
exclude certain API-excipient combinations (Figure 6).  
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Figure 6: (a) Hansen solubility based interaction parameters and their predicted miscibility 
with PEG 6000, where 𝜒 < 0.98 was classified as ‘Type I’, 𝜒 = 5.19-28.27 was classified 
as ‘Type II’, and 𝜒 = 1.09-4.19 was classified as ‘Type III’. (b) Example free energy phase 
diagrams for API which are ‘Type I’ or miscible (green dot-dash line), ‘Type II’ or 
immiscible (red dotted line), and ‘Type III’ or partially miscible (yellow solid line) with 
PEG. Adapted from the Journal of Pharmaceutical Sciences, Vol 102(7), S. Thakral, N.K. 
Thakral, Prediction of drug-polymer miscibility through the use of solubility parameter 
based Flory-Huggins interaction parameter and the experimental validation: PEG as model 
polymer, Pages No. 2254-2263, Copyright 2013, with permission from Elsevier.87 
 
Although the proposed model is promising, the authors’ experimental investigation 
of only 3 compounds suggests that further studies are necessary, particularly in an effort to 
better distinguish between partially and fully miscible mixtures. It is also possible that the 
use of a 10 °C/min ramp rate for Tm depression analysis, may have contributed to difficulty 
in distinguishing between partially and fully miscible mixtures by differential scanning 
calorimetry (DSC), owing to the kinetic effects of the polymer on mixing (see section  
2.2.3. ). The authors also generated a Bagley plot, which reasonably approximated the 
miscibility behavior of the compounds tested,87 and appeared to better separate between 
drugs that were partially miscible versus those that were immiscible in PEG 6000 (Figure 
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7). While the FHIP allowed the free energy phase diagram to be determined, the results did 
not appear to offer significant benefit over the solubility parameter alone, since, at least 
with the data presented, the Bagley plot appeared to be equally effective at separating 
predictions of partially miscible from fully miscible compounds.  
  
 
Figure 7: Bagley plot of PEG 6000 with a series of drugs. PEG 6000 is located at the center 
of the black dotted circle, and compounds within the radius of the circle are expected to be 
miscible with the polymer. The key refers to predictions made using the FHIP. The Bagley 
plot appears to offer a better separation between predicted immiscible and partially 
miscible compounds. Adapted from the Journal of Pharmaceutical Sciences, Vol 102(7), 
S. Thakral, N.K. Thakral, Prediction of drug-polymer miscibility through the use of 
solubility parameter based Flory-Huggins interaction parameter and the experimental 
validation: PEG as model polymer, Pages No. 2254-2263, Copyright 2013, with 
permission from Elsevier.87 
 
2.3.2.2.  Melting Point Depression  
Marsac et al. used two methods to investigate application of the Flory-Huggins 
lattice theory to the prediction of miscibility for ASDs.30 The first was the solubility 
parameter approach described by Equation (11). The second was the melting point 
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depression method, which was extended from the polymer literature88 and applied to API-
polymer systems, resulting in Equation (12): 
 
(12)                         (
1
Tm
mix −
1
Tm
pure) =  −
R
ΔHfus
[lnϕdrug + (1 −
1
m
) ϕpoly + χϕpoly
2 ] 
 
Above, Tm is the melting point (of the mixture and pure API), R is the gas constant, ΔHfus 
is the enthalpy of fusion, ϕ is the volume fraction, and m is the ratio of the volume of 
polymer to that of the lattice site.30 Favorable drug-polymer interactions were manifest as 
a depression in Tm due to reduced thermodynamic activity of the drug in the presence of 
polymer, relative to its pure form. Depression of Tm was experimentally determined for 
mixtures of polymer and API at different ratios, using a low ramp rate (1 °C/min) and 
controlled particle size (45-75 μm) to reduce kinetic effects. At low polymer volume 
fractions, a linear relationship was identified: 
 
(13)                 (
1
Tm
mix −
1
Tm
pure) ∗
ΔHfus
−R
− lnϕdrug − (1 −
1
m
) ϕpoly   vs.   ϕpoly
2  
 
Linearity was lost with increasing polymer concentrations owing to the composition 
dependence of 𝜒 and the increasingly unfavorable mixing kinetics as the Tm approached Tg 
of the polymer.30 Despite this, the method resulted in more reasonable values of 𝜒 relative 
to those predicted from the solubility parameter method, when compared to experimental 
solubility data for nifedipine in polyvinylpyrrolidone (PVP) monomer solution,30 and 
reflects the cohesion from specific interactions such as hydrogen-bonding. 
  35 
While this method estimates the FHIP quite well, its application is not without 
limitations. The method assumes that thermodynamic mixing occurs over the timescale of 
the experiment,85 however, caution may be necessary when evaluating high polymer 
concentrations where the increased viscosity can negatively impact mixing kinetics. 
Particle size may also have an impact since the intimate contact afforded by increased 
specific surface area of smaller particles can decrease Tm. The authors were careful to use 
slow DSC heating rates to approximate equilibrium. The most appropriate method for 
approaching ‘pseudo-equilibrium’ using DSC remains a topic of debate, and Tm has been 
determined using both onset30, 87, 89 and offset30, 90, 91 values. Offset temperatures are 
believed to represent more complete molecular mixing, and therefore, may better estimate 
Tm of the final mixture.
85, 92 With that said, the experimental time required to approximate 
equilibrium may be prohibitive for large studies, and an underestimation of Tm depression 
is expected. Marsac et al.85 demonstrated kinetic effects on experimental data by showing 
a further decrease in Tm when analyzing crystalline felodipine in contact with a molecular-
level dispersion of felodipine:PVP.  Since the dispersion had a plasticized Tg relative to the 
pure polymer, there was a greater increase in mobility at a lower temperature, allowing 
more thorough mixing of crystalline felodipine with the dispersion, compared to polymer 
alone. Consequently, this method is most applicable for systems where Tg of the mixture 
is sufficiently different from Tm of the drug, with a difference of 20 °C recommended to 
facilitate mixing.92  
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2.3.2.3.  Recrystallization method 
Mahieu et al.93 proposed a method to reduce the time needed to determine the FHIP. 
The equilibrium solubility was determined via de-mixing (i.e., induced phase separation), 
the kinetics of which were expected to occur more rapidly than dissolution.93 Mixtures 
were milled to form supersaturated glass solutions, which were annealed above Tg, causing 
supersaturated API to phase separate from the polymer and recrystallize. Samples were 
then cooled and reheated to determine Tg, which was subsequently used to predict the 
equilibrium solubility via the Gordon-Taylor equation. Experiments at different 
concentrations allowed generation of a solubility curve at an estimated ten times faster than 
by using the Tm depression method,
93 however, this may overestimate method efficiency 
since selection of an appropriate annealing temperature required additional experiments. 
Figure 8, below, compares this method with the Tm depression method. 
 
 
Figure 8: Comparison of the (a) melting point depression30 and (b) recrystallization 
methods93 for approximating the equilibrium solubility, and subsequently, the interaction 
parameter (𝜒). 
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It is also important to note that this method assumed that the experimental Tg 
accurately predicted the concentration via the Gordon-Taylor equation; yet, the Gordon-
Taylor equation assumes ideal mixing of polymer and API. Deviations can occur, therefore, 
if the adhesive and cohesive interactions vary greatly from one another.94, 95 Furthermore, 
Knopp et al.95 showed that preparation of supersaturated glass solutions using three 
different methods (ball milling, film casting, and spray drying) resulted in method-
dependent inconsistencies in predicted equilibrium solubility and variable fit to the Flory-
Huggins model. 
The experimental efficiency offered by this method is appealing, however, it should 
be noted that, in order to be quantitative, complete crystallization of the phase-separated 
drug is required. If the supersaturated portion of the drug does not fully separate from the 
sample, the resulting Tg will be plasticized, and therefore, inexact. In addition, the 
recrystallization rate is expected to slow as the concentration of phase separated amorphous 
drug molecules decreases, making determination of its end point difficult. If this reduced 
rate of crystallization falls below the detection limit of DSC, the equilibrium solubility will 
likely be overestimated.92 Moreover, the crystallization tendency of an API (as described 
by Baird et al.96 and Van Eerdenbrugh et al.97) may also influence the kinetics of 
recrystallization during annealing, making API with a greater tendency to remain 
amorphous, less suited to this method.  
 
2.3.2.4.  Solubility in liquid polymer analog  
Marsac et al. also investigated the use of a low molecular weight analog of PVP, 1-
ethyl-2-pyrrolidone, to estimate the solubility of API in that polymer.85 This method 
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allowed estimation of 𝜒 at room temperature, while the Tm depression method gave an 
estimate of 𝜒 at Tm (Equation (12)). The authors suggested that this solubility value may 
be useful since it was less affected by inhibited mixing kinetics, and by the variation in 
activity coefficient with temperature and concentration.85 Perhaps the main limitation to 
wider adoption of this approach is the availability of liquid polymer analogs. PVP is an 
ideal polymer in this respect, since 1-ethyl-2-pyrrolidone is chemically equivalent to the 
polymer repeat unit, and the analog is readily available. In contrast, hypromellose acetate 
succinate, another common ASD carrier, has heterogeneous chemical substitutions on its 
cellulose rings, making it difficult to identify monomers that appropriately emulate the 
polymer. Nonetheless, where liquid analogs are available, representative estimates of 
thermodynamic solubility in that polymer are possible. For example, Paudel et al.98 used 
multiple methods to determine the solubility of naproxen in PVP, ultimately concluding 
that the liquid polymer analog method resulted in the most realistic values, since this 
method gave the FHIP at room temperature,98 and included specific interactions between 
drug and carrier. More recently, Rask et al.99 also applied this method to determine the 
solubility of celecoxib in polyvinylpyrrolidone-vinyl acetate copolymer (PVPva) using N-
vinylpyrrolidone and vinyl acetate. In this study, the authors noted the potential for this 
method to overestimate the solubility when interactions are expected between API and 
repeat units since in the polymeric form, the drug may be sterically hindered from 
interacting with each repeat unit.99  
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2.3.2.5.  Temperature-Composition Phase Diagrams 
A method allowing calculation of the complete temperature-composition phase 
diagram for binary ASDs was proposed by Lin and Huang using Tm depression 
experiments.91 A relationship between temperature and the FHIP was determined using 
Equation (14). 
 
(14)                          χ = A +
B
Tm
mix 
 
where 𝑇𝑚
𝑚𝑖𝑥 is the melting point of the mixture, A is a constant reflecting the non-
combinatorial entropic contribution, and B/T is a constant reflecting the enthalpic 
contribution.91, 100 The linear relationship between 𝜒 and 1/T is used to solve for A and B, 
allowing a phase diagram relating temperature and volume fraction of the drug to be 
constructed. This diagram predicts the solubility of API in polymer at any temperature, and 
was previously difficult to complete owing to experimental limitations resulting from 
increased polymer viscosity at lower temperatures.91 A curve separating a metastable 
system from an unstable system (known as the spinodal curve100) can also be generated by 
setting Δ𝐺𝑚𝑖𝑥
′′ = 0 (Figure 9).91  
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Figure 9: Theoretical Drug-Polymer Phase Diagram. Adapted with permission from Y. 
Tian, J. Booth, E. Meehan, D.S. Jones, S. Li, G.P. Andrews, Construction of Drug–Polymer 
Thermodynamic Phase Diagrams Using Flory–Huggins Interaction Theory: Identifying the 
Relevance of Temperature and Drug Weight Fraction to Phase Separation within Solid 
Dispersions, Mol. Pharm. 10(1) (2013) 236-248. Copyright 2013 American Chemical 
Society.101 The area above the drug-polymer solubility curve will be a stable, one phase 
system. Co-solidified mixtures at drug fractions and temperatures below the spinodal curve 
are predicted to phase separate. Between the spinodal and solubility curve, the system is 
expected to be metastable. 
 
Several studies using experimentally determined phase diagrams89, 91, 102-104 have 
shown promising results. For example, Tian et al.101 generated temperature-composition 
diagrams, selected drug-compositions representing both the unstable and metastable areas, 
and ultimately found that the predictions matched experimental observations. In a separate 
paper, Tian et al.104 concluded that the Flory-Huggins phase diagram was useful for ranking 
suitable polymer candidates for ASD formulations. 
Despite their usefulness89, 91, 95, 101-105  the phase diagrams for very few API (e.g., 
indomethacin, felodipine, ketoconazole, and aceclofenac) have been published to date. One 
potential limitation to their more widespread use could stem from the exclusion of 
considerations of experimental and prediction error. In their paper describing the method, 
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Lin et al.91 acknowledged that the possible dependence of 𝜒 on drug concentration and 
higher temperatures was neglected. A separate publication by Zhao et al.89 also expressed 
some concern regarding the oversimplified correlation in Equation (14).  
Continued development of the phase diagram method as a formulation tool would 
benefit from including predictions applicable to long-term storage to better facilitate 
understanding of ASD physical stability. Lu et al.102 found that phase diagrams for 
dispersions of ketoconazole and felodipine in Soluplus® successfully predicted physical 
stability for up to 3 months of storage at accelerated conditions. However, sorption of water 
at high relative humidity could introduce a third component to these systems, complicating 
interpretation of the data. At the completion of the writing of this chapter, no studies were 
found that compared phase diagrams to experimental data beyond 3 months. Additionally, 
use of this method should also consider how the accuracy and precision of predictions may 
be impacted by issues such as sample preparation method (known to affect the FHIP95), or 
experimental error owing to kinetic effects in the Tm depression method. Knopp et al.
106 
recently performed a statistical analysis of this method, and concluded that the predicted 
miscibility curve could not be trusted as a result of poor statistical confidence.106 This 
conclusion was based on identification of a violation of the assumptions of regression 
resulting from the linear transformation used in Equation (14) (specifically, the reciprocal 
transformation of temperature). The impact of bias introduced by this transformation is 
shown in Figure 10.  
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Figure 10: Visualization of the impact of the reciprocal transformation to linearity used in 
equation (14) on the statistical validity of Flory-Huggins phase diagrams.106 (a) The 
extrapolated confidence intervals are shown, indicating poor confidence in the predicted 
interaction parameter at lower, pharmaceutically relevant temperatures. (b) Comparison of 
the least squares estimate of equation (14) using raw data and (c) using average values. The 
best fit line varies significantly, ultimately resulting in opposite inferences regarding 
miscibility. Adapted from the Journal of Pharmaceutical Sciences, 105(1), M.M. Knopp, 
N.E. Olesen, Y. Huang, R. Holm, T. Rades, Statistical Analysis of a Method to Predict 
Drug–Polymer Miscibility, Pages No. 362-367, Copyright 2015, with permission from 
Elsevier.106 
 
Finally, it has been suggested that current DSC instruments may be insufficiently 
precise for the generation of reliable phase diagrams,106 as the prediction accuracy is 
dependent on the accuracy of the experimental data.91 Additional work is needed to assess 
the underlying physical assumptions of the Tm depression method to ensure that extensions 
of this method (e.g., to generate phase diagrams) are valid.106 
 
2.3.2.6.  Polymer in Solution Method 
A new method proposed by Knopp et al.107 hypothesizes that drug-polymer solubility 
can be determined from the increase in drug solubility due to concomitant presence of 
dissolved polymer in an inert solvent,107 where a linear increase in drug solubility with 
increasing polymer concentration was observed for all mixtures tested. Additionally, for 
the majority of the samples tested, the prediction intervals were narrower than those 
determined using the Tm depression method. It was also expected that more realistic 
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interactions were likely compared to the liquid monomer method, since factors such as 
steric hindrance were not overlooked. The method may also perform better than the Tm 
depression method since there is no need to extrapolate results to room temperature.107 It 
is notable that this method assumes the dissolved polymer and API remain representative 
of their solid form, which may be problematic for polymethacrylic and cellulosic polymers 
that ionize in solution. While this method shows promise, the recent development of this 
approach necessitates further research to identify other potential limitations.  
 
2.3.3.  Limitations of Flory-Huggins Interaction 
Parameter 
The FHIP offers insight into the thermodynamics of binary ASD systems. Both the 
entropic and enthalpic effects are considered and, in general, the effect of specific 
interactions is included. However, application of this approach (and its derivative methods) 
requires caution under certain circumstances. For example, the assumption that 
concentration has a negligible impact on the FHIP is not always true. Saturable interactions 
are not considered by the Flory-Huggins lattice theory,98 and concentration dependence 
will be significantly important for a drug and polymer whose mixing is enhanced by 
hydrogen-bonding. As the concentration of drug increases, the number of potential 
hydrogen-bonds that it can form with the polymer may plateau, thereby affecting its 
solubility in that carrier.  Additionally, as discussed in the introduction to Section 2.3, 
system kinetics, which are important for understanding ASD stabilization, are also not 
considered by the Flory-Huggins theory. For example, an increase in polymer chain length 
will increase the entropic contribution to mixing, which will be reflected in the FHIP.  The 
  44 
commensurate increase in viscosity, however, which will inhibit API crystallization in 
longer chain polymers, will not contribute to the FHIP calculation, potentially making 
predictions incomplete.  
The methods for determining the FHIP may also suffer from experimental 
limitations. It is difficult to accomplish molecular mixing in situ (e.g., using DSC), and 
may be prohibitive as the drug concentration drops below approximately 70% w/w.89 
Additionally, these thermal methods are only applicable for compounds that are thermally 
stable, particularly in the recrystallization method, which requires lengthy annealing times 
during which the drug must remain stable.95  
 
2.4.  Molecular Descriptors 
The methods discussed thus far have largely ignored the effect of system kinetics on 
the miscibility of drug and polymer in ASD formulations. Since molecular mobility in the 
solid state is greatly reduced, ASDs can remain kinetically stable for pharmaceutically 
relevant time periods, even in formulations where the miscibility limit may have been 
exceeded. Predicting the ability of drugs to disperse in polymer, including the formation of 
supersaturated systems, may also be useful for formulation development, although no first 
principles model for kinetic stability currently exists. 
Quantitative structure-activity relationships (QSAR) and quantitative structure-
property relationships (QSPR) have been explored since a model for molecular structure 
was developed in the late 1800s. The history of chemoinformatics, QSAR, and molecular 
descriptors is described elsewhere, and the reader is directed to the cited literature for more 
information.34-36, 108, 109 The fundamental assumption of QSAR/QSPR is that the structure 
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of a molecule is responsible for its physical, chemical, and biological properties.35 If the 
chemical structure is related to these properties, it follows that these properties can be 
predicted using structure alone; however, the relationships between specific properties and 
chemical structure are too complex to discern using first principles models, necessitating 
an indirect process.34  
 
Figure 11: The QSAR/QSPR approach. Figure adapted from Gasteiger.34  
 
Molecular descriptors were developed as a tool enabling indirect association of 
molecular structure with properties of interest (Figure 11). Molecular descriptors are 
defined by Todeschini and Consonni108 as “the final result of a logical and mathematical 
procedure which transforms chemical information encoded within a symbolic 
representation of a molecule, into a useful number, or the result of some standardized 
experiment.” They are the basic tool for transforming chemical information into a 
numerical code for application in QSAR modeling.35 Molecular descriptors may represent 
the physiochemical properties of a molecule, or may be derived from molecular structures 
using algorithmic techniques.109 For completeness, some of the discussions in this section 
also include easily determined physiochemical properties (e.g., Tg and Tm). While these 
properties are not considered molecular descriptors by definition, they are included owing 
to their general availability during early method development. In some cases, these 
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properties can also be accurately predicted and, therefore, applied as molecular descriptors 
without the need for experimentation. For example, in many cases, Tg has been shown to 
be highly correlated with, and, therefore, easily predicted from Tm.
110 It may also be 
possible to predict Tg using other molecular descriptors.
111  
Historically, the application of molecular descriptors in the pharmaceutical industry 
has been applied most commonly to drug discovery.35-37 Tian et al.38 reviewed the 
application of drug-likeness modeling to pharmaceutical science. The following sections 
will discuss the application of molecular descriptors to formulation screening, amorphous 
systems (glass forming ability and physical stability), and their application toward ASDs. 
 
2.4.1.  Formulation Screening 
Following drug discovery, an appropriate formulation is selected to enable drug 
delivery. This task can be exceedingly challenging, owing to the number of potential 
delivery methods, and the large number of formulation and process variables that can 
interact in complex ways.39 High-throughput screening has led to an increasing number of 
poorly water-soluble drug candidates, and identification of the most suitable formulation 
is often challenging. Methods that apply molecular descriptors are commonly used to aid 
scientists in these areas. For example, Amidon et al.40 proposed the well-known 
biopharmaceutics classification system (BCS), which allows rapid categorization of new 
chemical entities and aids the selection of appropriate formulations strategies. The ‘Rule 
of 5’ proposed by Lipinski et al.41 uses descriptors to identify the ‘drugability’ of new 
chemical entities and can be applied to screen compounds most likely to reach the market 
based on their similarity to existing drugs. As recently as 2015, an assessment of the 
  47 
DrugBank database112 showed that 85.4% of the 1543 uploaded FDA approved drugs met 
the Rule of 5 criteria.38  
Application of molecular descriptors in product development may help scientists 
make informed formulation decisions, especially as a potential means of addressing the 
‘combinatorial explosion’ of poorly water-soluble compounds. As the number of potential 
formulation methods has increased, the number of possible combinations to reach a suitable 
product has become exceedingly large.42 Branchu et al.42 identified several key decision 
points in the development process, the first of which was the selection of either 
‘conventional’ or ‘non-conventional’ (e.g., solid dispersion, lipid/surfactant system, 
crystalline nanoparticle) formulations. If a non-conventional formulation was deemed most 
appropriate, a second decision regarding the formulation strategy was required, and made 
based on the physicochemical properties of the molecule of interest. The authors generated 
11 statistical models and 11 decision trees to aid this decision process (Figure 12). 
Unfortunately, the complete model is proprietary and very few performance statistics were 
divulged, making it difficult to assess or apply the model. Nevertheless, the study illustrates 
the potential for application of molecular descriptors to speed formulation development.   
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Figure 12: Example decision tree process. Adapted from the European Journal of 
Pharmaceutical Sciences, S. Branchu, P.G. Rogueda, A.P. Plumb, W.G. Cook, A decision-
support tool for the formulation of orally active, poorly soluble compounds, 32(2), Pages 
No. 128-139, Copyright 2007, with permission from Elsevier.42  
 
In a separate study, Kuentz & Imanidis43 ranked drug candidates using molecular 
descriptors, based on the solubility advantage that their amorphous form offered over the 
crystalline form. By applying this method, the authors hoped to use molecular descriptors 
to identify compounds most likely to benefit from formulation approaches such as ASDs. 
Two models were developed to predict the ideal solubility advantage using partial least 
square (PLS) modeling. The first consisted of 9 terms, while the second included additional 
quadratic terms for the 5 most important variables, although inclusion of these terms 
resulted in only a minor increase in model fit (R2 increased from 0.803 to 0.820), and a 
decrease in predictive performance (Q2 from 0.792 to 0.729) for the second model relative 
to the first. Nonetheless, the authors identified 4 descriptors as potentially useful for 
identifying compounds that could benefit from amorphous formulations (Table 1).  
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Table 1: Compilation of molecular descriptors used for prediction related to amorphous API or ASDs. Variables which require 
experimental work to determine are bolded.   
Molecular Descriptors 
(correlation direction and/or 
cutoff value, if reported) 
Description 
# of compounds  
(train/ test/ validation) 
Reference 
F
o
rm
u
la
ti
o
n
 S
cr
ee
n
in
g
 
MW(≤500), ClogP (≤5), HDon(≤5), 
HAcc(≤10) 
Lipinski’s rule of 5 
2245 Lipinski et al.41 
An, Dn, Do Biopharmaceutics Classification System N/A Amidon et al.40 
Dissociation constants, HDon, PSA, 
%PSA, Lipinski score, Distribution 
coeff, Dose, Do (see Figure 12) 
11 PLS models or decision trees. 73 (73/0/0) 
Cross-Validation (CV) 
performed 
Branchu et al.42 
MW(+), #RoBo(+), HAcc(+), 
PSA(+), Tm(+), logS(-), logP(+), 
HLB(+), HDon(+) 
PLS model to guide formulation selection for poorly 
soluble compounds. 
56 (56/0/0) 
CV performed 
Kuentz et al.43 
A
m
o
rp
h
o
u
s 
–
 G
F
A
 
Mv(+), Tg(+) MV and Tg found to correlate with disordering 
potential. Mv indicates geometric constraint and Tg 
believed to indicate resistance to recrystallization 
17 (17/0/0) Lin et al.16 
XMOD(+), VAR(+), Whete(+), # 
benzene rings(-) 
Branching of carbon skeleton, molecular symmetry, 
distribution of electronegative elements, number of 
benzene rings 
32 (16/16a/0) Mahlin et al.44 
MW(+), #RoBo(+), ∆Hfus(-), ∆Sfus(-
), Tm(-), Tg,  ∆Gv(+) 
Parameters investigated showed no strong correlation 
with GFA or glass stability, suggesting that they may 
not be ideal for prediction purposes. The GFA 
classifications were made using experimental 
techniques, and ultimately, no model using 
descriptors was built. 
51 (N/A) Baird et al.96 
MW(+, 300 g/mol) MW alone predicted GFA with 84% accuracy 101 (33/17/51a) 
CV performed 
Mahlin et al.45 
T_Grav3_3D(+, 15.5) T_Grav3_3D reflects size, shape, and bulk properties 
of molecule and allowed prediction of GFA with 86% 
accuracy. 
131 (100/31/0) Alhalaweh et al.46 
MW(+, 200-300 g/mol), pi Fukui 
index(-, 14), presence of ring 
structures excluding benzene(+, 
Y/N) 
MW from 200-300 g/mol showed decreased 
prediction accuracy. A decision tree was developed 
using molecular descriptors to improve predictions in 
this range. Fukui index indicates tendency of an atom 
to lose electron. 
  
 
5
0
 
Table 1 (continued) 
 
Molecular Descriptors 
(correlation direction and/or 
cutoff value, if reported) 
Description 
 
# of compounds  
(train/ test/ 
validation) 
Reference 
A
m
o
rp
h
o
u
s 
–
 P
h
y
si
ca
l 
S
ta
b
il
it
y
 
∆Sconfig(+) Stability of glass above Tg may not be related to stability below Tg. 12 (12/0/0) Graeser et al.113 
MW(+), Tg(+), Tcr(+) Sigmoidal relationships were identified between these descriptors and 
stability after 1 month in dry conditions. 
24 (24/0/0) Mahlin et al.45 
MW(+, 200 g/mol): Class I 
∑Hückel_pi_C(+), HAcc(+): Class 
II & III 
PCA model applying a SVM algorithm used to classify between 
crystallization tendency classes II and III. 
77 (61/16/0) 
CV performed 
Alhalaweh et al.46 
MW(+), ∆Hfus(-) Several models were developed (e.g., see equation (15)). Model 6 used 
the descriptors indicated to the left, and showed the best correlation with 
physical stability using more easily acquired variables. 
25 (25/11a/0) Nurzyńska et al.47 
MW(+), #RoBo(+), ∆Hfus(-), 
∆Sfus(-), Tg(+), ∆Gv(+) 
PCA models were developed in an attempt to predict classifications of 
crystallization tendency. 
96 (93/3/0) 
CV performed 
Van Eerdenbrugh 
et al.97 
Tg(+), Molecular flexibility(+), 
HDon(-)  
General rules deduced from models constructed from stability data 
(40°C/75%RH) for ASDs created using multiple polymers and 
preparation methods. 
10 (10/0/0) 
CV performed 
Fridgeirsdottir et 
al.114 
A
S
D
 
R3m(+) May give an indication of electronegative atoms along periphery and 
their separation distance. 
15 (12/3/0) 
CV performed 
Moore et al.48 
PSA(-), DECC(-), MOR21v(-), 
DP06(-), MATS6m(-) 
Descriptors helped to identify molecule polarity, shape, size, 
eccentricity, and atomic mass distribution as being potentially important 
for solubility in lipid excipients. 
30 (20/10/0) 
CV performed 
Persson et al.115 ICR(-), JG16(+), MOR21v(-), 
PSA(-) 
Tm(-), nN(-), nDB(-) 
Abbreviations: An (absorption number), ClogP (calculated logarithm of the partition coefficient), CV (cross-validation), DECC (eccentric), Dn (dissolution 
number), Do (dose number), DP06 (molecular profile no. 06), ∆Gv (free energy difference between the crystalline and amorphous states), HAcc (hydrogen 
bond acceptors), HDon (hydrogen bond donors), ∆Hfus (enthalpy of fusion), HLB (hydrophilic-lipophilic balance), ∑Hückel_pi_C (sum of the absolute values 
of the Hückel pi atomic charges for only carbon atoms), ICR (radial centric information index), JG16 (mean topological charge index of order 6), logP 
(logarithm of the partition coefficient), logS (log of the aqueous solubility), MATS6m (Moran autocorrelation lag 6 weighted by atomic masses), Mor21v 
(3D-MoRSE signal 21 weighted by atomic van der Waals volumes), nDB (number of double bonds), nN (number of nitrogen atoms), PSA (polar surface 
area), R3m (R autocorrelation of lag 3 weighted by atomic masses), #RoBo (number of rotatable bonds), ∆Sconfig (configurational entropy), ∆Sfus (entropy of 
fusion), Tcr (crystallization temperature), T_Grav3_3D (topological equivalent of cube root gravitational index), VAR (variation), Whete (Wiener-type index 
from electronegativity weighted distance matrix), XMOD (modified Randic connectivity index). 
Bolded descriptors/properties indicate those which may require experiments to determine. 
 (a) Indicates test or validation data sets which were obtained from the literature. 
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2.4.2.  Amorphous Systems 
2.4.2.1.  Glass Forming Ability 
Glass forming ability (GFA) is defined as “the ease of vitrification of a liquid on cooling.”96 
Poor glass formers rapidly recrystallize on cooling, while good glass formers will persist in the 
amorphous form through the cooling process, and beyond. GFA can give an indication of the 
physical stability of a drug during processing, and for example, inform the likelihood of 
recrystallization during melt-extrusion. Prediction of this property may, therefore, be useful in 
identifying materials most suitable for ASD formulations.96  
Mahlin et al.44 developed a model to predict GFA using a PLS discriminant analysis model. 
Sixteen compounds were classified as either glass formers or non-glass formers based on 
experimental inferences made after processing using 3 different methods. The final model 
contained 4 molecular descriptors (see Table 1), which the authors related to the size, symmetry, 
branching, distribution of electronegative atoms, and the number of aromatic rings. The training 
set performed quite well with a misclassification rate of approximately 6%. The test set was 
obtained from literature and resulted in 25% misclassification of GFA. It is important to note that 
the test set used a different technique to generate amorphous samples. The source of the test set 
was Lin et al.,16 who investigated amorphization potential using cryomilling. In contrast, Mahlin 
et al.44 used spray drying, melt quenching, and repeated compression cycles in a tableting machine 
to induce glass formation for the training set. Although the authors generally found similar 
outcomes for all of the methods applied, comparing the outcome of these different processes could 
be detrimental. Even for the two amorphization processes involving mechanical activation, it is 
 52 
 
possible that the different stress states inherent to cryomilling, versus compaction (e.g., impaction 
force, extent of normal and shear stresses, sample size, thermal effects, etc.), were not captured in 
the PLS model. This may account for the increased misclassification rate for the test set, since PLS 
models are unsuited for extrapolation.116 Nevertheless, the model appears to perform relatively 
well for the prediction of GFA, and may have identified some properties important for GFA. For 
example, the Whete descriptor is related to distribution of electronegative atoms, and may reflect 
the role of hydrogen-bonding pattern in glass formation.44  
Molecular descriptors have also aided the identification of molecular size as important 
factors for GFA. Lin et al.16 previously showed that a combination of molar volume (Mv) and Tg 
could be used to predict amorphization caused by high-shear mechanical processing. In other 
studies, GFA was also found to be more likely for compounds having high molecular weight (MW) 
and complex molecular structure,96, 97 and Mahlin et al.45 noted that MW alone was a significant 
predictor of GFA. Alhalaweh et al.46 extended this work by showing that MW was generally an 
excellent predictor of GFA except in the 200-300 g/mol range. Figure 13 gives a visual 
representation of the relationship of Mv and MW with GFA.  
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Figure 13: The relationship of GFA with Mv and MW. (a) A logistic regression model predicting 
amorphization by mechanical activation. Adapted from the Journal of Pharmaceutical Sciences, 
Vol 98(8), Y. Lin, R.P. Cogdill, P.L.D. Wildfong, Informatic Calibration of a Materials Properties 
Database for Predictive Assessment of Mechanically Activated Disordering Potential for Small 
Molecule Organic Solids, Pages No. 2696-2708, Copyright 2009, with permission from Elsevier.16 
Error bars are included where Tg was predicted from Tm. (b) Relationship between MW and GFA. 
A cutoff of 300 g/mol is indicated by the red dotted line. 50 compounds are shown with 90% 
correctly sorted using MW alone. Reprinted from the European Journal of Pharmaceutical 
Sciences, Vol 49(2), D. Mahlin, C.A.S. Bergstrӧm, Early drug development predictions of glass-
forming ability and physical stability of drugs, Pages No. 323-332, Copyright 2013, with 
permission from Elsevier.45 (c) MW is a good predictor of GFA except in the 200-300 g/mol range 
(based on data obtained from Alhalaweh et al.46). 
 
Alhalaweh et al.46 attempted to further improve the GFA prediction accuracy for 
compounds having MW ranging between 200-300 g/mol using molecular descriptors. Through the 
application of support vector machines (SVM), the authors found that several descriptors helped 
to improve prediction accuracy (Table 1). The authors also attempted to use molecular descriptors 
to predict GFA when excluding MW from the model to avoid bias. A single descriptor, the 
topological equivalent of the cube root of the gravitation index (T_Grav3_3D), was able to classify 
GFA with 86% accuracy. Like MW, T_Grav3_3D is also related to the size and shape of the 
molecule; however, it appeared to achieve better prediction accuracy than MW, suggesting that it 
may have captured additional information about the molecule related to GFA. Notably, the authors 
did not evaluate the correlation between MW and T_Grav3_3D. As shown in Figure 14, these 
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variables appear to be highly correlated, making the true benefit of T_Grav3_3D over MW unclear, 
as it is possible that the improved model performance occurred by chance. Additional data, 
especially for compounds within the 200-300 g/mol range, as well as those having lower MW 
should be examined to ensure that the improved prediction using T_Grav3_3D is not the result of 
random chance. 
 
 
Figure 14: High correlation observed between MW and T_Grav3_3D. (a) The linear and 
logarithmic relationship between MW and T_Grav3_3D indicates that the improved prediction of 
GFA using T_Grav3_3D may have occurred only by chance. (b) The residuals vs. predicted plot 
shows a potential violation of the assumption of linearity. (c) Logarithmic transformation of MW 
appears to correct this. These figures were based on data obtained from Alhalaweh et al.46  
 
2.4.2.2.  Physical Stability 
The physical stability of glasses is equally important to the development of amorphous-
based formulations as GFA. In this case, physical stability refers to the persistence of the formed 
glass with respect to time, beyond its initial formation. Accurate prediction of physical stability 
would allow formulators to take a more informed approach, with the potential to significantly 
reduce financial and time investment.  
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Previous studies investigated relationships between thermodynamic parameters and 
stability. For example, Graeser et al.113 argued for a deviation from the more common case-study 
approach of formulation development, and attempted to identify general thermodynamic and 
kinetic parameters important to physical stability. In this case, configurational entropy was found 
to correlate best with physical stability for samples stored above Tg.
113 It is notable, however, that 
physical stability is multifactorial, and Laitinen et al.117 compiled a useful table of factors and 
relevant references for many of these factors, including molecular mobility, entropic barrier to 
crystallization, enthalpic driving force, hydrogen-bonding, etc. Readers are also directed to 
reviews by Bhugra et al.118, Janssens et al.,119 and Baird et al.120 for additional information 
regarding kinetic and thermodynamic factors that have been considered with respect to glass 
physical stability. Unfortunately, many of these terms require determination using rigorous and 
precise experimentation; even then, conflicting results indicate no clear correlation between these 
parameters and physical stability. For example, Graeser et al.113 found that conformational entropy 
correlated well with physical stability (r=0.83), while Nurzyńska et al.47 observed essentially no 
correlation (r=-0.05).  Nurzyńska et al.47 also noted a positive correlation between physical 
stability and the number of aromatic and aliphatic rings, whereas Mahlin et al.44 observed a 
negative correlation. Molecular descriptors may offer a method for rapid prediction of physical 
stability in the amorphous state without the need for more complex and time-consuming 
experiments, which may lead to such variable conclusions.  
Baird et al.96 and Van Eerdenbrugh et al.97 classified the crystallization tendency of many 
APIs, designating class I, II, and III respectively for rapid, intermediate, and slow crystallization 
tendencies. Crystallization tendency was also investigated as an indicator for physical stability of 
the amorphous form, suggesting that class III compounds were more likely to remain physically 
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stable (and, therefore, be more suitable for ASD formulations) than class I compounds.97 
Crystallization tendency from undercooled melts can be experimentally determined using DSC as 
described by Baird et al.,96 but descriptors were also investigated in an attempt to identify 
physiochemical properties important to crystallization tendency . In their study, Baird et al. built 
a PCA model for predicting crystallization tendency using seven physiochemical properties (Table 
1). Some differentiation in crystallization tendency was observed, indicating that multiple 
physiochemical properties played a role in crystallization tendency96 (Figure 15a). Class I 
molecules tended to have lower MW and fewer rotatable bonds compared to class III molecules.96 
Additionally, class I molecules had higher Δ𝑆𝑓𝑢𝑠, Δ𝐻𝑓𝑢𝑠, and lower Δ𝐺𝑣 values on average than 
class III molecules.96 However, the model could not sufficiently separate classifications of 
crystallization tendency to justify its application for prediction.  
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Figure 15: Principal component analysis model scores plots colored according to crystallization 
tendency: (a) From undercooled melts (Adapted from the Journal of Pharmaceutical Sciences, Vol 
99(9), J.A. Baird, B. Van Eerdenbrugh, L.S. Taylor, A Classification System to Assess the 
Crystallization Tendency of Organic Molecules from Undercooled Melts, Pages No. 3783-3806, 
Copyright 2010, with permission from Elsevier).96 (b) From rapid solvent evaporation (Adapted 
from the Journal of Pharmaceutical Sciences, Vol 99(9), B. Van Eerdenbrugh, J.A. Baird, L.S. 
Taylor, Crystallization Tendency of Active Pharmaceutical Ingredients Following Rapid Solvent 
Evaporation—Classification and Comparison with Crystallization Tendency from Under cooled 
Melts, Pages No. 3826-3838, Copyright 2010, with permission from Elsevier).97 Class I (red), class 
II (blue), class III (green). Diamonds represent individual molecules and triangles represent 
averages of each class. Note: 3 principal components were used to generate both models, but the 
3rd principal component is not shown since it did not contribute to discrimination.96  
 
Van Eerdenbrugh et al.97 continued this research by investigating crystallization tendency 
during rapid solvent evaporation. In general, classifications of crystallization tendency were 
consistent between preparation methods.97 The PCA model generated in this case showed some 
additional separation of classes, especially between classes I and III (see Figure 15b). The authors 
then built an individual three-component PCA model for each class (i.e., soft independent 
modeling of class analogues, ‘SIMCA’), which showed greater potential for discrimination of class 
I from class II, indicating that easily accessible descriptors could be applied to predict 
crystallization tendency.97 It is possible, however, that the individual PCA models were negatively 
influenced by the size and distribution of their datasets. For example, the class II PCA model was 
generated using data from only 11 compounds and, if by chance these compounds were not 
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representative of the population of class II compounds, the resulting PCA model might not be as 
useful for prediction. For example, Nurzyńska et al.47 examined data for 1327 poorly water-soluble 
drugs, which were obtained from the DrugBank112 database. Data for each available property was 
entered into a PCA model and subsequently clustered. One drug from each cluster was selected 
for the test set, and finally, the distribution of the test set was compared to the population to ensure 
the test set had a representative distribution. A PCA model using data confirmed to be 
representative of the broader population will be less likely to suffer from insufficient variability. 
Alhalaweh et al.46 also attempted to predict crystallization tendency to make inferences 
about physical stability. The authors found that class I molecules could be identified using MW 
alone (<200 g/mol), however, MW was not useful for distinguishing between class II and III 
compounds. In this case, a model was developed using two descriptors (see Table 1) and SVM 
was applied to identify a classification boundary in the principal component space. This model 
may be useful for future predictions, but again, this is true only if the data included in the training 
set are representative of the population. This concern is illustrated by the misclassifications of class 
II compounds (4/6) in the test set, which appears to be poorly predicted using the current model. 
Incorporation of the test data into the calibration set would likely result in a significant change to 
the SVM boundary. Nevertheless, the potential application of this type of model was well 
illustrated by the authors, and addition of more poorly soluble compounds could result in a more 
stable model boundary. 
Mahlin et al.45 also found a strong relationship between physical stability and 
crystallization temperature for amorphous compounds stored below Tg. Glass transition 
temperature and MW also resulted in a reasonable prediction, having 78% accuracy. 
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Unfortunately, these models were not tested using an independent data set, so further research is 
necessary to confirm their broader application.  
These studies have shown the potential for the application of molecular descriptors for 
prediction of physical stability, where Table 1 summarizes the molecular descriptors used to this 
end.  MW appears to be a very useful descriptor for physical stability, due to its recurring presence 
across several models. Descriptors that may indicate the number or strength of hydrogen bond 
interactions (e.g., HAcc, Δ𝐻𝑓𝑢𝑠) and molecular mobility (e.g., Tg) also appear in these models with 
some frequency. 
 
2.4.3.  Amorphous Solid Dispersions 
A method for reliably predicting the dispersability and stability of amorphous dispersions 
would be very beneficial to drug development efforts. Application of molecular descriptors may 
also advance scientific understanding of binary ASDs.  
Moore and Wildfong48 investigated the use of molecular descriptors for the prediction of 
solid dispersion potential of twelve API with PVPva prepared by melt-quenching. A single 
molecular descriptor, R3m (the atomic mass weighted 3rd order autocorrelation index), was found 
to correlate well with dispersion potential, and a logistic regression model applying this descriptor 
correctly predicted the dispersability for all compounds, including 3 additional test compounds. 
Unfortunately, the physical reasons for the predictive accuracy of the R3m descriptor were not 
obvious.48 It is also important to note that the applicability of the R3m model was restricted to the 
design space of the existing model. For example, the molecular descriptors were calculated only 
for the API molecules, so the properties of the polymer were not considered. If R3m describes 
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some combination of complex interactions between the API and polymer, these will likely change 
if a different polymer is selected. Finally, caution is necessary when screening a large number of 
independent variables. Moore et al.48 used the E-Dragon software containing 1602 descriptors to 
screen against observations of dispersion formation. As the number of independent variables tested 
against the dependent variable increases, the probability of incorrectly rejecting the null hypothesis 
(i.e., that no correlation exists) is much larger than the initial level of significance, and continues 
to grow with each test made.50 An adjustment of the significance level using multiple comparison 
corrections (e.g., Bonferroni method) is advised to avoid selecting an erroneous independent 
variable by chance.50  While the R3m descriptor appears promising for the prediction of 
dispersability in PVPva using the melt-quench technique, model expansion is necessary to confirm 
its statistical validity.  
Persson et al.115 investigated the solubility of API in lipid-based formulations. While this 
research did not examine ASDs specifically, the work illustrates the potential benefit of molecular 
descriptors for predictions of solubility in binary systems. The authors experimentally determined 
the solubility of 30 API in four commonly used lipid carriers. PLS models, as well as multiple 
linear regression (MLR) models, were successfully generated for two of the lipids (soybean oil 
and Captex355) using molecular descriptors and API Tm. These models indicated that size, shape, 
topological charge, polar surface area, number of double bonds, and number of nitrogen atoms 
contributed to API solubility (see Table 1). Unfortunately, models were successfully built for only 
two of the four lipids. The authors cite the low variability in the API solubility in these two 
lipids,115 illustrating the importance of carefully selecting compounds for the calibration data set.   
Consideration of the studies above suggests certain emerging patterns. The R3m descriptor 
used to model API dispersability in PVPva is expected to increase in magnitude when a molecule 
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has peripheral electronegative atoms positioned such that their interatomic distances are 
minimized.48 Additionally, the Whete descriptor, useful for predicting GFA, was also related to 
the distribution of electronegative atoms in a molecule.44 There are some additional parallels 
between the models, specifically with respect to molecule shape, eccentricity, and polar surface 
area, illustrating the potential usefulness of molecular descriptors.  
 
2.4.4.  Limitations of Molecular Descriptors 
Modeling physical phenomena using molecular descriptors is not without limitations. A 
common criticism of these models is often made when the descriptors are applied in circumstances 
where a connection to well understood physical properties is unclear. However, Todeschini and 
Consonni argue that the usefulness of molecular descriptors is not limited to cases for which they 
are easily interpretable,35 rather the inability to understand descriptors using well-established 
chemical concepts might instead help to reveal new concepts.35 Even so, it is prudent to apply 
descriptors with caution when no clear understanding of their meaning can be found, and models 
should only be accepted once their usefulness for prediction has been well established. This can 
be accomplished through appropriate model testing and validation to avoid issues such as 
overfitting, and to increase statistical certainty. Model validation is essential to confirm its 
applicability for prediction.116 At a minimum, cross-validation should be performed; even then, a 
useful descriptor should be further investigated to elucidate the underlying reason for its efficacy.   
Development of molecular descriptor models requires careful consideration of the 
assumptions inherent to the applied model to avoid inadvertent incorporation of errors. 
Additionally, inclusion of practically unimportant, but statistically significant predictors can 
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negatively impact both model interpretation and prediction accuracy.50 For example, MLR is 
commonly used in an attempt to better describe the response variable by using additional 
explanatory variables,121 but should be accompanied by examination of variable multicollinearity 
to prevent generation of highly unstable regression coefficients, and, consequently, inaccurate 
predictions.50 In recent work by Nurzyńska et al.47 several different models were developed using 
MLR, and the model that was expected to have the greatest prediction accuracy is shown in 
Equation (15):  
 
(15)             log(Solubility) = −0.02Tm −  0.05Hfus +  0.03Tg +  0.28Gconfig −
                                     0.01τ +  0.03HDon − 0.28ClogP +  0.17 CHA +  6.42 
 
Above, Tm is the melting temperature, Hfus is the entalpy of fusion, Tg is the glass transistion 
temperature, Gconfig is the configurational free energy, τ is the relaxation time, HDon is the number 
of hydrogen bond donors, ClogP is the calculated logarithm of the partition coefficient, and CHA 
is the ratio of carbon atoms to heteroatoms. The model included melting temperature and glass 
transition temperature as separate parameters, however, these two terms are correlated to the extent 
that Tm can be used to predict Tg.
110, 111 Although the results of this work predicted solubility 
reasonably well, inclusion of collinear terms in the model may negatively impact predictions due 
to unstable regression coefficients.  
Modeling of the physical stability of amorphous solids is also common.47, 113 Some caution 
is warranted with respect to linear regression approaches in that both the dependent and 
independent variables are assumed to be continuous. Typically, physical stability is assessed by 
analyzing samples at specific time points (e.g., 1 week, 1 month, 2 months, etc.), which bins the 
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data in such a way that the independent variable (stability) is no longer truly continuous.  Likewise, 
the common means of measuring physical stability is to report amorphous content as percentages 
with respect to time.  Since the variable is bounded (i.e., between 0% and 100%) a linear model 
may result in difficult to interpret values (e.g., <0% or >100%).  
Despite some limitations, application of molecular descriptors may help to elucidate 
properties that are important for the formulation of ASDs. Future work might involve the 
expansion of existing models to strengthen their validity, investigation of model applicability for 
different polymers, and advancement of the understanding of relevant descriptors via correlation 
with physical properties. Ultimately, application of molecular descriptors may be limited until they 
can be associated with specific physical and/or chemical properties. 
 
2.5.  Molecular Modeling 
Molecular modeling is the study of “molecular structure and function through model-
building and computation.”122 Molecular systems are most often modeled using molecular 
mechanics, which assumes that cumulative physical forces can be used to describe molecule 
geometries and energies.98 Molecular energy is assumed to be expressed as the sum of potentials 
derived from physical forces, and these potentials are described using force fields (FFs).122 FFs 
estimate forces between interacting atoms, considerably increasing the speed of calculations 
relative to quantum mechanical models.123 Molecular dynamics (MD) is the application of 
molecular mechanics to observe system behavior over time. For additional details of molecular 
modeling and MD, readers are referred to the cited literature.122-124 Modeling and simulation can 
help connect microscopic mechanisms with the collective properties of a system.124 Ultimately, 
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the goal of applying molecular modeling to ASDs is to observe the microscopic interactions of a 
system in an attempt to explain what is experimentally observed at macroscopic scales, such as 
physical stability or phase separation. For this reason, molecular simulations are expected to be an 
important tool for the future of ASD development. 
 
2.5.1.  Molecular Modeling and Dynamics to Aid Existing 
Prediction Methods 
Many of the methods described above for predicting compatibility of API and excipients 
for ASD formulations can be enhanced using molecular modeling. For example, estimates of 
solubility parameters have been made using molecular modeling and MD. Huynh et al.125 
calculated the solubility parameter using MD simulations, since it was expected that these would 
result in more accurate values owing to the consideration of specific interactions between atoms. 
The authors concluded that MD was a useful method for ranking excipients by their potential to 
stabilize specific API. Langer et al.126 applied MD simulations to aid prediction of miscibility in 
order to address regions of low confidence for solubility parameter predictions (i.e., the Δ𝛿 8-15 
√𝑀𝑃𝑎 range). MD simulations led to the identification of a new potentially useful parameter; the 
polar interaction term (Pi).
126 Gupta et al.127 also applied MD simulations to calculate solubility 
parameter values, which agreed well with GC methods, and are potentially applicable in the 
absence of GC values.  
Molecular modeling and MD have also been used to improve calculations of the FHIP. 
Pajula et al.128 applied Monte Carlo simulations to rapidly determine the temperature-dependent 
FHIP for 1122 compound pairs, an approach that was extended in a later article where the authors 
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predicted phase separation in binary mixtures using a computational approach to calculate the 
FHIP.129 The method correctly predicted immiscibility in 7/8 compounds. Patel et al.130 later 
applied MD to calculate both solubility parameter and FHIPs, leading to the suggestion that the 
MD-FHIP approach was superior owing to its consideration of the local packing environment of 
API and polymer, with predictions that were consistent with experimentally determined solubility 
for both of the drug-polymer systems examined. This assertion was supported in a later study by 
Xiang and Bradley where the authors showed that the experimental data available for 
indomethacin:PVP dispersions were best predicted using FHIPs calculated from MD simulations, 
since the strong interactions between the polymer and API were captured.131 
Perhaps the most important benefit of molecular modeling is its ability to include 
directional interactions into the Flory-Huggins and solubility parameter values.127 In addition, MD 
can be used to calculate these parameters at different temperatures, and the calculations are not 
limited by availability of GC values.127 Variability due to changes in molecule conformation can 
also be accounted for using molecular modeling.129 It is expected that inclusion of these additional 
complexities will result in more reliable predictions of miscibility.  
The limitations of molecular modeling and dynamics are also apparent in the combinations 
of molecules studied in the cited literature. In general, these reports examined only binary mixtures 
of small molecules, with the exception of a few publications, such as those of Gupta et al.127 and 
Xiang et al.132, 133 This was a result of the increased complexity of large molecules (e.g., polymers), 
and the subsequent requirement for extended simulations. These limitations currently prevent the 
application of MD for screening large numbers of small molecules against realistic representations 
of polymers.  
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2.5.2.  Molecular Modeling of Binary Systems – Novel 
Approaches 
While MD involving large molecules such as polymers requires extensive computation 
time, use of small molecule analogues, characteristic of the polymer (e.g., monomers or dimers), 
can enable much more complex modeling. Docking has been proposed as a method for rapidly 
screening molecules for crystallization inhibition of API, a method most often applied in the 
pharmaceutical industry to aid virtual screening. For more information on docking, readers are 
referred to the cited review.134  
Pajula et al.135 hypothesized that small molecule additives (or ‘inhibitors’) having 
computationally determined high binding affinity on crystal API surfaces would slow nucleation 
and crystal growth, resulting in increased amorphous stability. The authors assumed that 
complicating effects of steric forces and anti-plasticization were not possible since the compounds 
examined had low molecular weight, relative to well-known inhibitors such as polymers.135 
However, this assumption could be violated if the presence of inhibitor molecules impacts the 
availability of free API molecules for crystal growth, since the relative concentration of inhibitor 
molecules in the melt will increase as the API continues to crystalize. Additionally, the authors 
measured the crystallization rate by polarized light microscopy, which may have proven 
quantitatively challenging in this case due to the speed of crystallization. The potential for both 
components in the mixture to simultaneously crystallize could also complicate the assessment of 
crystallization rate for a single phase. Nonetheless, application of docking to ASD formulation 
development is novel, and may aid rapid identification of potential interactions between polymer 
and API without the need for more computationally intensive methods.  
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Density functional theory (DFT) uses a quantum mechanical approach, and, therefore, 
includes representations of electron density with a balance of accuracy and computational 
requirements.122 Maniruzzaman et al.136 applied DFT to identify possible non-covalent bonding 
interactions between API and monomers of potential polymers. Their predictions were confirmed 
using X-ray photoelectron spectroscopy, demonstrating that this modeling technique could be used 
to predict both the presence of non-covalent interactions, and their strength. Nie et al.137 also 
successfully applied DFT modeling to support understanding of clofazimine:hypromellose 
phthalate interactions, ultimately identifying the most probable conformation of interactions 
between the species. The use of simplified molecular substitutes for the polymer (e.g., monomers), 
however, may not completely capture API:polymer interactions. For example, long chain polymers 
will have the ability to take on many conformations, and steric effects could reduce the amount of 
sites available for hydrogen bonding. A long-term study would be useful to identify if the 
calculated strength of interactions translates into extended physical stability.  
 
2.5.3.  Limitations of Molecular Modeling & Dynamics 
Molecular modeling and dynamics are expected to become an increasingly important tool 
for ASD formulation development; however, there are several limitations to these techniques that 
must be recognized. The first of these is the steep learning curve that accompanies their use, and 
the resulting potential for their misuse. For example, appropriate application of MD simulations 
can require extensive experience to avoid erroneous conclusions. Starting conditions such as the 
number of molecules and system dimensions must be carefully selected to balance real-world 
systems and computational complexity. The importance of starting conditions is illustrated in the 
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study by Patel et al.130 The authors noted that for systems containing large molecules such as 
polymers, there is insufficient time to undergo very drastic reorientation and relaxation.130 It was 
necessary, in this case, to have the starting conditions be as representative of the equilibrium state 
as possible, since equilibrium could not be computationally achieved within a reasonable time. 
Correspondingly, the authors selected the starting conditions of their system using well accepted 
approximations and experimental evidence.130 Additionally, constraints may need to be applied to 
certain degrees-of-freedom to reduce computational requirements, and system conditions can be 
maintained using several algorithmic thermodynamic ensembles. Appropriate selection of these 
conditions is necessary to generate meaningful data.  
Perhaps the most important consideration that must be taken into account is appropriate FF 
parameterization, which requires a thorough understanding of the underlying chemistry, 
thermodynamics, statistical mechanics, and the computational tools and algorithms currently 
available. FFs are of utmost importance to MD since they are the only input information 
representing the specific physical properties of the molecules, and result in the simulation of 
physiochemical properties for different systems.124 While empirical FFs have been developed, and 
are continually improved (e.g., CHARMM138, AMBER139), the structural variability of small 
organic molecules often requires time consuming manual parameterization, which is subject to 
errors.123 Crystal structure data can be used to aid this parameterization, as demonstrated for 
indomethacin by Xiang et al.,140 however, solved crystal structures are not always available, so 
parameterization may rely even more heavily on the experience of the scientist. Tools such as the 
CHARMM general FF (CGenFF)141 and FF tool kit (fftk)142 have been developed to facilitate 
parameterization, but the process remains complex. 
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Another consideration of modeling and MD addresses limitations inherent to FFs, even 
after appropriate parameterization. These include inability to describe reactions involving 
electronic rearrangements, such as polarization, bond formation, and bond cleavage.122 Perhaps 
the most restrictive of these with respect to pharmaceutical applications is the exclusion of 
polarization effects. Some FFs, which include polarizability have been developed,143 but these are 
generally focused on biomolecules, and are even more computationally intensive.123 Other 
methods have been proposed that attempt to incorporate polarization, such as DFT (see section 
2.5.2. ), and the conductor-like screening model for real solvents (COSMO-RS).144 COSMO-RS 
has shown reasonable prediction of API solubility in excipients in one study,145 but is beyond the 
scope of this review.  
Finally, while simulation of increasingly complex systems has become possible with 
computational advances, interpretations must be made with caution.  A simulation will always 
provide a result, so it is necessary to consider the limitations of the computation and to compare 
results with other physical models, where available, to ensure that each output is meaningful. For 
example, MD simulations were used to investigate the molecular structure of ibuprofen ASD 
formulations prepared by HME,146 which suggested a new model describing polymer 
conformation in ASDs. This model proposed that polymers formed random coils and API 
interacted on the outside surfaces of these coils, seemingly contrasting the previously established 
theory of polymer entanglement in melts, which is reviewed elsewhere.100, 147, 148 The authors used 
polymer representations containing 20 or fewer monomers to generate their model, which may not 
adequately capture steric effects anticipated to be a driving force behind the entanglement model. 
It is possible that by performing the same simulations using longer polymer chains, the simulation 
results may have more closely aligned with the polymer entanglement model; however, it can be 
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difficult to balance realistic representations of polymer chains with reasonable computation times. 
In the end, new models predicted by MD simulation may be real, or they may be limited by input 
parameters.  Ultimately, it is necessary to not only apply computational tools correctly, but also to 
support computational results with experimental evidence, whenever possible. 
Despite current limitations, molecular modeling and MD can aid exploration of both 
thermodynamic and kinetic interactions important to ASD formation and stability. As 
computational speed increases and new computational methods are developed, modeling and MD 
are expected to become an increasingly important aspect of ASD formulation development.  
 
2.6.  Conclusions 
ASD formulations continue to show significant promise as a strategy to improve the apparent 
aqueous solubility of poorly soluble APIs. Despite this potential, significant barriers to more 
widespread adoption of ASD formulations are extant, owing to the complexity associated with 
predicting whether new chemical entities can form dispersions in suitable polymeric carriers, and 
further estimation of physical destabilization of these materials. Several approaches have been 
established to assist in predicting API:polymer mixtures that form viable ASDs at meaningful drug 
loads, in an attempt to reduce experimental burden, decrease time-to-market, and moderate risks 
assumed with pursuing metastable formulations. Successful future development of ASD 
approaches rests in continued research to better understand the applicability of these predictive 
methods, as replacements for the experimental trial-and-error methods of the past. Ultimately, 
methods that can rapidly direct scientists toward formulations having greater probability of success 
will prove beneficial to both pharmaceutical development and human health.  
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Throughout this chapter, efforts to make predictions about ASD formation and stability were 
discussed, including the use of solubility parameters, Flory-Huggins interaction parameters, 
molecular descriptors, and molecular modeling. Experimental results and predictive methods have 
been described, and limitations addressed, with the intent of reinforcing that no model should be 
used indiscriminately. Although each approach suggests progress in predicting ASD behavior, 
simplifying assumptions, limitations in current analytical methods, lack of diverse supporting data, 
and/or computational limitations indicate that further studies are needed. As research in this 
particular area grows, and as computational modeling capabilities continue to improve, it is 
projected that scientific understanding of the complexities of ASDs will advance as a result, 
leading to improved predictions of ASD formation and physical stability.  
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Chapter 3. Differential Scanning Calorimetry 
Isothermal Hold Times Can Impact Interpretations of 
Drug-Polymer Dispersability in Amorphous Solid 
Dispersions 
As described in the previous chapter, there are many existing methods for the modeling 
and prediction of ASD formation. For models based on experimental data, it is certainly necessary 
to have a good understanding of the analytical methods applied. It is arguably even more important 
to know the limitations of each analytical method. In this chapter some of the potential pitfalls in 
the application of differential scanning calorimetry (DSC) are discussed.  DSC is a commonly 
employed analytical technique for the analysis and characterization of ASDs, however, steps 
typical of standard temperature programs can alter the material in situ. It is important that the 
analyst not misinterpret changes that occur in situ during heating as indicative of the original state 
of the sample. In this chapter data for two active pharmaceutical ingredients are detailed, wherein 
isothermal hold times, traditionally employed to remove thermal history and/or residual solvent, 
were observed to impact the observed dispersability of the compounds in polyvinylpyrrolidone 
vinyl-acetate copolymer (PVPva). Re-crystallized tolbutamide was observed to re-dissolve in 
PVPva, while terfenadine was observed to crystallize during the isothermal hold period. Exposing 
co-solidified drug-polymer mixtures to temperature changes and experimental hold times can 
potentially confound correct categorization of dispersability, particularly when DSC is used as the 
lone characterization technique. This chapter further illustrates the importance of using a suite of 
characterization techniques to improve the certainty of conclusions made with respect to the true, 
initial physical state of a co-solidified mixture,28 while taking care to understand the impact that 
each has on complex analytical data. 
 73 
 
3.1. Introduction 
Amorphous solid dispersions (ASDs) provide a promising formulation strategy for 
improving the apparent aqueous solubility of poorly water soluble drugs.9, 12, 149 Many 
characterization techniques are commonly applied to assess the physical state of ASDs. 
Differential scanning calorimetry (DSC) is one of the most commonly employed, however, this 
method is not without its limitations with respect to characterizing drug-polymer behavior.120 In 
general, the presence of a single glass transition temperature (𝑇𝑔) and the absence of API melting 
is interpreted as evidence of a dispersed system. However, when a drug and polymer have similar 
𝑇𝑔 values, these transitions may overlap merely as a result of the relative proximity of their pure 
component values.120 Additionally, different materials can have variations in the magnitude of heat 
capacity changes (∆𝐶𝑝) and widths associated with glass transition events, potentially exacerbating 
this issue.120 DSC is also known be limited with respect to the domain size of separated phases, 
with estimates that phase separation at domain sizes smaller than approximately 50 nm may go 
undetected.24   
The impact of thermal history may also be detrimental to interpretation of ASD 
characterization data, particularly when applying relationships such as the Gordon-Taylor150 or 
Couchman-Karasz151 equations, where the location of the glass transition temperature for the 
mixture (𝑇𝑔,𝑚𝑖𝑥 ) relative to the pure components is central to subsequent inferences. As a result, 
it is recommended that the thermal history of co-solidified mixtures be erased prior to thermal 
characterization,110 since the position of 𝑇𝑔,𝑚𝑖𝑥  is dependent on the thermal history of the 
sample.152, 153 Likewise, residual water or other solvents has the potential to plasticize 𝑇𝑔,𝑚𝑖𝑥 ,  
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and/or obscure important thermal events as a result of evaporation, and should be removed from 
samples.  
Thermal history erasure and solvent removal can be accomplished in DSC experiments by 
preliminarily ramping to an elevated temperature, e.g., 105 °C,48 which is isothermally maintained 
for a period of time (herein referred to as the “hold time”).  The potential negative impact of such 
a heat treatment was identified by Kerč and Srčič, who advised that care should be taken to avoid 
inadvertently eradicating transitions of interest.110   
 For the present work, it was hypothesized that increasing isothermal hold times prior to 
DSC characterization could impact the experimentally observed dispersability of the drug in 
polymer, where dispersability was defined in Chapter 1 as the observation of a homogeneous 
mixture of API and polymer at the time of characterization, and does not necessarily indicate 
thermodynamic stability of that mixture. The goal of this chapter was to demonstrate that DSC 
hold times, which are often used to erase thermal history and remove moisture or other solvents 
from samples, can lead to erroneous conclusions regarding the initial state of a co-solidified 
mixture. Two API were selected based on their previously established dispersability in 
polyvinylpyrrolidone vinyl acetate copolymer (PVPva). Increasing isothermal holds were shown 
to have the potential to obscure the initial state of the co-solidified mixture by either inducing 
crystallization of the API, or re-dissolution of the API into the polymer. 
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3.2. Materials & Methods 
3.2.1. Materials  
Tolbutamide was purchased from MP Biomedicals (Solon, OH). Terfenadine was 
purchased from Sigma-Aldrich (St. Louis, MO). Kollidon VA64 (PVPva) was a gift from BASF 
(Ludwigshafen, Germany).  
 
3.2.2. Preparation of Co-Solidified Mixtures 
 Co-solidified mixtures were prepared using a standard in-house melt-quench method, 
which has been previously described.48 Briefly, polymer and API were weighed and combined in 
a scintillation vial where they were manually dry blended for a period of approximately 5 min to 
form mixtures reported as w/w ratios. The contents were then transferred to a crucible, which was 
immersed in a silicone oil bath that was held at a preparation temperature (𝑇𝑝𝑟𝑒𝑝) of approximately 
165 °C. This temperature was above the respective melting temperatures of both API, and high 
enough to sufficiently lower the viscosity of PVPva to permit mixing. Molten mixtures of drug 
and polymer were manually stirred approximately every 5 min, and after 30 min, each mixture was 
quenched by immersion of the crucible into an ice water bath under dry nitrogen purge. The 
resulting co-solidified mixture was transferred to a disposable petri dish and stored in a desiccator 
over P2O5 (approximately 0% RH) for at least 18 h. Prior to sample preparation, thermogravimetric 
analysis (TGA) was used to confirm the thermal stability of the API over the planned duration of 
heating (i.e., 30 min at 165 °C) as indicated by weight loss <2%.  
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3.3. Characterization 
3.3.1. Differential Scanning Calorimetry (DSC) 
 A model Q100 DSC (TA instruments, New Castle, DE) was used with a 50 mL/min 
nitrogen purge. Samples weighing ~3-7 mg were placed into Al hermetic pans with punctured lids. 
Enthalpy calibration was performed using In, and temperature calibration was performed using Sn, 
In, and o-terphenyl. The initial DSC method is shown in Figure 16a, in which Step 2 was adjusted 
to investigate the impact of hold time duration on inferences made with respect to the state of the 
co-solidified mixture. As such, further references to ‘hold time’ in this chapter refers specifically 
to the duration of the isothermal hold during Step 2. The ‘pre-heat’ step refers to Steps 1 and 2, 
during which the samples were heated to 105 °C to remove residual moisture and erase thermal 
history (see Figure 16b). In experiments where ‘no pre-heat’ is indicated, Steps 1 and 2 were 
excluded, and the sample was immediately cooled from the instrument standby temperature (40 
°C) to low temperature (𝑇𝑙𝑜𝑤).  At a minimum, 2 replicate samples were tested for each hold time. 
Inferences made with respect to the dispersability of the API in PVPva were based on the presence 
of a single glass transition temperature, and the absence of a melting endotherm.  
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Figure 16: (a) General DSC method, (b) A plot visualizing example DSC methods where  
Tlow = -60°C, c) representative DSC thermograms for tolbutamide:PVPva (3:1 w/w) and d) 
terfenadine:PVPva (3:1 w/w) subject to increasing isothermal holds (105°C) prior to initiation of 
temperature program. 
 
3.3.2. Powder X-Ray Diffraction (PXRD) 
 PXRD patterns were collected using an X’Pert Pro MPD system (PANalytical B.V., 
Almelo, Netherlands) in transmission mode, with an operating voltage of 45 kV and amperage of 
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40 mA.  The instrument was equipped with an elliptical mirror, Cu anode (λ= 1.5406° Å), and 
X’Celerator™ detector. Co-solidified mixtures were placed between two Kapton® films in a ring 
holder and rotated to permit full volume interrogation. Diffractograms were collected using an 
angular step size of 0.017° 2θ over a range of 2 to 100° 2θ, with an irradiation time of 51.04 s per 
step.  
3.3.3. Polarized Light Microscopy (PLM) 
 An Olympus BX-51 optical microscope with dual polarizing filters was used to inspect 
samples for birefringence and to collect photomicrographs. The presence of crystallinity was 
informed by observations of birefringence in prepared co-solidified mixtures. Hot-stage polarized 
light microscopy (HSM) was performed using an Instec HCS 302 Pelletier temperature-adjustable 
stage with an STC 200 temperature controller (Instec, Boulder, CO) to observe the behavior of the 
binary mixtures when exposed to increases in temperature and during isothermal holds at elevated 
temperature (105 °C).  
 
3.4. Results & Discussion 
 Tolbutamide and terfenadine were selected as model compounds owing to their observed 
differences in dispersability with PVPva the day after preparation.48 These conclusions were 
confirmed via repeat preparation and characterization using DSC, PLM, HSM, and PXRD. 
Crystallization of terfenadine in 3:1 w/w terfenadine:PVPva preparations was indicated by 
birefringence observed in the co-solidified solid (see Figure 17a). A small endotherm consistent 
with the melting temperature of terfenadine was also sometimes observed by DSC. In contrast, 
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tolbutamide was dispersable in PVPva one day after preparation as indicated by a single 𝑇𝑔,𝑚𝑖𝑥, 
absence of characteristic diffraction peaks in PXRD diffractograms, and no observable 
birefringence consistent with the melting point of the drug, as informed by PLM and HSM. 
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Figure 17: Characterization of terfenadine:PVPva following 24 h of storage at room temperature 
over P2O5 and with an additional 1 hour storage at 105 °C; (a) PLM image showing small 
crystallites after 24 h over P2O5. (b) PLM image showing significant crystal growth after an 
additional 1 h storage period in an oven at 105°C. (c) DSC thermogram showing a significant 
increase in melting enthalpy after storage at 105°C for 1 h. (d) PXRD diffractograms show no 
detectable crystallinity in the co-solidified mixture after 24 h over P2O5 (green diffractogram), but 
characteristic peaks are apparent after the 1 h storage period at 105°C (orange diffractogram) when 
compared to the diffractogram of crystalline, as received terfenadine (black diffractogram).  
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3.4.1. Isothermal hold times may induce sample 
crystallization 
 Co-solidified samples of 3:1 w/w terfenadine:PVPva mixtures were characterized by DSC 
as described in section 2.3.1. Repeat preparations consistently resulted in the formation of small 
crystallites throughout the co-solidified mixture, whose birefringence was observed by PLM. DSC 
results were less consistent, with up to 3 distinct 𝑇𝑔 values appearing, sometimes accompanied by 
an endotherm consistent with the melting point of the drug. Regular observation of the melting of 
recrystallized drug was expected to be a limitation of sample size, and the relative amount of 
crystalline API sampled from the whole. Nonetheless, as isothermal hold times were increased 
(105 oC for up to 30 min) terfenadine also appeared to recrystallize in situ, with endotherms 
attributable to melting appearing more consistently from sample-to-sample. Figure 16d shows 
representative DSC thermograms of the terfenadine:PVPva samples, demonstrating that increasing 
the DSC experimental hold time resulted in a commensurate increase in the degree of terfenadine 
crystallization. The presence of distinct endothermic peaks may be the result of varying crystallite 
sizes, or the crystallization of multiple polymorphs during sample storage. The likely presence of 
distinct polymorphs of terfenadine was more evident when the experimental ramp rate was reduced 
to 0.5 °C/min, as previously described by Leităo et al.154 (see Figure 54 in the Appendix).  
 The recrystallization of terfenadine induced by holding at 105 °C for different durations 
was further supported by dividing a co-solidified mixture of terfenadine:PVPva in half after 
overnight storage over P2O5. One half was returned to the P2O5 desiccator at room temperature, 
while the other half was placed in an oven maintained at 105 °C for 1 h, after which it was allowed 
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to cool back to room temperature. Figure 17a and Figure 17b respectively show representative 
PLM images of the samples maintained continuously at room temperature and those heated in the 
oven.  The sample heated to 105 °C for 1 h shows that this exposure resulted in substantial 
terfenadine crystallization. DSC analysis (Figure 17c) also showed a significantly larger 
endotherm for the oven-stored sample, relative to the half that was continuously maintained at 
room temperature. PXRD patterns of each subsample are shown in Figure 17d, showing that the 
oven-heated sample contains several diffraction peaks characteristic of terfenadine. 
 HSM was used to visually observe a portion of each co-solidified mixture at 105 °C, in real 
time.  Figure 19 shows a series of images depicting the increasing amount of recrystallized 
terfenadine over time, which becomes visually evident after 15 min at 105 °C on the hot stage 
(Figure 19c) and continues to increase over time. These results show that the co-solidified mixture 
of 3:1 w/w terfenadine:PVPva has the potential to crystallize during isothermal DSC periods 
typically used for the removal of solvent and thermal history. In this case, the crystallization 
appeared to occur slowly enough to avoid detection by DSC, but could be detected using PLM. 
Further characterization of these samples by HSM (Figure 19) revealed that the crystallization of 
terfenadine occurred quite slowly during the hold time, resulting in changes in heat flow over time 
that were apparently below the detection limit of DSC.  While the kinetics of terfenadine 
crystallization at 105 °C may be slow enough to prevent significant deviation from the original 
state of the sample at reasonable hold times in this case, this example demonstrates the potential 
for inadvertent crystallization to occur during thermal analysis, particularly if erasing the thermal 
history is standard protocol, as it often is. It is possible that such a thermal treatment could 
significantly change the physical state of the sample, causing an analyst to come to conclusions 
about the physical state which are inconsistent with its true state at room temperature.  
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3.4.2. Isothermal hold times may induce dissolution of API 
in polymer 
 Co-solidified samples of 3:1 w/w tolbutamide:PVPva mixtures were characterized by DSC 
and consistently showed a single 𝑇𝑔, indicating that the tolbutamide was dispersed in PVPva. 
Increasing the durations of isothermal hold time (105 °C for up to 30 min) showed no detectable 
change in the state of the sample, as shown in Figure 16a. Only the thermogram for the sample to 
which no isothermal hold was applied (i.e., the ‘no pre-heat’ sample) was observably different 
from the others, showing an endothermic event between approximately 60-100 °C, which was 
most likely the result of water loss from the sample.     
 A subsample of the tolubtamide:PVPva co-solidified mixture was subjected to the oven 
experiment as described in the previous section. No birefringence was observed when examined 
using PLM after exposure to 105 °C for 1 h (Figure 18b), consistent with observations for the 
sample of the same mixture continuously maintainted at room temperature (Figure 18a), 
suggesting that tolbutamide did not recrystallize when held at elevated temperatures in the oven. 
This conclusion was supported by both DSC and PXRD analyses, from which representative 
thermograms and diffractograms are respectively shown in Figure 18c and Figure 18d.  
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Figure 18: Characterization of tolbutamide:PVPva following 24 h of storage at room temperature 
over P2O5 and with an additional 1 h storage at 105 °C; (a) PLM image showing no birefringence 
after 24 h over P2O5. (b) PLM image showing no change after an additional 1 h storage period in 
an oven at 105°C. (c) DSC thermogram showing no significant difference after storage at 105°C 
for 1 h. (d) PXRD diffractograms show no detectable crystallinity in the co-solidified mixture after 
24 h over P2O5 (yellow diffractogram), or after the 1 h storage period at 105°C (blue diffractogram) 
as compared to the crystalline, as received tolbutamide (black diffractogram). As received 
tolbutamide was determined to be polymorph I (see Figure 55a in the Appendix, CSD-
ZZZPUS02)155, 156).  
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Figure 19: HSM of terfenadine:PVPva (3:1 w/w) stored at room temperature over P2O5 for 24 h. 
A heating ramp of 10°C/min was applied. (a) 25°C (b) 105°C (c) Isotherm at 105°C for 15 min (d) 
Isothermal at 105°C for 30 min (e) Isothermal at 105°C for 60 min. Crystallization of terfenadine 
is observed. 
 
 Tolbutamide:PVPva co-solidified mixtures were stored in a desiccator over P2O5 for 
approximately 9 months and re-analyzed by PLM, where significant recrystallization of the drug 
was observed (Figure 21a). However, initial re-characterization of aged samples by DSC using a 
2 min hold time at 105 °C appeared to show no evidence of crystallinity in the sample. Elimination 
of the hold time in DSC experiments revealed the rapid dissolution of the tolbutamide crystals into 
the polymer, as evidenced by the endotherm ranging from approximately 40-110 °C in Figure 20, 
which was confirmed by HSM images (Figure 21). During HSM, as the temperature was increased, 
the viscosity of the sample was reduced, and the sample flowed more easily (Figure 21c). 
Dissolution of the crystals was immediately apparent, and after only 1 min at 105 °C (Figure 21e), 
birefringence was no longer observed in the aged samples. Although tolbutamide is known to have 
a low melting temperature polymorph (Form V, Tm ≈ 102 °C157), it was confirmed by PXRD that 
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the endotherm observed in DSC analysis of aged samples was the result of dissolution into the 
PVPva during heating and not melting of a different solid form. The polymorphic form of 
tolbutamide as received, was Form I, while the recrystallized tolbutamide in the aged samples was 
determined to be Form II (Tm ≈ 117 °C158). PXRD data can be found in Figure 55 in the Appendix.  
 
 
Figure 20: 9 month aged Tolbutamide:PVPva (3:1 w/w) DSC analysis 
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Figure 21: HSM of tolbutamide:PVPva (3:1 w/w) aged at room temperature over P2O5 for 9 
months. A heating ramp of 10 °C/min was applied. (a) 25 °C (b) 80 °C (c) 90 °C (d) 100 °C (e) 
isothermal at 105 °C for 1 min. Re-dissolution of the tolbutamide into the polymer is observed. 
 
 In this case, the initial inferences about the dispersability of the tolbutamide:PVPva 
dispersions remain unchanged, owing to the application of a suite of analytical techniques.28 
Characterization of the aged 3:1 w/w tolbutamide:PVPva co-solidified mixtures illustrates the 
potential for DSC hold times to result in rapid re-dissolution of crystalline API into the polymer, 
potentially leading to erroneous conclusions about the initial dispersability of the sample. Similar 
events have been described previously, such as the re-dissolution of felodipine and hesperetin into 
poly(ethylene glcyol) observed by Bikiaris et. al.159 These results suggest that when developing a 
DSC method, each step should be carefully considered with respect to its potential to physically 
influence the sample.  
 Perhaps most importantly, these data also confirm that relying on a single analytical 
method to characterize an ASD is ill-advised, and classification of ASD phase behavior is more 
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appropriately confirmed by multiple analytical techniques.28, 160 As demonstrated here, important 
thermal events can potentially be obfuscated as the sample is subjected to changing temperatures. 
This can result in in situ phase changes such as crystallization or dissolution of crystalline API into 
the polymer, subsequently resulting in erroneous conclusions regarding the true initial physical 
state of an amorphous solid dispersion.  
 
3.5. Conclusions 
 Exposing co-solidified drug-polymer mixtures to temperature changes and experimental 
hold times typical of post-manufacturing solvent removal and pre-DSC thermal history erasure 
can potentially confound correct categorization of dispersability behavior, particularly when DSC 
is used as the lone characterization technique. DSC hold times impacted dispersability conclusions 
by either inducing crystallization of the API (e.g., in the case of terfenadine in PVPva) or by 
causing dissolution of the API into the polymer (e.g., in the case of aged tolbutamide in PVPva).  
The former example illustrates a situation in which a co-solidified mixture might be categorized 
as partially dispersable in PVPva as a result of the DSC method imposed during categorization.  In 
the latter example, tolbutamide might be categorized as fully dispersed in PVPva even after 
extended storage, if the absence of melting in the thermogram was assumed to be from complete 
persistent dispersion in the polymer during preparation, rather than dissolution of residual crystals 
in the polymer at elevated temperatures during the DSC experiment. Relying on any one technique 
will increase the likelihood of erroneous inferences with respect to the true state of the system due 
to the inherent limitations of each analytical technique. The present work illustrates the importance 
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of using a combination of techniques (e.g., DSC, PXRD, PLM, HSM) to improve the certainty of 
conclusions made with respect to the true physical state of a co-solidified mixture.  
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Chapter 4. Modeling and Prediction of Drug 
Dispersability in Polyvinylpyrrolidone-Vinyl Acetate 
Copolymer using a Molecular Descriptor 
Having reviewed the literature for methods for the prediction of ASD dispersion, and 
having discussed the limitations and pitfalls of a particular analytical method, this chapter will 
describe the expansion of a model for the prediction of ASD dispersability using a molecular 
descriptor. This chapter will describe the experiments and data analysis associated with specific 
aim I (confirm the usefulness of the R3m model), and touch briefly on specific aim II (improve 
the interpretability of the model). 
This chapter describes the expansion of a novel in silico model that predicts the 
dispersability of 18 small organic molecule drug substances in PVPva. The molecular descriptor 
R3m (atomic mass weighted 3rd order autocorrelation index) is shown to be predictive of the 
formation of amorphous solid dispersions at two drug loadings (15% and 75% w/w), using two 
preparation methods (melt-quenching and solvent evaporation using a rotary evaporator). Co-
solidified samples were characterized using a suite of analytical techniques, which included 
differential scanning calorimetry, powder X-ray diffraction, pair distribution function analysis, 
polarized light microscopy, and hot stage microscopy. Logistic regression was applied, where 
appropriate, to model the success and failure of compound dispersability in the water soluble 
dispersion platform copolymer PVPva. R3m had a combined prediction accuracy greater than 90% 
for tested samples. The usefulness of this descriptor appears to be associated with the presence of 
relatively heavy atoms on molecules in the API library (e.g., Cl) in the molecular structure of the 
API, and their location with respect to the geometric center of the molecule. Given the higher 
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electronegativity and atomic volume of these types of atoms, it is hypothesized that they may 
impact the molecular mobility of the API, or increase the likelihood of forming non-covalent 
bonding interactions with the carrier polymer.  
 
4.1. Introduction 
 Amorphous solid dispersions (ASDs) are a proven formulation strategy for improving 
dissolution of poorly water soluble drug substances.  This approach has received substantial 
attention owing to the prevalence of water insoluble molecules in current pipelines of the 
pharmaceutical industry.161 There are, however, significant challenges with respect to the 
successful development of ASDs, as evidenced by the relatively few formulations that have been 
approved for human use, since potential benefits to absorption were first observed,3 and the 
pharmaceutical application of solid solutions was first proposed.162 More recently, the number of 
ASDs that have successfully reached the market has increased, nevertheless, limited fundamental 
understanding remains, particularly with respect to issues surrounding their formation and physical 
stability.4  
Several specific and non-specific interactions have been proposed to be of importance with 
respect to successful formation and persistence of ASDs, including crystallization inhibition due 
to a kinetic barrier for nucleation,5 antiplasticization effects that reduce molecular mobility,6 and 
specific non-bonded interactions, such as hydrogen bonding.7, 8 Reliable prediction of ASD 
dispersability, however, remains difficult, particularly with new chemical entities for which 
limited quantities are available during early development. It is ultimately necessary to perform 
extensive experimental studies to confirm that an API can successfully form an amorphous solid 
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dispersion by intimate mixing with a carrier polymer, followed by co-solidification without 
recrystallization (herein referred to as ‘dispersability’). Additionally, confirmation that the 
formulation remains physically stable for pharmaceutically relevant periods of time is important 
for dispersable API in order to estimate product viability. Assessment of dispersability and 
physical stability by trial-and-error is costly, and may not be feasible, depending on the quantities 
of API available. Improved prediction of dispersability has the potential to reduce development 
costs by preemptively identifying promising binary mixtures, thereby reducing the experimental 
burden. If such a ‘go/no-go’ decision can be made before experiments are necessary by identifying 
attributes of an API essential for dispersability in a given polymer, it is expected that development 
costs and time-to-market will decrease.  
Successful dispersability of an API molecule in a polymer matrix likely depends on a 
complex combination of materials properties that facilitate the interactions necessary to form an 
ASD. Molecular descriptors are being investigated to help elucidate those properties that are most 
important for dispersability. It is hypothesized that molecular descriptors most highly correlated 
with ASD formation are reflective of the combined attributes of the API molecule necessary for 
dispersion in a given carrier polymer, in this case, polyvinylpyrrolidone-vinyl acetate copolymer 
(a.k.a. PVPva or copovidone). Previous work showed that a single molecular descriptor (R3m) 
was predictive of solid dispersion potential for a 12-member API library in PVPva48 prepared by 
melt-quenching (M/Q) at a fixed drug loading (75% w/w). Although these initial results were 
promising, it remained uncertain if predictions made using R3m were more broadly applicable. 
The objective of this work was to further examine the usefulness of the R3m molecular descriptor 
as a predictive tool for dispersability of API in PVPva at different concentrations, prepared using 
different manufacturing processes. 
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4.2. Materials and Methods 
4.2.1. Materials 
 Bicalutamide (90357-06-5) was purchased from Enzo Life Sciences (Farmingdale, NY). 
Ketoconazole (65277-42-1) was purchased from Spectrum Chemicals (Gardena, CA). 
Sulfanilamide (63-74-1) was purchased from Acros Organics (Geel, Belgium). Chlorpropamide 
(94-20-2) and Tolbutamide (64-77-7) were purchased from MP Biomedicals (Solon, OH). 
Cloperastine HCl (14984-68-0), Indomethacin (53-86-1), Quinidine (56-54-2), and Terfenadine 
(50679-08-8) were purchased from Sigma-Aldrich (St. Louis, MO). Cimetidine (51481-61-9), 
Felodipine (72509-76-3), Itraconazole (84625-61-6), Nifedipine (21829-25-4), and Propranolol 
HCl (3506-09-0) were purchased from TCI Chemicals (Tokyo, Japan). Melatonin (73-31-4) was 
purchased from Alfa Aesar (Ward Hill, MA). ABT-072 (1132936-00-5), ABT-102 (808756-71-
0), ABT-348 (1227939-82-3) and PVPva (25086-89-9, BASF, Kollidon VA 64 Fine) were 
obtained from AbbVie Inc. (North Chicago, IL). The molecular structures of APIs used in the 
present work are shown in Figure 22. 
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Figure 22: Molecular structures of API in the compound library. 
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4.2.2. Dispersion Preparation 
4.2.2.1. Melt-Quench (M/Q) Method 
 API and PVPva were separately weighed and transferred to a scintillation vial in the desired 
weight percent proportions. The powders were physically mixed for 5 min by manual agitation. 
The entire sample was then transferred to a crucible, which was heated by immersion in a silicone 
oil bath for 25-30 min at a temperature 10°C-15°C above the melting temperature of the API 
(Tm,API). In the event that Tm,API was less than 150°C (for example, melatonin with a Tm,API = 
118°C), the mixture was held isothermally at 165°C to ensure polymer viscosity conducive to 
liquid mixing. Hold times between 25-30 min (as determined by thermogravimetry) were used so 
that no API lost more than 2% weight at the preparation temperature, due to thermal degradation. 
Based on this criterion, no API:PVPva mixture was maintained at temperature for less than 25 
min, during which the molten mixtures were mixed periodically. Finally, the liquid mixtures were 
immersed in an ice water bath under nitrogen purge until hardened (1-2 min). Samples were 
transferred to a 0% RH desiccator containing P2O5 to remove any residual water, as well as to 
prevent moisture uptake and consequent plasticization. All co-solidified mixtures were prepared 
in triplicate and characterized after 24 h. 
 
4.2.2.2. Solvent-Evaporation (S/E) Method 
 A single solvent (methanol) was used to prepare all of the co-solidified mixtures, to avoid 
complicating factors that would result from using a variety of different solvents. These factors 
include variable evaporation kinetics (a longer drying time can promote undesired API 
recrystallization), and changes in molecular-level interactions of solvent with the polymer and/or 
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API. API solubility in methanol was obtained using literature values, where available, or estimated 
by visual inspection. Solids were weighed and transferred to 500 mL evaporating flasks to which 
methanol was added, followed by sonication to aid in dissolution. The flask was then attached to 
a Büchi rotavapor R-210 equipped with a vacuum pump (KNF Laboport, Model N820). The flask 
was immersed in a water bath set to maintain an experimental temperature of 50°C, and oriented 
at an immersion angle that was generally 21°.  For samples in which the solubility of the API in 
methanol was comparatively lower, larger volumes of methanol were required, and the immersion 
angle was adjusted to 28°. Samples were left on the rotary evaporator for at least 1 h after the 
appearance of solid inside the flask. The flask was then stored in a vacuum (approximately -14 
psi) at room temperature with P2O5 to remove residual solvent and moisture. All co-solidified 
mixtures were prepared in triplicate and characterized after 24 h. 
 
4.2.3. Characterization 
 Previous work demonstrated the necessity of using multiple complementary 
characterization techniques to appropriately classify phase behavior of amorphous solid 
dispersions.28, 163, 164 When used independently, the inherent limitations of each method can lead 
to erroneous inferences regarding the true state of the system.165 In the present work, a combination 
of techniques including DSC, PXRD, polarized light and hot stage microscopy, and PDF analysis 
of PXRD data were collectively used for these experiments, to improve the certainty of 
dispersability classifications. The use of this particular suite of analytical techniques to accurately 
categorize solid dispersion behavior was discussed in detail in a previous publication.28 
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4.2.3.1. Powder X-ray Diffraction (PXRD) 
 PXRD patterns were generated consistent with previous work with these systems, to allow 
comparison.48 Diffraction data were collected using an X’Pert Pro MPD system (PANalytical 
B.V., Almelo, Netherlands) in transmission mode, equipped with a Cu anode (λ = 1.5406° Å), 
elliptical mirror, and X’Celerator™ detector. The operating voltage and amperage were set to 45 
kV and 40 mA, respectively. Samples were held between two Kapton® films, mounted in a ring 
holder and rotated throughout experimentation, to allow for full volume interrogation. Irradiation 
time was set to 51.04 s per step with an angular step size of 0.017° 2θ over a range of 2 to 100° 
2θ. A total of three PXRD patterns were collected for each preparation.  
 
4.2.3.2. Differential Scanning Calorimetry (DSC) 
 A model Q100 DSC (TA instruments, New Castle, DE) was regularly calibrated using  
o-terphenyl, In, and Sn to perform a three-point temperature calibration. Enthalpy calibration was 
performed using In. N2 was used as the purge gas during all experiments, at a rate of 50 mL/min. 
Solid samples were weighed (3-7 mg) into Al hermetic pans with pin-holed lids, which were 
subsequently crimped. The experiments began with a 20°C/min heating ramp to 105°C, followed 
by a 2 min isothermal hold to expel residual moisture and erase thermal history. The sample was 
then cooled at a rate of 20°C/min to -20°C, or a temperature at least 20°C below the glass transition 
temperature of the API to allow baseline equilibration. The sample was then heated at 20°C/min 
to Tm,API + 10°C, and all thermal events were identified and interpreted. At least three separate 
DSC measurements were performed on samples from each solid preparation. 
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4.2.3.3. Microscopy 
 An Olympus BX-51 optical microscope with dual polarizing filters was used to observe 
samples and collect photomicrographs. Birefringence informed the presence of crystalline API in 
prepared samples. To confirm that the crystallinity was associated with the API, a portion of each 
sample was also heated at 10°C/min to a temperature above Tm,API using an Instec HCS 302 
Pelletier hot stage with an STC 200 temperature controller (Instec, Boulder, CO). Hot-stage 
microscopy was also used to corroborate DSC data, as it allowed visual observations of the samples 
during non-isothermal experiments. 
 
4.2.3.4. Pair Distribution Function (PDF) 
 The pair distribution function is a total scattering technique which is well described 
elsewhere.26 Its application in the pharmaceutical sciences has also been previously described,166, 
167 and its usefulness to help differentiate between phase-separated and fully disperse systems has 
been previously shown.48, 166, 168 PDF transforms of PXRD data were performed for each individual 
amorphous component, as well as for the co-solidified mixtures. Diffraction patterns having 
crystalline peaks were excluded from PDF analysis. Where pure component amorphous API solids 
could not be prepared, usually owing to very rapid recrystallization, PDF analysis could not be 
performed. The PDF transforms for the independent components were linearly combined and 
compared to the PDF transform of the co-solidified mixture. When a system is fully dispersed, it 
is expected that the short range order would change relative to that of a physical mixture of the 
same individual components, owing to the well distributed, intimate intermingling of polymer and 
API molecules in the disperse system. PDF data suggestive of dispersions are, therefore, expected 
to show significant deviations from simulated PDFs that result from the weighted linear 
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combination of independent amorphous components. In contrast, the PDF data suggestive of a 
phase separated system are expected to have similar PDF patterns to the weighted linear 
combination of independent amorphous components. PDF analysis was performed using in-house 
software developed using MATLAB (v.2012b, MathWorks®, Natick, MA). 
 
4.2.3.5. Classification 
 Figure 23 shows representative characterization data. A scheme for the classification 
process used for each preparation is shown in Figure 24. Analytical observations (PXRD and PDF-
transformed diffraction data, DSC, PLM, and HSM) were combined to categorize the 
dispersability (or not) of the binary systems, at a specific concentration, 1 day after each was 
prepared. Co-solidified mixtures characterized as non-crystalline and/or disperse systems by all 
methods were classified as containing API that ‘successfully dispersed’ in PVPva, while solids for 
which one or more techniques revealed either crystallinity or phase separation, were classified as 
having API that ‘failed to disperse’ in PVPva. This dichotomous classification was applied to 
enable logistic regression of the phenomenology for the purposes of screening correlations with 
molecular descriptors.  
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Figure 23: Representative characterization data for several compounds in the library. (a) PXRD 
data confirm crystallinity in quinidine 15% (S/E) co-solidified mixtures. Note: Quinidine 
recrystallized as a methanolate (CSD ID: MUHZUM18). Cimetidine 15% (M/Q) is X-ray 
amorphous, as indicated by the absence of diffraction peaks. (b) DSC data representing three 
potential outcomes: Ketoconazole 15% (M/Q) appears to be dispersed, based on the appearance of 
a single Tg. Melatonin 15% (M/Q) is phase separated, as indicated by the presence of 2 distinct 
Tg’s. Quinidine 15% (S/E) is partially crystalline, as indicated by the appearance of an endotherm. 
(c) PLM data representing two possible outcomes: Chlorpropamide 15% (M/Q) appears 
amorphous, as indicated by the lack of birefringence. Quinidine 15% (S/E) is birefringent, 
indicating crystallinity. (d) PDF data representing two possible outcomes: The melatonin 75% 
(M/Q) co-solidified mixture does not significantly deviate from the linear combination of the 
individual components, suggesting phase separation. The felodipine 15% (S/E) co-solidified 
mixture does (deviations shown in green), suggesting molecular dispersion.166  
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Figure 24: Dispersion classification decision tree. A suite of analytical techniques is necessary to 
reduce the likelihood of incorrect inferences that can result from the limitations of any individual 
technique.10 The applied analytical techniques include powder X-ray diffraction (PXRD), 
differential scanning calorimetry (DSC), polarized light microscopy (PLM), hot-stage microscopy 
(HSM), and analysis of pair distribution function (PDF) transformed X-ray data. 
 
4.2.4. Calculation of Molecular Descriptors 
 Chemical structures were converted into SMILES format169 for entry into the  
E-DRAGON170, 171 software. Within E-DRAGON, three-dimensional coordinates were generated 
using the CORINA172 algorithm. The R3m descriptor was previously found to have statistically 
significant correlation with successful dispersability of API in PVPva when prepared using the 
M/Q method at 75%w/w loading.  Dispersability under these conditions was modeled for a 12 API 
library, and successfully confirmed using 3 extra-library test compounds.48 Continued 
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investigation of R3m has, therefore, been of primary interest in this work under expanded 
preparation conditions.  R3m (the atomic mass weighted 3rd order autocorrelation index) is a 
geometric molecular descriptor of the R-GETAWAY family, which are described in detail 
elsewhere.35, 51 The equation for the calculation of R3m is reprinted below for convenience 
(Equation (16)):  
(16)                R3m =  ∑ ∑
√hii∙hjj
rij
∙ mi ∙ mj ∙ δ(3; dij) j>i
A−1
i=1  
Above, h is the leverage (obtained from the diagonal of the molecular influence matrix), r is the 
geometric distance between atoms i and j (obtained from the geometry matrix), m is the atomic 
mass (for atoms i and j), d is the topological distance between atoms i and j, and δ(3;dij) is a Dirac 
delta function. For the descriptor R3m, this Dirac delta function results in the consideration of only 
pairs of atoms where the topological distance is equal to 3. 
 
4.2.5. Statistical Modeling 
 Characterization of each co-solidified sample culminated in a final dichotomous inference 
of either successfully dispersed (coded as 1), or failure to completely disperse, as informed by the 
presence of phase separation and/or crystallinity (coded as 0). Logistic regression was performed 
using JMP (SAS Institute Inc., Cary, NC) and/or MATLAB. Regression coefficients were 
calculated using maximum likelihood estimation, while significance was tested using the 
likelihood ratio, which follows a χ2 distribution. The likelihood ratio was determined by calculating 
the change in deviance between the reduced model (containing only the intercept) and the full 
model. Where multiple logistic regression was performed, statistical significance of the full model 
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relative to the reduced model was assessed using drop-in-deviance tests (a.k.a. nested likelihood 
ratio tests).  
 
4.3. Results 
4.3.1. Data Summary 
4.3.1.1. Melt-Quench (M/Q) Preparations 
 Summaries of individual experimental observations and the subsequent inferences made 
regarding dispersability for co-solidified mixtures prepared using the M/Q method can be found 
in the Appendix (Table 12 and Table 13). Table 2 shows the final inferences made based on the 
analytical data from the combined techniques described in the Methods section.  Figure 24 shows 
a schematic for classification decisions.   
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Table 2: Final dispersability inferences based on interpretations of data from the suite of analytical 
techniques outlined in Figure 23. A value of 1 indicates successful dispersion of the API in PVPva, 
while a 0 indicates failure to disperse in PVPva. R3m values listed for each compound were 
calculated as outlined in the Methods section, using Equation (16). 
  Melt Quench  Solvent Evaporation   
  15% API 75% API 15% API 75% API R3m 
Propranolol HCl 0 0 0 0 0.342 
Cimetidine 0 0 0 0 0.403 
Melatonin 0 0 0 0 0.407 
ABT-102  N/A N/A 1 0 0.547 
Terfenadine 0 0 1 1 0.561 
Cloperastine HCl 0 0 0 0 0.562 
Nifedipine 0 0 1 0 0.568 
Quinidine 0 0 0 0 0.593 
Sulfanilamide 0 0 0 0 0.595 
ABT-072 N/A  N/A 1 0 0.614 
Tolbutamide 1 1 1 0 0.687 
ABT-348 N/A  N/A 0 N/A  0.703 
Indomethacin 1 1 1 1 0.737 
Ketoconazole 1 1 1 1 0.814 
Itraconazole 1 1 0  N/A 0.872 
Chlorpropamide 1 1 1 1 0.927 
Felodipine 1 1 1 1 0.964 
Bicalutamide 1 1 1 1 1.001 
 N/A (S/E) Insufficient Solubility in Methanol – Not Applicable 
 N/A (M/Q) Thermal Degradation – Not Applicable 
 
Figure 23 shows typical examples of characterization data, which inform the final classifications 
shown in Table 2. Compounds received from AbbVie (ABT-102, ABT-072, and ABT-348) 
underwent significant degradation above their respective melting temperatures, indicated by 
extreme discoloration during preparation and significant weight loss observed during 
thermogravimetric analysis. Additionally, these compounds had much higher Tm,API, thereby 
requiring much higher preparation temperatures to achieve melting, relative to those used for any 
other materials in the library.  Attempts to assess dispersability of AbbVie compounds in PVPva 
via M/Q, therefore, required preparation at temperatures above those recommended for working 
with the polymer.173 For these compounds, the M/Q preparation method was deemed inappropriate 
for dispersing API in copovidone.  
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Attempts were also made to co-solidify mixtures involving ABT-102, ABT-072, and ABT-
348 at temperatures below the Tm,API, but discoloration due to thermal degradation persisted. Even 
so, it was expected that this deviation from the M/Q method used for all other compounds may 
have negatively impacted the potential to consistently prepare amorphous dispersions, as it relied 
on dissolution of API crystals into molten polymer, a process that was expected to occur more 
slowly relative to compounds in which molten API was mixed with liquid polymer prior to 
solidification. As such, ABT-102, ABT-072, and ABT-348 were excluded from the M/Q analyses.  
 
4.3.1.2. Solvent-Evaporation (S/E) Preparations 
 A summary of the final dispersability inferences for each co-solidified mixture prepared 
by the S/E method can also be found in Table 2. Summaries of individual experimental 
observations and the subsequent inferences made regarding co-solidified mixtures prepared using 
the solvent evaporation method can be found in the Appendix (Table 14 and Table 15). Two 
compounds (itraconazole and ABT-348) were poorly soluble in methanol, making preparation of 
the 75% w/w API mixtures impractical. At this targeted drug concentration for an eventual 
dispersion, preparations involving both API required using a significantly higher starting volume 
of methanol during the solidification process in order to yield enough solid for characterization. In 
fact, the amount of solvent required for these S/E experiments would have necessitated the use of 
much larger round-bottom flasks capable of holding a much greater volume of API-polymer-
methanol solution, making the duration of solvent evaporation much longer, with kinetics that 
would have been substantially different from the other solidifications performed using this method. 
Correspondingly, these compounds were not included in the S/E model at this concentration.  
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 Thermogravimetry indicated that the volatile content (residual water and methanol) in 
samples prepared by S/E ranged from 1.6-4.8% w/w. Residual solvent can change the 
characteristics of the dispersion significantly, reducing the Tg and increasing molecular mobility 
of this ternary system. These changes can impact dispersability, potentially leading to less 
predictability with S/E than M/Q.  It may be possible to reduce the residual solvent by using a 
more efficient preparation method that allows for rapid solvent removal (e.g., spray drying), or by 
using more intense secondary drying. As neither option was available for the present work, 
operating parameters and storage conditions were controlled to make the final mixtures as 
consistent as possible.  
 
4.3.2. Data Modeling 
 Figure 25a shows the originally published R3m model (red triangles), which resulted in a 
boundary value of approximately 0.65 and 100% prediction accuracy of dispersability in PVPva.48  
Expansion of this model to investigate predictions of dispersability at lower API concentrations 
(15% w/w) resulted in identical experimental observations for all API in PVPva (orange circles), 
and therefore, the same model boundary (R3m = 0.65) persisted. The perfect separation that was 
observed made the application of logistic regression inappropriate, since this would result in 
unstable estimations of the coefficients. For the library studied, a decision boundary of R3m = 0.65 
resulted in 100% accurate predictions regarding API dispersability in PVPva, when prepared using 
the M/Q method, regardless of drug loading, the value of which was determined based on the 
midpoint of the interval between the R3m values for compounds across which the change in 
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dispersability was observed.  This means that the exact location of this boundary is subject to some 
uncertainty and could change as more compounds across this R3m interval are evaluated.    
Unlike the compounds prepared using M/Q, perfect separation of dispersability results on 
either side of a single value of R3m was not observed for S/E preparations, allowing the use of 
logistic regression for modeling. While very good prediction (90.6% overall success rate) was 
achieved, R3m was less predictive of dispersability for S/E prepared samples relative to M/Q 
prepared samples. Despite this, increasing R3m values for individual API continued to correlate 
well with increasing probability of dispersability in PVPva. Figure 25b shows the logistic 
regression models for co-solidified API:PVPva mixtures prepared by S/E at both API 
concentrations studied. Compared to 15% w/w API, the 75% w/w API solvent evaporation model 
showed better separation between API that were dispersable in PVPva and those that were not. 
Each model did, however, show statistical significance, indicating that the R3m molecular 
descriptor is a useful tool for predictions of dispersability in PVPva, even when mixtures are 
prepared using S/E.  Table 3 summarizes the modeling statistics for each of the models.  
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Figure 25: Modeling of dichotomous classifications of API dispersability in PVPva for co-
solidified mixtures prepared by (a) melt quenching and (b) solvent evaporation, against the 
molecular descriptor R3m. Separation is observed in the melt quench models; all API having R3m 
> 0.65 were dispersable in PVPva. Logistic regression was used to model solvent evaporation 
behavior. Increasing values of R3m are still well correlated with dispersability in PVPva. 
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Table 3: Modeling statistics for R3m models of dispersability in PVPva prepared by either the 
M/Q or S/E methods. The abbreviation LR refers to the likelihood ratio. 
Method Regression Equation 
LR 
(χ²) 
Standard 
Error 
Misclassification 
Rate 
MQ (15% API) N/A - Critical dividing value N/A N/A 0% (n = 15) 
MQ (75% API) N/A - Critical dividing value N/A N/A 0% (n = 15) 
SE (15% API) logit P(Y) = -3.96 + 6.48(R3m) 4.65* 
Intercept: 2.31 
Slope: 3.58 
27.8% (n = 18) 
SE (75% API) logit P(Y) = -12.47 + 18.16(R3m) 12.36† 
Intercept: 6.31 
Slope: 9.68 
6.3% (n=16) 
 * p-value < 0.05 
† p-value < 0.0005 
 
 Attempts to improve model performance for dispersability predictions of S/E preparations 
were considered. API solubility in methanol was categorized according to the USP 34 table for 
approximate solubility of a compendial substance (see Table 16 of the Appendix), which was 
included as a covariate in the R3m dispersability model.  This resulted in a drop in deviance (χ2 
test statistic) of 1.56 for the 15% API S/E model, and 2.65 for the 75% API S/E model (see Table 
17 and Table 18 in the Appendix), indicating no statistically significant improvement over the 
models containing R3m alone.  
 
4.4. Discussion 
 Molecular descriptors are the final result of a logical and mathematical procedure that 
transforms chemical information encoded within a symbolic representation of a molecule, into a 
useful number.108 A fundamental assumption of quantitative structure-property relationships 
(QSPR) is that the structure of a molecule is responsible for the physical, chemical, and biological 
properties of that molecule.35 Both chemical and physical properties have been shown to be 
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important for the formation and stability of ASDs (e.g., hydrogen-bonding influences 
crystallization kinetics,7 higher molecular weight increases glass forming ability,45 polymers 
increase the kinetic barrier to API crystallization or re-crystallization5). However, the extent to 
which each of these properties contributes to the dispersability of API in a given polymer remains 
uncertain. Additionally, the presence of such interactions does not automatically ensure 
dispersability. The application of molecular descriptors could be related to the aforementioned 
properties, and thereby simplify predictions. Such a model (if established) could significantly 
reduce costs associated with ASD development programs by aiding ‘go/no-go’ decisions, and 
helping to identify polymers of interest before performing any experimental work. Although the 
current model, based on correlating the R3m descriptor of an API with its dispersability behavior 
in PVPva, is only applicable for that particular polymer, expansion of this work could aid ASD 
development by identifying a series of relevant molecular descriptors that relate to manufacturing 
methods and polymers that have the highest probability of resulting in a successful ASD 
formulation. Such a rapid formulation development tool would reduce experimental costs, and 
speed time to market.  
 The results presented in this work indicate that the R3m molecular descriptor is predictive 
of API dispersability in PVPva over a wide concentration range, and for two preparation methods. 
In the case of solids prepared using M/Q routines, the R3m model was 100% accurate, correctly 
predicting dispersability in PVPva for all API having an R3m value >0.65, at either 15% w/w or 
75% w/w drug loading (Figure 25a). Excellent model performance with M/Q preparations seems 
most likely to have been the result of the relative simplicity in the physical and processing 
environments.  As binary mixtures, the interactions between the API and PVPva that enable or 
prevent dispersability are dominant.  Consistent with the hypothesis, the strong correlation 
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between the value of R3m and the dispersability in PVPva, suggests that the complex combination 
of physical and chemical attributes reflected in values of R3m >0.65 are necessary for dispersion 
in PVPva. In contrast, API having R3m < 0.65 suggests that these molecules are missing some 
essential contribution from the physical and chemical attributes needed to facilitate dispersion in 
PVPva, and, therefore, these API failed to disperse in all experiments. 
 These data also indicate that the R3m descriptor predicts dispersability of a series of 
molecularly diverse API in PVPva, when prepared using a S/E method, at a rate that is much better 
than random chance.  As shown in Table 2 the dispersability of this library of API in PVPva was 
less predictable in S/E solidifications containing 15% w/w drug, where the R3m model had a 
prediction accuracy of 72.2%. In contrast, at 75% w/w concentration, the R3m model performed 
better, with approximately 93.8% probability of correctly predicting dispersability. Strictly 
speaking, direct comparison between the performance of the 15% w/w and 75% w/w S/E models 
is complicated because the model at 15% w/w had two more observations than the model at 75% 
w/w. It should be noted that the exclusion of itraconazole and ABT-348 from the 75% w/w S/E 
model was made for physically valid reasons, discussed below.  
 When considered against the relative clarity of the M/Q models, at either concentration, 
the S/E data suggested that the solvent may contribute to the variability in observations for the S/E 
preparations, by adding to the complexity of molecular-level interactions introduced by the 
solvent, while the dispersion is forming. R3m appears to be more representative of the physical 
and chemical attributes necessary for dispersability in binary systems of API and PVPva, such as 
those that result from the M/Q method.  In contrast, the S/E method required dissolution in 
methanol during processing, and residual methanol was retained following drying.  Although the 
presence of an additional component (residual methanol) in S/E prepared systems does not prevent 
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modeling, correlation of a molecular descriptor with dispersability is expected to be contingent on 
that descriptor capturing the attributes of the API that are most important for its interaction with 
the carrier polymer. However, the R3m model may not be able to completely account for the added 
complexity introduced by the presence of solvent molecules as the dispersion forms and/or during 
storage.  
 As described above, the performance of the 75% w/w S/E model benefited from the 
exclusion of itraconazole and ABT-348, because their solubilities in methanol did not allow 
sufficient mass of drug to be dissolved, even with the maximum volume of solvent allowed by the 
flasks used for this method. In other words, correct predictions of dispersability of API in PVPva 
became more probable when compounds not physically suited to preparation under the conditions 
established for consistent S/E were excluded. Similarly, when itraconazole and  
ABT-348 were excluded from the 15% w/w S/E logistic regression model, a more pronounced 
boundary between successful and unsuccessful dispersability resulted, as illustrated by the 
steepening of the slope in Figure 26.  Although the 15% w/w S/E model improves by the exclusion 
of itraconazole and ABT-348, their exclusion from the model could not be similarly justified since 
their preparation was not limited by methanol solubility, as was the case at the higher drug loading.  
As a result, they were retained to minimize the potential to inadvertently induce bias into the 
model.  
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Figure 26: The logistic regression model for dispersability predictions of 15% w/w API in PVPva 
improved when itraconazole and ABT-348 are excluded (indicated with x symbols), relative to the 
original model at this drug loading. 
 
 In an attempt to encompass the potential effect of API solubility in methanol on 
dispersability, this factor was investigated as a possible covariate with dispersability predictions 
for the more complex solvent-based preparations. The solubility ranking was categorized 
according to the USP 34 table for approximate solubility of a compendial substance (Table 16), 
and was included as a continuous variable in the model to avoid further reductions in the degrees 
of freedom. Table 17 and Table 18, as well as Figure 56 and Figure 57 in the Appendix show the 
changes in model performance that resulted from inclusion of the solubility ranking. Ultimately, 
drop in deviance tests showed that there was no statistically significant improvement over the 
univariate model for either of the API concentrations. This may be the consequence of an 
insufficiently balanced model, with respect to solubility. Capturing the impact of API solubility in 
methanol warrants further investigation to better understand S/E systems.  
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 It is important to note that the S/E model prediction accuracies, discussed above, reflect 
shifting R3m classification boundaries for each model corresponding to a probability equal to 50%. 
These shifts were caused by different conclusions for the respective calibration data sets (i.e., R3m 
≈ 0.61 for the 15% w/w API model and R3m ≈ 0.69 for the 75% w/w model). It is hypothesized 
that this shift is partially due to the library containing fewer compounds that were dispersable at 
the higher drug concentration. This was anticipated, since the dispersability in PVPva was 
expected to vary with concentration, owing to increasing levels of supersaturation in the polymer. 
For example, tolbutamide and ABT-072 successfully dispersed at 15% w/w, but failed to disperse 
at 75% w/w. These compounds have R3m values that border the initial decision boundary, and the 
change in dispersability with concentration contributes to the shift in probability. A similar shift 
was initially hypothesized for the M/Q model, where it was expected that reducing the amount of 
API in the binary mixture would result in more compounds being dispersable in the PVPva. 
However, observations of dispersability remained consistent between concentrations for co-
solidified mixtures prepared by M/Q.  
 For completeness, the accuracies of the logistic regression models generated for the  
15 % w/w S/E preparations (classification boundary of R3m ≈ 0.61) and 75% w/w S/E preparations 
(classification boundary of R3m ≈ 0.69) were compared to the accuracy of the original 
dispersability boundary determined from M/Q data (classification boundary of  
R3m ≈ 0.65). The accuracy of the models were between 5 and 6 % better than the predictions based 
on the original 0.65 boundary. These differences were due to one additional compound being 
misclassified at each concentration by the original boundary compared to the predictions of the 15 
% w/w and 75 % w/w S/E models. Expanding the compound libraries will help clarify the 
boundary locations. 
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 It should also be noted that not all of the co-solidified mixtures prepared using S/E that 
successfully dispersed at 15% w/w drug loading fell at the decision boundary. For example, two 
compounds having lower values of R3m (nifedipine and ABT-102) successfully dispersed at 15% 
w/w when prepared by S/E. The behavior of terfenadine also appeared to be an outlier, in that it 
was dispersable at both concentrations when prepared using S/E, while it failed to disperse at both 
concentrations when prepared using M/Q. In contrast, the itraconazole at both concentrations was 
dispersable in PVPva when prepared by the M/Q, while it failed to disperse at 15% w/w and could 
not be prepared using S/E at 75% w/w (see Figure 58 for a version of Figure 25 with relevant 
compounds labeled). These results are all thought to be the result of the differences inherent to the 
M/Q and S/E methods, specifically, the presence or absence of methanol as the dispersions are 
forming. The facilitated dispersability of terfenadine in PVPva during S/E may be the result of 
unique interactions with the methanol during preparation that were not present during M/Q 
preparation. Likewise, the failure of itraconazole to disperse in PVPva during S/E suggests that 
the methanol negatively impacted the drug-polymer interactions that were capable of forming and 
persisting during co-solidification during M/Q.  Ultimately, there were no immediately apparent 
differences in the physical or chemical properties of any of these compounds that clearly identified 
a cause for these outcomes, so further investigation is necessary.  
 Considering all these data, the molecular descriptor R3m clearly correlates with API 
dispersability in PVPva, suggesting that it numerically represents a complex combination of 
critical chemical and physical attributes of the API. It has been argued that the usefulness of 
molecular descriptors is not limited to cases for which they are easily interpretable,35 and that the 
inability to understand a descriptor using well-established chemical concepts may not necessarily 
eliminate descriptor usefulness, rather, it could help reveal new concepts.35  A model that can 
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predict the dispersability of an API in a specific polymer would undoubtedly be useful for 
formulation development, but a convincing argument for the broader application of this descriptor 
can only be expected once the physical and chemical meaning of R3m becomes more apparent.  
As shown in equation (16), R3m is weighted by the mass of the atoms, relative to carbon. 
For the library of compounds used to build the models (Figure 22), the heaviest atoms were 
nitrogen, oxygen, fluorine, sulfur, and chlorine; all of which also have a higher electronegativity 
and atomic volume relative to any other intramolecular atoms studied. As such, further references 
to heavy atoms in this chapter refer specifically to N, O, F, S, and Cl, and not all atoms with high 
atomic mass. These atoms are ‘heavy’ only with respect to the atoms in the molecules used to build 
the R3m model. Their importance in the model of the extant library is, however, thought to be 
because these relatively heavy atoms may reduce the molecular mobility of the API, or increase 
the likelihood of forming non-covalent bonding interactions with the polymer, either of which 
would reduce the potential for API recrystallization, and allow for persistence of a metastable 
dispersion.  
Notably, R3m encompasses more information than provided by atomic weight alone. This 
is demonstrated by Figure 27, where the relationship between R3m and both molecular weight 
(MW) and average molecular weight (AMW) are shown. While MW gives the total weight of 
atoms, AMW gives a representation of the distribution of atomic weight for the atoms in the 
molecule. Library molecules having more of the relatively heavy atoms will have a higher AMW. 
Similarly, molecules comprised of heavier atoms will result in a larger value of R3m, particularly 
when those heavy atoms are close to each other in three-dimensional space. However, investigation 
of both MW and AMW as predictors of dispersability showed inferior performance compared to 
R3m. This suggests that other molecular attributes encoded into the R3m descriptor, but absent 
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from average molecular weight must be important for dispersability in PVPva. Further research is 
underway to evaluate the physical meaning of R3m. 
 
Figure 27: Scatter plot showing the relationship between R3m and both molecular weight (circles) 
and average molecular weight (triangles). The solid blue and dotted orange lines show the linear 
regression of both molecular weight and average molecular weight against R3m, respectively. 
 
4.4.1. Model Limitations 
 As with all models, dispersability predictions involving these R3m models are limited to 
the modeling-space established by the compounds from which they are calculated. Further 
investigation is necessary to expand the models so that dispersability predictions can be made 
without the need for extrapolation. As an example, the current model applies only to binary 
mixtures of an API with the polymer PVPva. Extrapolation of the R3m molecular descriptor for 
the prediction of dispersability in any other polymer is not recommended without further study. 
As hypothesized, the strong correlation between R3m and API dispersability in PVPva reflects a 
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complex combination of chemical and physical attributes of each compound, which are 
collectively necessary for dispersion in the polymer. Changing the carrier to a different polymer 
will change the physical environment in which the API is dispersed as well as the potential to form 
specific, non-covalent chemical interactions between the API and polymer that contribute to its 
ability to form a dispersion.  This makes it likely that a different molecular descriptor (or 
combination of descriptors) is needed to reflect those changes. Furthermore, the R3m model is not 
necessarily expected to be applicable to a formulation that contains surfactants, commonly used in 
ASD formulations.  In fact, new and perhaps multiple descriptors may be required when 
surfactants are added to the formulation, as the additional components contribute to a different 
physical and chemical environment into which the API is being dispersed.   
 Another limitation imposed by the current modeling space is that the R3m model consists 
primarily of molecules having melting and glass transition temperatures within the respective 
ranges of approximately 118-193°C and 13-69°C. Three of the compounds, ABT-102, ABT-072, 
and ABT-348, constituted outliers with respect to these properties. This is illustrated in Figure 28, 
in which the glass transition temperatures and melting temperatures of ABT-102, ABT-072, and 
ABT-348 are much higher relative to the rest of the library API. Further expansion of the models 
will focus on filling in these gaps in order to ensure that meaningful predictions can be made using 
R3m for compounds having a wider range of properties.  
 
 
 119 
 
 
Figure 28: Histograms and outlier boxplots (shown above the histograms) for the distribution of 
(a) glass transition temperatures and (b) melting temperatures for model compounds (in Kelvin). 
The blue box indicates the interquartile range. The red line within the box indicates the median. 
Whiskers indicate the largest and smallest value in the distribution, excluding outliers. The red 
cross marks indicate outliers from a normal distribution. ABT-102, ABT-072, and ABT-348 all 
have higher glass transition and melting temperatures than the other library compounds. The 
boxplot indicates that in either case ABT-102, ABT-072, and ABT-348 were considered outliers 
in the model. 
 
 Finally, it is important to note that the observed correlation between R3m and 
dispersability, while statistically significant, is based on a relatively small experimental dataset. 
This is reflected in the standard error of the coefficients in Table 3, where the relatively high values 
result from the small sample size. Future work will focus on validation of the model with an 
external dataset, and continued expansion of the model to increase the sample size.  
 
4.5. Conclusions 
 R3m was shown to predict the dispersability of a library of up to 18 API in PVPva, prepared 
at two different concentrations, using two different preparation methods. Dispersability predictions 
using the R3m model were 100% accurate for dispersions prepared by melt-quenching. All API 
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having an R3m > 0.65 were dispersable in PVPva, at concentrations of both 15% w/w and 75% 
w/w, while API having an R3m < 0.65 failed to disperse in this polymer.  
 R3m predictions were less accurate for dispersions prepared using a solvent-evaporation 
method, however, the prediction accuracy remained high and performed much better than random 
chance alone. At a concentration of 15% w/w, it was 72.2% probable to correctly predict API 
dispersability in PVPva for molecules having an R3m > 0.61. The S/E model accuracy improved 
at a drug concentration of 75% w/w, at which it was 93.8% probable to correctly predict API 
dispersability in PVPva when R3m > 0.69.  If the R3m boundary was kept consistent across 
preparation methods (i.e., R3m = 0.65 for both M/Q and S/E), the overall prediction accuracy 
decreased from 90.6% to 87.5%. The slight changes in prediction accuracy for preparations 
involving S/E were likely the result of additional interactions encountered during processing, 
between the API, polymer and methanol. Additionally, the slow kinetics of dispersion formation 
that occurred during rotary evaporation of methanol and the potential for differences in API 
mobility caused by the presence of residual solvent in samples solidified according to the S/E 
scheme are also likely to have created differences between the M/Q and S/E samples, and the 
inferences that can be made about dispersability. These results warrant further investigation of 
R3m to potentially aid in ASD formulation development, especially the physical interpretation of 
the R3m descriptor.  
 The results described in this chapter have significantly strengthened the R3m model and 
its interpretation. These data suggest that R3m is useful for the prediction of ASD formation, 
however, the physical meaning of the molecular descriptor remains relatively uninterpretable. It is 
necessary, therefore, to decipher a clearer meaning for R3m to obtain a more interpretable model, 
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and to advance scientific understanding of the formation of ASDs. The next chapter will describe 
the investigation into the meaning of the R3m descriptor.  
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Chapter 5. Examining the Physicochemical Meaning 
of a Molecular Descriptor which is Predictive of 
Amorphous Solid Dispersion Formation for API in 
Polyvinylpyrrolidone Vinyl Acetate 
 The previous chapter significantly strengthened the R3m model by expanding the dataset 
and showing continued statistically significant predictive performance for ASD formation with 
PVPva. However, the physical meaning of the molecular descriptor remained relatively 
uninterpretable. It is necessary, therefore, to decipher the physicochemical meaning of R3m to 
obtain a more interpretable model. The goal of the research described in this chapter is to elucidate 
the physicochemical meaning of R3m and connect these properties to ASD formation.  
 
5.1. Introduction 
 The utility of the R3m descriptor was supported by expanding the model to include 
additional API concentrations and ASD preparation methods (Chapter 4).174 While the value of 
R3m>0.65 for an API was predictive of dispersability in PVPva, direct physical interpretation of 
this molecular descriptor remained nebulous. It has been argued that the usefulness of molecular 
descriptors is not limited to cases for which they are easily interpretable, and that the inability to 
interpret descriptors may ultimately lead to new concepts.35 Nevertheless, it is prudent to 
cautiously apply models based on descriptors when no clear understanding of their meaning can 
be found. Ultimately, a model that is both predictive and interpretable is more useful than a model 
that is not as clearly related to well understood properties.36   
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 Since molecular descriptors are derived from a representation of a molecule, and it is 
assumed that similar molecular structures have similar physical and chemical properties,35 
interpreting the R3m descriptor in terms of API physicochemical properties most useful for 
promoting dispersion formation in PVPva is expected to enhance the scientific understanding of 
its utility as a formulation tool. The formation of ASDs is complex, and dependent on combinations 
of thermodynamic and kinetic factors. For example, the presence of specific non-covalent 
interactions has been shown to be important for the formation of ASDs, as has been demonstrated 
for indomethacin and polyvinylpyrrolidone (PVP).7 However, the presence of these interactions is 
not always necessary, and in some cases ASDs can be formed in the absence of such interactions, 
as has been demonstrated with PVP and ketoconazole.6 This complexity makes it much more 
difficult to make a priori predictions of ASD formation. The application of a simple model for the 
prediction of ASD formation based on individual studies, such as the number of hydrogen bond 
donors an API possesses, would be an oversimplification, and therefore, would often fail when 
applied to API which are the exception to the presumed rule (e.g., in this example, ketoconazole 
and PVP). Given the complexity of ASD formation, its a priori prediction was assumed to require 
a model constructed from a more complicated combination of properties than those usually 
reported. It was, therefore, hypothesized that R3m would better predict dispersability in PVPva for 
the extant library of API (Figure 22) relative to any other descriptor or physicochemical property, 
because it captures more physical and chemical information that is relevant to ASD formation in 
this polymer.  
 To investigate this hypothesis, first, inferences were made from the R3m equation. Next, 
the matrices which are used to calculate R3m were investigated in more detail, including the 
specific impact of these matrices on library API. Other more interpretable descriptors were 
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investigated for improved prediction for the formation of ASDs, but no other descriptor performed 
as well across multiple preparation methods and concentrations. Finally, multiple linear regression 
modeling of other descriptors against R3m was attempted to support inferences. In general, large 
molecules, having increased topological connectivity (reflective of increased branching), 
molecules having more of the relatively heavy atoms common to the extant API library (higher 
molecular density), and having those intramolecular heavy atoms positioned furthest from the 
geometric center (on the periphery of the 3D conformation of the molecule) have higher R3m 
values, suggesting these attributes conform to R3m>0.65, which corresponds to API which are 
dispersable in PVPva. 
 
5.2. Experimental Section 
5.2.1. Preparation of Co-solidified Mixtures 
 Co-solidified mixtures were prepared using 2 preparation methods at 2 concentrations 
(75% and 15% API). The preparation of co-solidified mixtures by either melt-quenching or solvent 
evaporation is described in Chapter 4. Briefly, the melt-quench method involved dry blending the 
polymer and API at specific weight ratios and transferring to a crucible.  Mixtures were then heated 
to 10 °C above the melting temperature of the API, and isothermally held for approximately 30 
min with intermittent stirring. The molten mass was then quenched by immersion of the crucible 
in ice water over which a dry N2 (g) purge was applied. The resulting solids were then stored 
overnight in a P2O5 desiccator.  
 The solvent evaporation method required dissolution of API and polymer in methanol at 
specific weight ratios in a round bottom flask. The flask was then attached to a rotary evaporator 
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and methanol was evaporated under vacuum, using a water bath to maintain a consistent 
temperature at 50 °C. The resulting solids were then stored overnight in a P2O5 desiccator under 
vacuum.  
 As described in Chapter 4, all resulting solids were characterized using powder X-ray 
diffraction (PXRD), differential scanning calorimetry (DSC), and hot-stage polarized light 
microscopy to categorize experiments as either dispersed or not in the PVPva.  The resulting 
phenomenology was regressed against a database of molecular descriptors, from which R3m 
emerged as the only significant descriptor capable of accurately separating the API library shown 
in Figure 22 into groups of dispersable and not dispersable in this polymer.  The models are shown 
in Figure 29, each of which showed statistically significant performance (p<0.05), indicating that 
R3m was a useful descriptor for the prediction of ASD formation over 2 concentrations and 2 
preparation methods. The reader is referred to the relevant literature for additional details.174 
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Figure 29: Modeling of dichotomous classifications of API dispersability in PVPva for co-
solidified mixtures prepared by (a) melt-quenching and (b) solvent evaporation, against the 
molecular descriptor R3m. Separation is observed in the melt-quench models; all API having R3m 
>0.65 were dispersible in PVPva. Logistic regression was used to model solvent evaporation 
behavior. Increasing values of R3m are still well correlated with dispersability in PVPva. 
Reproduced from Chapter 4, Figure 25 for convenience. 
 
5.2.2. Molecular Descriptors 
 Molecular descriptors were calculated using E-DRAGON170 (http://www.vcclab.org) and 
the QSAR module of Materials Studio v.7.0 (Dassault Systèmes BIOVIA, San Diego, CA).175 
Additional properties were collected experimentally, from cited literature, or from databases such 
as PubChem,176 Cambridge Crystallographic Data Center (Cambridge, UK),156 and SciFinder.177  
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 Logistic regression was applied between experimental conclusions regarding dispersability 
and select molecular descriptors and physicochemical properties to investigate simpler or more 
interpretable models. Single and multiple linear regressions (MLR) were performed to assess 
correlation of other physicochemical properties and molecular descriptors with R3m. For MLR, 
the independent variables were checked for multicollinearity. Variables having high collinearity 
were excluded from the models, since multicollinearity will result in unstable regression 
coefficients, and likely lead to inaccurate future predictions.50 Statistical analyses were performed 
in JMP and MATLAB. 
 For comparisons of three-dimensional structures, coordinates were obtained using the 
CORINA algorithm178 (https://www.mn-am.com/) and the Cambridge Crystallographic Data 
Center (CCDC).156 The calculation of R3m was performed using E-DRAGON or in-house 
MATLAB code.  
 
5.2.3. The Calculation of R3m 
 R3m is a molecular descriptor from the R-indices sub-type of the R-GETAWAY family of 
descriptors. GETAWAY is an acronym for GEometry, Topology, and Atom-Weights AssemblY. 
This family of descriptors was first proposed by Consonni et al in 2001.51 The relevant matrices 
and equations necessary for the calculation of this family of descriptors have been previously 
described.35, 51, 179 Specific equations and matrices necessary for the calculation of R3m are given 
below for convenience, but for additional information the reader is referred to the source 
material.35, 51, 179  
 The general equation for R-indices is given below (Equation (17)).  
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(17)       Rk(w) = ∑ ∑
√hii∙hjj
rij
∙ wi ∙ wj ∙ δ(k; dij)   k = 1,2, … , di>j
A−1
i=1  
Here, A is the number of atoms in the molecule, w is the weighting, i and j refer to 2 separate 
atoms, hii and hjj are the leverages, and δ(k:dij) is a delta-Dirac function, where k is the topological 
distance. For R3m, the topological distance (k) is equal to 3, and the weighting (w) is the atomic 
mass relative to carbon. R3m is, therefore, known as the R-GETAWAY third order 
autocorrelation index weighted by the atomic mass. The R3m equation is given below (Equation 
(18)). 
(18)         R3m = ∑ ∑
√hii∙hjj
rij
∙ mi ∙ mj ∙ δ(3; dij) i>j
A−1
i=1  
Here, m is the atomic mass normalized to carbon for atoms i and j. The delta-Dirac function causes 
the equation to equal zero for cases where the topological distance between i and j does not equal 
3.  
 The terms used to calculate R3m are calculated using several matrices. The first of these 
matrices is the molecular matrix (M). This matrix is a 3 column by A row matrix (where A is the 
number of atoms in the molecule of interest) containing the three-dimensional coordinates of each 
atom. The molecular matrix is then used to calculate the molecular influence matrix (H) as shown 
in Equation (19), which resembles the leverage matrix of linear regression.51 The leverage values 
are obtained from the diagonal of the molecular influence matrix (H), which is calculated as shown 
in Equation (19). 
 (19)            H = M ∙ (MT ∙ M)−1 ∙ MT 
Here M is the molecular matrix and a superscripted T indicates a transposed matrix. The diagonal 
terms in this matrix (e.g., hii and hjj as shown in Equation (17)) are known as the leverage values. 
Equation (19) is calculated in the same manner as the projection or hat matrix for linear regression, 
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and its interpretation is similar. In linear regression, data points furthest from the model center will 
have the highest leverage.50 Similarly, for three-dimensional molecules, atoms furthest from the 
geometric center of a molecule will have the highest leverage, and represents the influence of each 
atom over the overall shape of a molecule.179 It is important to note that the leverage values for a 
molecule will always sum to the number of dimensions considered. Only three-dimensional 
structures are considered here and, therefore, the sum of the diagonal of the molecular influence 
matrix will equal 3 for each molecule. If, however, a planar molecular such as benzene were 
considered, the leverage values would sum to 2.  
 The geometry matrix (G) is calculated from the molecular matrix, and is an A×A symmetric 
matrix containing the Euclidean distances between each pair of atoms in the molecule. The 
geometry matrix is shown in Equation (20), below, where r is the geometric distance between the 
subscripted atoms. 
(20)           G ≡ [
0
r2,1
…
rA,1
r1,2
0
…
rA,2
…
…
…
…
        
r1,A
r2,A
…
0
] 
 The distance between atoms (ri,j) is determined by calculating the Euclidean distance 
between the atoms i and j, which is described by Equation (21).  
(21)        ri,j = √(Mi,x − Mj,x)2 + (Mi,y − Mj,y)2 + (Mi,z − Mj,z)2 
Mi,x, Mi,y, and Mi,z are, respectively, the x, y, and z coordinates for atom i from the molecular 
matrix.  
 Finally the influence/ distance matrix (R) is calculated using the geometry matrix (G) and 
molecular influence matrix (H) diagonal values (i.e., leverages), as shown in Equation (22).  
(22)              R =
√hii⋅hjj
rij
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The influence/distance matrix is an AxA symmetric matrix where the largest values for R arise 
from the most external atoms (which have higher leverages), and from atoms in close proximity 
to other atoms (low rij).
51  
 In summary, the calculation of R3m includes information regarding the Euclidean distance 
between atoms, the relative distance of individual atoms from the geometric center of a molecule 
(leverage), the atomic mass relative to carbon, and atom connectivity.   
 Visualizations of the matrices described above are provided for each of the 18 library API 
in Figure 59 through Figure 73 of the Appendix. 
 
5.3. Results & Discussion 
5.3.1. Inferences from the calculation of R3m 
5.3.1.1. Topology 
 R3m contains information about the topological complexity of a molecule. Molecules 
having more branching and/or more cyclic structures may result in a larger R3m value since 
increased intramolecular interatomic connectivity will lead to more topological connections equal 
to 3, and therefore, more contributions to the total. This is illustrated in Figure 30a, where the 
topological distances equal to 3 for the nitrogen (N6) in indomethacin are shown (excluding 
hydrogens for clarity). Given the structure of the molecule, the nitrogen atom has a total of 11 
topological connections equal to 3 when all hydrogens are included. These connections are 
indicated by arrows in Figure 30a (excluding hydrogens), where N6 has a topological connection 
of 3 to C4, C10, C14, C17, C19, and C22. Owing to the ring structures in indomethacin, N6 has 
more connections than it would in a linear molecule comprised of the same atoms. For example, a 
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central carbon atom in an octane molecule has only 6 topological connections equal to 3, while its 
terminal carbon atom has only 3 such connections. The number of topological connections for 
each API in the library is given in Table 4. 
 
 
Figure 30: Illustrations of the impact of some matrices relevant to the calculation of R3m. 
Indomethacin is used here as an example. (a) A topological distance is illustrated with the N6 
nitrogen in indomethacin. Arrows indicate 7 topological connections to nitrogen equal to 3 
(excludes hydrogens for clarity). When hydrogens are included, the number of connections for N6 
increases to 11. (b) The distance from the geometric center of the molecule is indicated with a red-
white-blue color scheme, (c) the leverage values for each of the atoms in indomethacin are given 
(excludes some hydrogens for clarity).  
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Table 4: Summary of data derived from the topology, weighted mass, and leverage components of R3m. 
        Topology Weighted Mass Leverage 
API R3m 
MW 
(g/mol) 
Total # 
Atoms 
# Topological 
Connections 
Topological 
Connections / # 
Atoms 
Max. 
# atoms with 
max. weighted 
mass 
Sum Avg. Max. Avg. 
Propranolol 0.342 259.38 40 94 2.35 1.33 2 21.59 0.54 0.21 0.075 
Cimetidine 0.403 252.39 33 59 1.79 2.67 1 21.01 0.64 0.23 0.091 
Melatonin 0.407 232.31 33 68 2.06 1.33 2 19.34 0.59 0.24 0.091 
Terfenadine 0.561 471.74 76 207 2.72 1.33 2 39.27 0.52 0.12 0.040 
Cloperastine 0.562 329.9 47 120 2.55 2.95 1 27.46 0.58 0.19 0.064 
Nifedipine 0.568 346.37 43 86 2.00 1.33 6 28.84 0.67 0.18 0.070 
Quinidine 0.593 324.46 48 131 2.73 1.33 2 27.01 0.56 0.15 0.063 
Sulfanilamide 0.595 172.23 19 37 1.95 2.67 1 14.34 0.75 0.40 0.158 
Tolbutamide 0.687 270.39 36 80 2.22 2.67 1 22.51 0.63 0.17 0.083 
Indomethacin 0.737 357.81 41 86 2.10 2.95 1 29.79 0.73 0.21 0.073 
Ketoconazole 0.814 531.48 64 157 2.45 2.95 2 44.25 0.69 0.15 0.047 
Itraconazole 0.872 705.71 87 216 2.48 2.95 2 58.75 0.68 0.11 0.035 
Chlorpropamide 0.927 276.77 30 65 2.17 2.95 1 23.04 0.77 0.24 0.100 
Felodipine 0.964 384.28 44 91 2.07 2.95 2 31.99 0.73 0.18 0.068 
Bicalutamide 1.001 430.41 43 100 2.33 2.67 1 35.83 0.83 0.18 0.070 
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 In addition to the connectivity, the overall size of the molecule can result in more 
topological connections. For example, any individual carbon in a benzene molecule will only be 
connected to 3 other atoms at a topological distance of 3. The relatively small size of benzene, and 
fewer bonds across which topological connections can occur results in R3m=0.134, which is a 
relatively small value. In contrast, indomethacin has a larger total number of atoms, as well as 
more atoms with larger atomic weights (e.g., chlorine, oxygen, and nitrogen) relative to the carbons 
and hydrogens that exclusively comprise benzene. In the case of indomethacin, the more numerous 
atoms results in R3m=0.737, considerably larger relative to benzene owing to the increase in the 
size of both the molecular and geometric matrices used to calculate it.  
 Table 4 summarizes the impact of topological complexity for the API library used to 
predict dispersability using R3m.  The importance of topology is further illustrated by cimetidine 
and itraconazole. Cimetidine has only 59 topological connections equal to 3, while itraconazole 
has 216 (see Table 4). This difference contributes to the discrepancy in their respective R3m values 
of 0.403 vs. 0.872. Here, the difference is partially a result of the variation in the number of atoms 
comprising their respective structures (33 for cimetidine vs. 87 for itraconazole). However, for the 
API library, topological complexity alone cannot sufficiently explain the predictive performance 
of R3m, as illustrated by quinidine. In this case, quinidine has 131 topological connections equal 
to 3 and also the highest ratio of topological connections per atom (2.73), in part, due to the 
presence of a bicyclic ring in its structure. Nevertheless, quinidine has a relatively low R3m value 
equaling 0.593, which is a result of fewer heavy atoms in its structure, and the impact of weighted 
atomic mass (see section 5.3.1.2).  
 While the ultimate contribution to the total value of R3m from individual pairs of atoms 
with a topological distance equal to 3 may sometimes be minimal due to low weighted mass or 
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large distance between atoms (see sections 5.3.1.2 and 5.3.1.3), it is important to note that these 
individual contributions will always contribute some positive number to the total. As a result, as 
the number of atoms in a molecule increases, the number of total topological connections will also 
increase, thereby increasing R3m. This is most clearly illustrated by itraconazole, which, at 87 
atoms has the most of any molecule in the library (see Table 4). Correspondingly, the 87 atoms 
comprising itraconazole result in 216 topological connections equal to 3, reflected in a relatively 
high R3m=0.872.   
 The extent to which an increase in the number of atoms contributes to R3m is not 
necessarily linear, and in some cases, may be small enough to be essentially inconsequential. To 
illustrate this, the effect of specific structural changes on R3m were investigated using simple 
carbon chains and rings. Figure 31a and b shows the impact of increasing carbon chain length on 
the value of R3m. Increasing the length of a linear chain (Figure 31a) shows a more significant 
increase in R3m as the length increases from 2 carbons to 5, but the rate of this increase slowly 
decreases as the chain length increases. The initial increase in R3m is primarily impacted by the 
increasing number of topological connections, while the slowing rate of the increase in R3m for 
longer chain lengths is primarily a result of the leverage. Figure 31b shows the impact of increasing 
carbon ring size on R3m. Similarly, the value of R3m increases rapidly until the ring size exceeds 
7 carbons. This is also a result of increasing topological connections and relatively short geometric 
distances between atoms with topological connections equal to 3. As the distances between atoms 
increase and become relatively consistent (cyclic systems >7 carbons), the R3m value remains 
relatively consistent.  
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Figure 31: The impact of iterative changes to the number of carbons in a (a) linear chain and (b) 
cyclic systems. 
 
 Returning to the data in Table 4, there are some points to note.  The molecules are listed in 
increasing rank order of R3m, while the columns describing the number of topological connections 
equal to 3, and these connections normalized to the number of atoms in the molecule do not appear 
to have any consistent trend.   That said, more topologically complex API tend to have higher R3m 
values, so there may be some threshold in complexity needed for a molecule to be potentially 
dispersable in PVPva.  This is illustrated by the simple hydrocarbon chains and rings considered 
in Figure 31.  The R3m for these simple molecules plateaus well below the critical value of 0.65, 
and have very few topological connections relative to any of the library API.  Moreover, linear or 
cyclic hydrocarbons are hydrophobic, containing no atoms with a particular affinity for PVPva, 
making their dispersability in this polymer extremely unlikely, in line with their small relative 
R3m.  This could suggest that dispersability in PVPva requires, in part, relatively complex 
structures because the atoms and arrangements of atoms responsible for higher R3m facilitate the 
API-polymer interactions needed to form an ASD.  Taken alone, topological complexity in 
isolation is insufficient to explain how R3m is able to separate the library shown in Figure 22 into 
those dispersable in PVPva from molecules that are not.  This reinforces the proposed hypothesis, 
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however, suggesting that the multiple matrices used in the calculation of R3m results in a value 
that is more complex than, in this case, topological complexity alone, owing to a nuanced 
combination of several different factors. 
 
5.3.1.2. Atomic Mass Weighting 
 The presence of relatively heavy atoms in a molecule will have a significant impact on the 
value of R3m, as demonstrated in the atomic mass weighting portion of the R3m equation 
(Equation (18)). Since the atomic mass weighting is relative to carbon, atoms heavier than carbon 
will have a more significant contribution to the total by multiplying the relevant portions of the 
R3m calculation by a value greater than 1. For the library of compounds used to build the models 
(see Figure 22), these relatively heavier atoms are nitrogen, oxygen, fluorine, sulfur, and chlorine, 
which have atomic mass weightings of approximately 1.17, 1.33, 1.58, 2.67, and 2.95, 
respectively, and are common to API or drug-like molecules. The maximum weighted mass for 
each API is also given in Table 4. In contrast to these relatively heavy atoms, the contribution of 
hydrogen atoms to the value of R3m is generally quite small, and often negligible, owing to an 
atomic mass weighting of hydrogen relative to carbon of approximately 0.08.  Correspondingly, 
this multiplier in Equation (18) significantly reduces the contribution of atoms paired with 
hydrogen to the overall magnitude of R3m.  
 It is important to note that of the atoms comprising molecules in the Figure 22 library, those 
considered relatively heavy are also more electronegative relative to the other atoms in organic 
molecules. Their presence may increase the likelihood of forming noncovalent bonding 
interactions with the polymer, which would reduce the potential for API recrystallization and allow 
for persistence of a metastable dispersion. For example, the library compound felodipine contains 
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2 Cl atoms that are connected through a phenyl ring, which results in the requisite topological 
distance of 3. These Cl atoms are also located on the periphery of the molecule, leaving them 
distant from the geometric center and resulting in relatively higher leverage values. This 
combination of high leverage for atoms having high atomic mass weighting results in their much 
more significant contribution to the value of R3m, ultimately leading to felodipine having one of 
the largest values for R3m in the experimental API library (R3m = 0.964). This is illustrated in 
Table 4, where felodipine has among the highest average weighted mass of the molecules studied.  
 While the presence of heavy atoms furthest from the geometric center of a molecule often 
results in a larger R3m value, this is not always the case. Cloperastine is an example of a molecule 
for which the heaviest atom (Cl) also has the highest leverage value. Nevertheless, the R3m value 
for cloperastine is 0.562, which falls below the critical boundary of R3m=0.65, indicating that this 
API is not dispersable in PVPva (previously confirmed experimentally48, 174). In this case, the R3m 
value is decreased relative to other Cl-containing library molecules because this API has one of 
the lowest average weighted masses of the molecules studied (see Table 4).  
 Looking more generally at the weighted mass data in Table 4, a few trends emerge.  All of 
the API found to be dispersable in PVPva (R3m>0.65) contain at least one S or Cl atom in its 
structure.  Although the presence of these atoms does not guarantee dispersion formation (i.e., 4 
of the library molecules contain either S or Cl and have R3m<0.65), most of the API found not to 
disperse in PVPva have N or O as their maximally heavy atom.  Computationally, this contributes 
to an overall lower R3m, but chemically, this suggests that S and Cl are commonly shared among 
dispersable library API, suggesting importance in stabilizing interactions between drug and 
polymer that allows ASD persistence.   
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 This is further reflected in the average weighted masses for library API, which follow a 
similar ascending rank order with R3m, with notable exceptions.  Molecules having the highest 
weighted mass frequently have high R3m values, falling above the critical threshold of 0.65.  
Cimetidine and sulfanilamide both have S atoms, while cloperastine has a Cl atom, increasing their 
respective values of R3m, but not exceeding the value conforming with observed dispersability.  
Although S and Cl atoms are common to all of the dispersable API in the Table 1 library, it seems 
possible that other features of these 4 molecules (e.g., cimetidine’s low topological complexity 
(see section 5.3.1.1), cloperastine’s low average atomic mass weighting, and sulfanilamide’s low 
molecular weight (see section 5.3.1.3)) could suppress any chemical advantage the presence of 
these atoms have on dispersion potential, aligning with lower R3m values indicative of molecules 
that are unable to be dispersed in PVPva.   
 As with the previous section, it is not unexpected that the individual contributions of 
weighted mass do not align perfectly with the rank order of R3m values.  Exceptions, such as 
cloperastine, are expected when only one part of the R3m calculation is considered.  These 
exceptions, however, illustrate how the combination of factors captured by the multiple matrices 
used in the calculation of R3m results in a single value which is more complex than, for example, 
the molecular weight (MW) alone. 
 
5.3.1.3. Geometric Distance & Leverage 
 The geometric distance between individual atoms is explicitly included in the rij term in 
the R3m equation (Equation (18)) and, therefore, certain information about the overall molecular 
size and shape is also captured by the magnitude of this descriptor. Geometric distance is also 
important to the calculation of leverage, since leverage increases as atoms become more distant 
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from the geometric center of a molecule. A compilation of leverage data and Euclidean distance 
data from both the geometric center and between relevant atoms for each API is shown in Table 
5.  
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Table 5: Summary of data derived from the molecular matrix (M) and influence/distance matrix (R) components of R3m. 
      Geometric Distance Influence/Distance (R) 
API R3m 
Molar 
Volume 
(cm3/mol) 
Max. distance 
from geometric 
center (Å) 
Avg. distance 
from geometric 
center (Å) 
Maximum 
rij (Å) 
Sum 
rij (Å) 
Average 
rij (Å) 
Maximum 
R 
Sum 
R 
Average 
R 
Propranolol 0.342 254.64 7.33 4.22 3.79 281.5 3.00 0.056 1.81 0.019 
Cimetidine 0.403 228.09 6.76 4.19 4.22 183.4 3.11 0.058 1.17 0.020 
Melatonin 0.407 216.86 6.56 3.74 3.83 210.4 3.09 0.079 1.55 0.023 
Terfenadine 0.561 470.61 10.77 5.97 3.87 625.9 3.02 0.047 2.08 0.010 
Cloperastine 0.562 310.05 6.52 3.87 3.99 361.4 3.01 0.058 2.14 0.018 
Nifedipine 0.568 293.59 4.97 3.46 3.87 269.3 3.13 0.070 1.19 0.014 
Quinidine 0.593 302.82 5.89 3.56 3.83 398.1 3.04 0.055 2.02 0.015 
Sulfanilamide 0.595 137.79 4.17 2.64 4.02 117.4 3.17 0.114 1.51 0.041 
Tolbutamide 0.687 240.50 6.99 4.13 4.02 242.7 3.03 0.056 1.90 0.024 
Indomethacin 0.737 300.69 6.68 3.81 3.99 274.9 3.20 0.064 1.43 0.017 
Ketoconazole 0.814 443.47 10.34 5.52 3.99 483.6 3.08 0.045 1.89 0.012 
Itraconazole 0.872 594.47 13.94 7.57 4.00 664.2 3.08 0.037 1.92 0.009 
Chlorpropamide 0.927 221.26 6.03 3.63 4.02 199.6 3.07 0.079 1.87 0.029 
Felodipine 0.964 317.56 5.99 3.64 4.01 284.6 3.13 0.070 1.34 0.015 
Bicalutamide 1.001 326.92 8.07 4.46 4.19 315.9 3.16 0.059 1.69 0.017 
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 A visualization of Euclidean distance from the geometric center is illustrated in Figure 30b, 
where the geometric center of a molecule is indicated for indomethacin using a red-white-blue 
color scheme for atoms that are closest (red) to farthest (blue) from the geometric center. The 
corresponding leverage values for each atom are shown in Figure 30c, where the highest leverage 
is observed for the Cl15 chlorine. Both the high leverage value and high relative mass weighting 
for Cl result in a relatively high R3m value for indomethacin (R3m = 0.737).  
 The impact of leverage is additionally shown in Figure 32, which illustrates how simulated 
changes in molecular conformation of chlorpropamide influence the resulting R3m value. Figure 
32d shows a bar plot comparing the leverage between atoms from the different conformations, the 
most striking difference of which is shown for O17, whose distance from the geometric center 
changes as a result of conformational changes. In conformation 1 (Figure 32b), O17 is very close 
to the geometric center of the chlorpropamide molecule, resulting in a very small leverage value 
for this atom. In conformation 2 (Figure 32c), however, O17 is rotated away from the geometric 
center, resulting in a much larger leverage value, which subsequently contributes to a significantly 
larger R3m value (0.824 vs. 1.046).  
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Figure 32: An illustration of the effect of 3D conformation on leverage used to calculate R3m. (a) 
Atom labels for library compound chlorpropamide. Example conformations 1 and 2 of 
chlorpropamide are shown in (b) and (c), respectively, with corresponding R3m values shown 
beneath. (d) A bar plot of the leverages which result from the respective conformations. Hydrogen 
atoms are excluded from the bar plot for clarity. 
 
 The combined impact of geometric distance and leverage is also supported by Equation 
(22), where the geometric distance term serves as the divisor. As a result, atoms having high 
leverage and which are closer to each other in 3D space will contribute more significantly to the 
R3m for their molecules. This is demonstrated by chlorpropamide. Table 4 and Table 5 list data 
such as the maximum leverage from an individual atom, the average leverage, and the average 
contribution of each atom to an API’s influence distance matrix for each library API. The chlorine 
in chlorpropamide is the highest leverage atom for the API, and this contributes to chlorpropamide 
having one of the largest average contributions to the influence/distance matrix (average R = 
0.029) for the library API. As indicated, chlorpropamide has the third highest R3m in the present 
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library at 0.927, corresponding to a prediction of its dispersability in PVPva (previously 
confirmed48, 174). In contrast, the API having the largest average contribution to the 
influence/distance matrix is sulfanilamide (average R = 0.04), which is a result of the negative 
correlation between MW and the average leverage (r=-0.80). This negative correlation is the result 
of larger molecules generally having atoms that are further from their geometric centers; as the 
molecule gets larger, and more atoms are included in the calculation of R3m, the leverage is 
distributed amongst more atoms. As previously noted, the total leverage used to calculate this 
descriptor will always equal 3, and therefore, as the number of intramolecular atoms increases, the 
largest possible leverage for any individual atom will decrease.  Since sulfanilamide is the smallest 
molecule in the library (MW = 172.23 g/mol), its individual atoms tend to have larger leverage 
values, resulting in its higher average contribution to the influence/distance matrix. This further 
illustrates how the multiple matrices used in the calculation of R3m captures more complex 
information about the physical and chemical properties of an API than, for example, API geometry 
alone. 
 Both the leverage and geometric distance capture information relevant to the 3D 
conformation of the API. The geometry of a molecule is important because of the potential 
implications with respect to ASD formation. If an accurate 3D representation of the API is captured 
by R3m (an assumption supported by an investigation described in Chapter 6), the descriptor is 
likely capturing information relevant to the kinetics of the ASD, as it forms. In melt-quenched 
sample preparation, for example, the supersaturation of the API in PVPva increases upon cooling. 
The API will then be thermodynamically driven to phase separate, and subsequently crystallize. 
However, if an API molecule has a large relative volume, and occupies more interstitial volume 
between polymer chains, kinetic inhibition of phase separation is more likely in these systems as 
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larger molecules will diffuse more slowly through the polymer chain network. As such, these 
larger molecules are more likely to be trapped in the dispersed state than an API molecule with a 
much smaller volume.  
 To compare the relative geometries of library molecules the molecular van der Waals 
volumes were calculated using the QSAR module in Materials Studio, and are reported in Table 
5.  The average Euclidean distance from the geometric center (Table 5) is highly correlated with 
the molar volume (r=0.92), where longer distances correspond with larger volumes.  For example, 
itraconazole has the highest molecular volume of any API in the library (594.47 cm3/mol), and 
also has the largest average Euclidean distance from the geometric center (7.57 Å).  
 In evaluating trends in the data from Table 5, consider that the API are again presented in 
increasing rank order of R3m, where R3m>0.65 corresponds with molecules dispersable in PVPva.  
As with other components of the R3m calculation, molar volume alone was not expected to follow 
the same rank order of R3m, however, there does not appear to be any trends with respect to the 
molar volumes of the API studied.  Chlorpropamide (R3m=0.927) has a relatively low molar 
volume (221.3 cm3/mol), but the third highest R3m, and forms dispersions with PVPva.  Compared 
to the contributions of topological connectivity (section 5.3.1) or the weighted mass (section 
5.3.1.2), trends in Table 5 with respect to molar volume, geometric distance, and influence/distance 
and the calculation of R3m are less obvious.  For example, small, moderate, and large volume API 
appear on either side of the R3m=0.65 dispersability boundary, without any apparent connection 
to the ascending rank order of R3m for library molecules. 
 The importance of geometry to the interpretation of R3m, therefore, likely incorporates 
details from the other matrices in contributing to calculating this descriptor.  One such way is by 
combining geometry with information about the relative location of heavy atoms within the 3D 
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representation of the molecule. This information may be useful for interpreting the meaning of 
R3m as it relates to dispersability in PVPva, considering that atoms furthest from the geometric 
center of an API will be most likely to interact with other polymer molecules in a potential 
dispersion, since these atoms will be on the external surface of the 3D conformation. Moreover, 
since the heavy atoms considered in the extant library are more electronegative than the other 
intramolecular atoms, high R3m values could suggest a greater potential for molecules to undergo 
noncovalent bonding with the PVPva. For example, the large dipole moment present in side groups 
of polyvinylpyrrolidone can strongly interact with other dipoles present in the system.173 The 
presence of highly electronegative atoms could induce a dipole, and lead to such dipole-dipole 
interactions.  Consider, again, the example of chlorpropamide, where the Cl atom having the 
largest leverage is also the intramolecular atom having the largest atomic weight, where the Cl is 
on the periphery of the molecule, fully exposed for potential interactions with the PVPva.  All of 
these factors combine synergistically to result in a larger R3m=0.927, while contributing to 
physical conditions that may favor dispersion formation.  In contrast, terfenadine, has one of the 
largest molar volume of the molecules found not to disperse in PVPva (R3m=0.561), also having 
one of the higher average distances from its geometric center for all of the library molecules.  As 
shown in Figure 22, and reinforced in Table 4, the two heaviest atoms in terfenadine are the O 
contained in OH groups well separated on the molecule.  Moreover, terfenadine also contains a 
single N atom near the center of the molecule.  Despite the presence of these relatively heavy 
atoms, none is located on the perimeter (e.g., the N has one of the lowest leverage values, see 
Figure 72h in the Appendix), decreasing the potential for their interaction with the PVPva.  
Additionally, the absence of the heavier and more electronegative atoms such as S and Cl typical 
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of all dispersable library API also contributes to the smaller R3m value, and helps to explain why 
terfenadine was not observed to successfully form a dispersion with PVPva. 
 
5.3.1.4. Connecting R3m with physical environment and chemical interactions 
 The usefulness of the R3m descriptor to predict dispersability in PVPva is believed to be a 
result of the physical and chemical information that is captured from the matrices derived from the 
3D representation of the molecule. In the extant API library, intramolecular S, N, O, Cl, and F 
atoms were all relatively heavier than any other intramolecular atoms (e.g., C and H).  The location 
and relative position of these heavier atoms is highly significant to the resulting R3m value. As 
described in section 5.3.1.2, when these atoms are located on the periphery of the molecule, the 
R3m value increases relative to when these same atoms are located closer to the geometric center 
of a molecule. In certain cases, these heavier atoms are more electronegative than the others (e.g. 
Cl, F).  This potentially explains some of the importance of peripheral intramolecular Cl or F atoms 
for dispersability in PVPva.  When these atoms are on the API perimeter, and not sterically 
hindered from interaction with the polymer, there is expected to be an increased probability for the 
formation of electrostatic interactions with the PVPva. For example, induced-dipole interactions 
have been observed between ketoconazole and the carbonyl group in the vinyl pyrrolidone 
monomer of PVPva,180 which is also consistent with our finding that ketoconazole is dispersable 
in this polymer, having an R3m value of 0.814. The location and position of atoms such as O and 
N could also capture information about the potential to form hydrogen bonds with the polymer, 
but the peripheral Cl leverages heavily into the calculation of R3m, which is well above the 
threshold indicative of dispersability in PVPva. In a separate example, indomethacin (R3m = 
0.736), whose carboxylic acid hydroxyl group has been shown to facilitate formation of stable 
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dispersions in PVP through the formation of hydrogen bonds with the amide carbonyl, also 
computes to an R3m value >0.65 owing to the presence of a peripheral Cl, promoting further 
stabilizing interactions with the PVPva.  
 It is also important, however, to note that the connection between the value of R3m and 
specific non-covalent drug-polymer interactions has limitations. The heavy intramolecular atoms 
in the API library tend to be more electronegative, and, therefore, the information about their 
potential to form stabilizing electrostatic interactions with PVPva during dispersion formation is 
captured indirectly. This is an important limitation of the model, since a molecule containing heavy 
intramolecular atoms will result in a larger R3m value regardless of whether or not those atoms 
are electronegative. As an example, consider iopanoic acid, which contains three I atoms in its 
structure, and computes to an R3m = 3.616, which is much higher than any value calculated for 
the extant API library.  With an R3m > 0.65, iopanoic acid would numerically predict to be 
dispersable in PVPva, however, electrostatic interactions between the polymer and the I atoms are 
highly unlikely. Ultimately, the introduction of API containing intramolecular atoms that were not 
in the calibration dataset used to build the original R3m model will be an extrapolation, and likely 
to result in poor predictions.  
Additionally, it is important to note that the value of R3m also does not give an indication 
of what type of API-polymer interactions can or do occur. Although a large value of R3m may 
occur for a molecule which undergoes induced-dipole interactions, another molecule having a 
similar R3m value may instead undergo hydrogen bonding, or may not be capable of establishing 
any significant non-covalent interactions with PVPva at all. To assess the presence or absence of 
specific interactions between the API and PVPva, further experiments must be performed (e.g. FT-
IR, solid state NMR, etc.). Alternatively, potential interactions could be explored using more 
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advanced computational methods such as DFT. These studies could be pursued in the future to 
draw a more direct connection between the presence of non-covalent interactions and the resulting 
value of R3m.   
 Beyond specific intramolecular atom types, the value of R3m also captures information 
about the size and shape of API molecules in the extant library (see sections 5.3.1.1 and 5.3.1.3), 
which, in relation to dispersability in PVPva, is expected to influence the kinetics of phase 
separation, and subsequently, nucleation and crystallization. A large, irregularly shaped molecule, 
which will tend to have a higher value of R3m, is expected to have a lower diffusivity during 
preparation of co-solidified mixtures than a small molecule with a more isotropic shape. In the 
melt-quench preparation method, for example, as the molten API-polymer mixture is cooled, the 
API may be thermodynamically driven to recrystallize owing to its rapidly decreasing solubility 
in the polymer. As the solubility decreases, the API will be thermodynamically driven to first phase 
separate from the polymer, and subsequently nucleate, and crystalize. Simultaneously, the mobility 
of the molecules will also decrease with temperature. A larger, irregularly shaped molecule will 
likely have a lower diffusivity as it attempts to move through the solidified network of polymer 
chains, while a smaller isotropic API molecule should be able to move with less resistance. 
Correspondingly, higher values of R3m, which are expected for large, branched molecules, may 
reflect the API’s greater likelihood to persist in the amorphous state beyond initial characterization, 
owing to much slower recrystallization kinetics.  In contrast, the smaller, more isotropic molecules 
in the API library, which tend to have lower values of R3m, may recrystallize very rapidly during 
(or shortly after) preparation, resulting in characterization as a system that failed to disperse in 
PVPva. 
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 The extent to which R3m captures the size and shape of API also has limitations, which 
are best illustrated by examining extreme cases. For very small molecules, such as methane, R3m 
cannot be calculated because the molecules do not contain any topological connections equal to 3, 
resulting in a value equal to zero. Perhaps more importantly, molecule size and shape are only 
captured to a certain extent by the numerical value of R3m, owing to the inverse relationship 
between leverage and size (see section 5.3.1.3).  This is also illustrated by Figure 31. As the 
molecule grows in size, the highest individual leverage values decrease because the sum total of 
all of the leverage values must equal 3. Therefore, for very large molecules, the degree to which 
size and shape impact R3m will decrease until it becomes essentially inconsequential.  
 While the molecules in the API library are relatively diverse in their chemical structure and 
3D geometry (at least insofar as examples of small organic drug molecules predominantly 
belonging to BCS Class II), the manners in which they are similar should not be ignored, as these 
similarities highlight the limitations of the model. For example, the molecular weight of the API 
in the library ranges from approximately 172 to 706 g/mol. The dispersability of molecules with 
molecular weights significantly outside this range may be poorly predicted in PVPva, owing to the 
limitations in the calculation of R3m with respect to extremes in this attribute, as described in the 
preceding sections. Likewise, the model considered co-solidified mixtures at two concentrations 
(15 and 75% w/w API). However, predictions made by R3m may not hold true at extremes of 
composition. As an example, consider the case of a mixture of 1% API to 99% PVPva. Such a low 
API concentration is expected to be below the solubility limit in the polymer, making phase 
separation and crystallization highly unlikely.  In turn, this would render predictions of 
dispersability using R3m moot, because all of the systems would likely form stable, homogenous 
mixtures. Likewise, R3m is also unlikely to be useful in the opposite case (99% API), since the 
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solubility limit is likely to be exceeded in all cases, making rapid crystallization far more probable 
and resulting in systems that all fail to form a dispersion. In summary, while R3m appears to 
capture useful information as described above, it is important to consider the dataset upon which 
the model was built. Applying R3m for prediction of dispersability for a significantly different 
API constitutes model extrapolation and is likely to result in poor predictions.  
 
5.3.1.5. Illustrating the combined impact of matrices on R3m 
 To further illustrate the impact of the different matrices used for the calculation of R3m, 
Figure 33 shows a visualization of the relevant matrices for felodipine. Figure 33a shows the 
labeled molecular structure, Figure 33b shows the molecular matrix with a blue-white-red color 
map, Figure 33c shows the topology matrix, where yellow blocks indicate atoms which are 
connected by a topological distance of 3. Visualization of the subsequent matrices have been 
simplified to show only relevant topological connections by multiplying these matrices by the 
topological matrix (resulting in non-relevant cells being reduced to a value of 0). Figure 33d shows 
the geometry matrix, where the Euclidean distance between atoms is shown for atoms having the 
appropriate topological connectivity. Figure 33e gives a visualization of the influence/distance 
matrix, and Figure 33f gives the weighted mass for each atom of felodipine. Figure 33g shows the 
influence/distance matrix multiplied by the associated weighted masses. The sum of this matrix 
divided by 2 (since the matrix is symmetric) gives the value for R3m. This figure, in particular, is 
helpful for visualizing the overall contribution of each atom to the final value of R3m. The pair of 
peripheral Cl atoms in felodipine, referred to earlier, can be seen as the bright yellow spots in 
Figure 33g (row 18, column 19 and row 19, column 18). This atom pair contributes approximately 
25% to the R3m value of felodipine. The substantial contribution from these heavy atoms in close 
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proximity on the molecule indicates that R3m can capture useful information regarding the dipole 
moment, which is significant since it may indicate an increased likelihood of interactions with the 
polymer.  This is also consistent with the observation that felodipine, like all library molecules 
with R3m>0.65, was dispersible in PVPva, suggesting that these molecules more readily interact 
with the polymer carrier. Finally, Figure 33h gives the leverages for each of the atoms in 
felodipine. A similar figure for each API is given in the Appendix (Figure 59 through Figure 73).  
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Figure 33: Felodipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices 
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix, 
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution 
to R3m, (h) bar plot of leverages. 
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5.3.2. Confirming No Simpler, More Interpretable Model 
Exists 
 While the application of R3m for the prediction of ASD formation has been supported via 
model expansion to different manufacturing methods and concentrations (Figure 29),174 
reinforcing that the specific matrices involved in its calculation combine to provide information 
essential to predicting dispersability in PVPva required confirmation that no simpler, more 
interpretable model could perform as well as, or better than the one developed using the R3m 
molecular descriptor. Ultimately, the application of a model that is difficult to interpret would be 
unnecessary if such a model did not outperform a simpler model. To investigate this, properties 
more typically studied for their influence on ASD formation and persistence were investigated for 
improved prediction of dispersability in PVPva across 2 different ASD preparation methods and 2 
different drug loading concentrations. Of specific interest were descriptors and properties 
previously reported in studies relevant to ASD formulation development and glass formation (see 
Table 6).16, 42-45, 96, 97, 115, 181 A few of these descriptors showed statistical significance (p<0.05) 
when modeled against the experimental data that confirmed dispersability of library compounds 
in PVPva, and are indicated in Table 6 in bold. Models constructed using either average molecular 
weight (AMW) and MW both showed statistically significant performance in predicting ASD 
formation for experimental data collected from the melt-quench method and for the 75% API 
solvent evaporation data. However, both models performed poorly for the 15% solvent evaporation 
data set. Nonetheless, the performance of the AMW and MW models in predicting some 
dispersability behavior of the library API prompted a more thorough investigation into potential 
relationships of these properties with R3m (see section 5.3.3). Of the properties listed in Table 6, 
none resulted in as statistically significant a model for prediction of ASD formation using the 
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present library of API as R3m over the multiple concentrations and preparation methods studied. 
The R3m dispersability model remained statistically significant across all concentrations and 
manufacturing methods examined, while no other property was able to model dispersion formation 
in PVPva with consistent significance under all circumstances.   
 
Table 6: Logistic regression model statistics for relevant molecular descriptors and 
physicochemical properties. 
Dependent Variable 
Melt Quench 
(n=15 API) 
15% API Solv. Evap. 
(n=18 API) 
75% API Solv. 
Evap. (n=16 API) 
χ2 p-value χ2 p-value χ2 p-value 
Average Molecular weight 7.46 0.006 1.36 0.24 4.38 0.04 
Crystallization Tendency‡ 0.59 0.44 0.49 0.49 2.24 0.13 
# H-bond acceptors 6.10 0.01 0.48 0.49 1.22 0.27 
# H-bond donors 1.80 0.18 0.73 0.39 1.66 0.20 
Heavy atom count 2.35 0.13 0.19 0.66 5.38 0.02 
log P† 0.78 0.38 1.81 0.18 2.12 0.15 
log S† 1.20 0.27 3.36 0.07 3.36 0.07 
Molecular weight 3.89 0.05 0.54 0.46 5.44 0.020 
# of Nitrogen 0.53 0.47 1.97 0.16 1.03 0.31 
R3m 20.73 < 0.0001 4.65 0.03 12.36 0.0004 
Rotatable bond fraction 0.04 0.85 0.09 0.77 0.02 0.90 
# Rotatable bonds 0.29 0.59 0.001 0.98 0.99 0.32 
Tg (K)* 0.24 0.63 0.05 0.82 0.40 0.52 
Tm (K)* 0.02 0.90 0.07 0.79 0.68 0.41 
Topological Surface Area 1.70 0.19 0.15 0.70 0.0004 0.98 
p-values < 0.05 are indicated in bold. 
†Calculated using ALOPS170 
‡Experimentally determined using the method described by Baird et al,96 or compiled from previously collected 
data in Baird et al96 and Alhalaweh et al181 
* Experimentally determined by DSC (20°C/min ramp rate) 
 
 In addition to the well understood properties and descriptors described in Table 6, other 
GETAWAY descriptors were investigated to confirm that R3m was truly the most predictive 
descriptor for ASD formation in its class. It is possible that another GETAWAY descriptor 
calculated using some other weighting and/or topological distance could outperform R3m when 
the more recently collected experimental dataset (Figure 29) is considered. The correlation 
between R3m and other R-GETAWAY descriptors is shown for the 18-member library API in 
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Figure 34. R-GETAWAY descriptors with similar topological distances were highly correlated 
with R3m (r > 0.75 for R2m and R4m), as shown in Figure 34a.  
 
 
Figure 34: Bar plots showing the correlation coefficient (r) between R3m and other R-GETAWAY 
descriptors. (a) Correlation between R3m and descriptors with different topological distances 
within the library (green bars). (b) The correlation between R3m and other descriptors with 
different weightings (u = unweighted, v = van der Waals volume, e = Sanderson electronegativity, 
p = polarizability, + = maximal) within the API library (orange bars). 
 
RTm, known as the R total index weighted by mass (Equation (23)), considers every possible 
topological distance, and was found to be the most highly correlated with R3m for the library API 
(see Figure 34a, r = 0.91).  
(23)          RTm = 2 ∙  ∑ ∑
√hii∙hjj
rij
∙ mi ∙ mjj>i
A−1
i=1  
This equation is similar to that of R3m (see Equation (18)), but the topological distance delta-Dirac 
function is excluded and, therefore, RTm considers every possible topological connection rather 
than being limited to only topological distances of 3. It is currently unclear why, specifically, a 
topological distance of 3 would be most important to predicting ASD formation in PVPva, from 
our library of API. The fact that these descriptors are highly correlated indicates that they contain 
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similar information, but the RTm descriptor may be more interpretable, since it assumes no 
specific topological distance is of particular importance for ASD formation. Interpretability 
notwithstanding, R3m remains the best predictor for dispersability using the existing library, 
having a consistently lower p-value than the remaining R-GETAWAY descriptors (see Table 7).  
 
Table 7: Logistic regression models for R-GETAWAY descriptors with differing atomic mass 
weighting, 
Method Predictor(s) Regression Equation LR (χ²) Misclassification Rate p-value 
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R3m logit P(Y) = -3.96 + 6.48(R3m) 4.65 27.8% (n = 18) 0.031 
R1m logit P(Y) = -2.896 + 2.715(R1m) 2.058 27.8% 0.152 
R2m logit P(Y) = -2.850 + 3.511 (R2m) 2.727 27.8% 0.099 
R4m  logit P(Y) = -2.37 + 5.122(R4m) 3.371 16.7% 0.066 
R5m logit P(Y) = -2.715 + 7.732(R5m) 5.177 22.2% 0.023 
R6m logit P(Y) = -2.341 + 7.872(R6m) 5.397 22.2% 0.020 
R7m logit P(Y) = -1.378 + 6.128(R7m) 3.299 27.8% 0.069 
R8m logit P(Y) = -1.153 + 7.047(R8m) 1.933 22.2% 0.164 
RTm logit P(Y) = -3.07 + 0.333(RTm) 3.683 16.7% 0.055 
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R3m logit P(Y) = -12.47 + 18.16(R3m) 12.36 6.3% (n=16) 0.0004 
R1m logit P(Y) = -4.238 + 3.177(R1m) 2.601 31.3% 0.107 
R2m logit P(Y) = -6.273 + 6.435(R2m) 6.188 12.5% 0.013 
R4m  logit P(Y) = -7.951 + 14.473(R4m) 10.031 12.5% 0.002 
R5m logit P(Y) = -5.218 + 11.644(R5m) 8.512 12.5% 0.004 
R6m logit P(Y) = -2.874 + 6.626(R6m) 4.913 12.5% 0.027 
R7m logit P(Y) = -1.75 + 4.378(R7m) 2.219 25.0% 0.136 
R8m logit P(Y) = -3.025 + 12.331(R8m) 4.443 18.8% 0.035 
RTm logit P(Y) = -9.862 + 0.920(RTm) 10.738 6.3% 0.001 
M
el
t 
Q
u
en
ch
 
(1
5
%
 &
 7
5
%
  
w
/w
 A
P
I)
 
n
 =
 1
5
 
R3m N/A (separation) 20.728 0% (n = 15) <0.0001 
R1m logit P(Y) = -8.707 + 7.411(R1m) 8.247 13% 0.004 
R2m logit P(Y) = -10.717 + 12.053 (R2m) 11.945 13% 0.0005 
R4m  logit P(Y) = -10.142 + 18.980 (R4m) 13.093 7% 0.0003 
R5m logit P(Y) = -4.371 + 10.281 (R5m) 7.404 13% 0.0065 
R6m logit P(Y) = -2.544 + 6.635 (R6m) 4.728 13% 0.030 
R7m logit P(Y) = -1.358 + 4.258 (R7m) 2.069 27% 0.150 
R8m logit P(Y) = -2.911 + 13.774 (R8m) 5.623 20% 0.018 
RTm logit P(Y) = -12.190 + 1.212 (RTm) 13.926$ 7% 0.0002 
 
 Another subset of R-GETAWAY descriptors considers weightings other than atomic mass. 
These include volume, electronegativity, polarizability, maximal (i.e., only the maximum value is 
considered) weightings, as well as the absence of a weighing (unweighted). The correlation of 
these descriptors with R3m for the library API is shown in Figure 34b. These descriptors were 
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more poorly correlated with R3m. The performance of models constructed using these differently 
weighted R-GETAWAY descriptors is shown in Table 8. Models with statistically significant p-
values (p<0.05) are indicated in bold. No R-GETAWAY descriptor with a different weighting 
performed as well as R3m, leading to the conclusion that the atomic mass weighting is important 
to the predictive performance of R3m. However, it is important to note that the usefulness of R3m 
is not derived solely from the mass weighting. As seen in Table 6, when only the number of non-
hydrogen heavy atoms, MW, or AMW was considered, ASD formation of the library of API in 
PVPva was not as successfully predicted as compared to R3m alone.  
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Table 8: Logistic regression models for R-GETAWAY descriptors which consider atom topology 
= 3, but different weightings (u = unweighted, v = van der Waals volume, e = Sanderson 
electronegativity, p = polarizability, + = maximal).  
Method Predictor(s) Regression Equation LR (χ²) 
Misclassification 
Rate 
p-value 
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R3m logit P(Y) = -3.96 + 6.48(R3m) 4.65 27.8% 0.031 
R3u logit P(Y) = 0.458 - 0.137(R3u) 0.0066 44.4% 0.935 
R3u+ logit P(Y) = 1.898 - 27.19(R3u+) 0.759 38.9% 0.384 
R3m+ logit P(Y) = -1.158 + 26.51(R3m+) 2.39 33.3% 0.122 
R3v logit P(Y) = -3.139 + 5.34(R3v) 1.255 27.8% 0.263 
R3v+ logit P(Y) = -0.240 + 19.24(R3v+) 0.036 38.9% 0.849 
R3e logit P(Y) = -0.381 + 0.346(R3e) 0.034 33.3% 0.854 
R3e+ logit P(Y) = 1.117 - 13.410(R3e+) 0.432 44.4% 0.511 
R3p logit P(Y) = -2.856 + 4.275(R3p) 1.115 27.8% 0.291 
R3p+ logit P(Y) = -1.024 + 45.526(R3p+) 0.483 38.9% 0.487 
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R3m logit P(Y) = -12.47 + 18.16(R3m) 12.36 6.3% 0.0004 
R3u logit P(Y) = 1.020 - 0.299(R3u) 0.028 37.5% 0.866 
R3u+ logit P(Y) = 0.180 - 11.109(R3u+) 0.114 31.3% 0.736 
R3m+ logit P(Y) = -2.458 + 34.688(R3m+) 3.939 25.0% 0.047 
R3v logit P(Y) = -7.540 + 11.063(R3v) 3.516 25.0% 0.061 
R3v+ logit P(Y) = -4.782 + 172.724(R3v+) 2.462 18.8% 0.117 
R3e logit P(Y) = -2.714 +1.263(R3e) 0.375 25.0% 0.540 
R3e+ logit P(Y) = -0.636 + 1.847(R3e+) 0.007 31.3% 0.929 
R3p logit P(Y) = -7.031 + 8.947(R3p) 3.249 31.3% 0.072 
R3p+ logit P(Y) = -4.723 + 147.920(R3p+) 3.752 18.8% 0.053 
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R3m N/A (separation) 20.728 0%  <0.0001 
R3u logit P(Y) = -1.095 + 0.566(R3u) 0.107 33.3% 0.744 
R3u+ logit P(Y) = 1.540 - 26.579(R3u+) 0.623 33.3% 0.4299 
R3m+ logit P(Y) = -5.874 + 105.384(R3m+) 10.04 13.3% 0.0015 
R3v logit P(Y) = -5.419 + 8.423(R3v) 2.583 20.0% 0.108 
R3v+ logit P(Y) = -3.033 + 118.41(R3v+) 1.242 26.7% 0.265 
R3e logit P(Y) = -3.439 + 1.898(R3e) 0.916 33.3% 0.339 
R3e+ logit P(Y) = -0.073 - 0.880(R3e+) 0.002 40.0% 0.9665 
R3p logit P(Y) = -5.445 + 7.360(R3p) 2.695 20.0% 0.101 
R3p+ logit P(Y) = -5.28 + 181.670(R3p+) 4.417 26.7% 0.0356 
 
5.3.3. MLR modeling to further explore the meaning of 
R3m 
 Until this point, correlations between R3m and other properties have been limited to the 18 
API for which experiments have been performed, consisting of ASD formation attempts with 
subsequent physical characterization. With relatively few API, any identified correlations between 
R3m and other descriptors or properties could be somewhat limited by the relatively small dataset. 
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However, many descriptors can be rapidly calculated using only 1D information (e.g., SMILES 
files). To investigate potential relationships between R3m and other properties, and thereby 
support the previously discussed inferences about the meaning of R3m, a larger dataset of 
descriptors for 176 primarily BCS class II compounds was compiled. A list of included compounds 
can be found in the Appendix (Table 21).  Of specific interest were more easily interpretable 
molecular descriptors, including descriptors which have been used in the literature (e.g., to predict 
glass forming ability, physical stability of glasses, etc.), such as the physicochemical properties 
and descriptors listed in Table 6, as well as descriptors which capture information about size, 
shape, and volume of the API (e.g., spatial descriptors in Materials Studio,175 Connolly surface 
area and volume, etc.), chemical information (e.g., number of hydrogen bond donors and 
acceptors, number of heavy atoms, calculated log P and log S, topological polar surface area), and 
information about molecular mobility (e.g., rotatable bond number, molecular flexibility, radius of 
gyration, etc.). 
 Among the descriptors of interest was AMW, which was previously found to have a 
moderate positive correlation with R3m (r = 0.75).174 This relationship appears to be mostly 
maintained with the larger dataset (see Figure 35, r = 0.66), and increases confidence in the 
chemical diversity of the original API library. If the original library had not been chemically 
diverse, these correlations may have changed much more significantly, since similar compounds 
would not have sufficiently captured the true variability of the descriptors of interest. The 
relationship between R3m and AMW is a direct result of the weighted mass portion of the R3m 
equation (Equation (18)). The weighted masses used in R3m are normalized to carbon, and since 
carbon is a major component of the organic small molecules which compose the library, it is likely 
that AMW will be correlated with this portion of the equation. However, as shown in Table 6, 
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AMW fails to perform as well as R3m for the prediction of ASD formation among the original 18-
compound library.  This suggests AMW helps explain the importance played by heavier atoms in 
contributing to higher values of R3m, but cannot be used as a surrogate to model dispersion 
potential in PVPva. 
 
 
Figure 35: The relationship between R3m and average molecular weight (AMW) for a dataset of 
176 API.  
 
 Multiple linear regression (MLR) was also applied to examine more complex relationships 
between R3m and other simpler descriptors in an attempt to further advance understanding of the 
physicochemical meaning of R3m. The most promising model is shown in Figure 36, where MW 
and molecular density help to illustrate what sort of information is being captured by the R3m 
descriptor. The collinearity of MW and molecular density was confirmed to be low (r = -0.07), and 
permits their application in an MLR model. Molecular density describes the atomic weight per 
volume of a molecule, reflecting the types of atoms and how they are packed within a molecule,175 
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such that API having a relatively small volume comprised of more heavy atoms will have a higher 
numeric value. Molecular density captures information very similar to AMW (r=0.96), but 
considers volume rather than total number of atoms.  The moderate correlation observed between 
R3m, MW, and molecular density supports the conclusions that the R3m descriptor captures 
information about the size and shape of a molecule, and that it captures information about the 
relative position of heavy atoms. 
 
 
Figure 36: A multiple linear regression model of molecular weight and molecular density vs. R3m. 
(a) a 3D surface plot showing the linear fit as a surface (R2 = 0.59), (b) the actual vs. predicted 
plot.  
 
In addition, the relationship between MW and descriptors which capture information about 
volume, area, and shape of molecules is illustrated in Figure 37. MW has a high correlation (r 
ranging from 0.68 to 0.97) with these descriptors, and the usefulness of MW in the MLR model 
with R3m further supports the idea that R3m is capturing information about the size and shape of 
the API molecules.  
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Figure 37: Correlation coefficient (r) between molecular weight and other descriptors which 
describe API shape, volume and area.  
 
 As a means of separating structurally diverse molecules into their respective dispersion 
behavior in PVPva, R3m appears to succeed relative to any other simple, more intuitive property 
precisely because it encodes structural information that is not obvious.  Given the complexity 
inherent to ASD formation, it is not surprising that identifying the nuanced combination of 
properties needed to form a dispersion in a polymer comes down to a complicated molecular 
descriptor. Moreover, ASD formation combines not only the chemistry of API and polymer, but 
also depends on a number of thermodynamic and kinetic factors, placing a nearly impossible 
burden on a simple physical or chemical property to capture all elements of this complexity.  For 
example, although MW may reflect some of the kinetic factors associated with ASD formation, 
since larger molecules are generally better glass formers, MW alone is unable to group library 
molecules according to dispersion formation in PVPva, as illustrated in Table 6. R3m, on the other 
hand, is influenced by MW, and captures some of the same information, but the impact of 
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molecular size on R3m changes as the molecular size increases owing to the competing impact of 
weighted mass and leverage, capturing other important information such as the relative 
intramolecular location of heavy atoms, whose positions may contribute to better or worse 
facilitation of the API-polymer interactions needed for ASD formation. Ultimately, the complexity 
of R3m is a result of its calculation from several matrices, each of which contains physically and 
chemically relevant information that appears to help separate the library with respect to dispersion 
formation with much greater accuracy than any other more intuitive or easy to interpret descriptor 
or property. 
 The results reported here have revealed additional information about the physicochemical 
meaning of R3m and its usefulness for the prediction of ASD formation. The formation of ASDs 
is believed to be a complex phenomenon that is impacted by both thermodynamic and kinetic 
factors. However, the extent to which R3m captures kinetic and thermodynamic information 
(independently or in combination) remains unclear. Future work will focus on investigating to 
what extent R3m captures specific thermodynamic and/or kinetic information. 
 
5.4. Conclusions 
 This chapter has discussed the calculation of R3m, has elucidated the physicochemical 
meaning of the molecular descriptor, and has revealed potential reasons for its usefulness as a tool 
for the prediction of ASD formation with the polymer PVPva. R3m contains information about 
the size and shape of an API molecule, the number and relative positions of intramolecular atoms 
in 3D space (with increasing significance for heavier atoms), and increasing topological 
connectivity which indicates increased branching. In general, large molecules, having increased 
topological connectivity (reflective of increased branching), molecules having more heavy atoms 
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(higher molecular density), and with heavy atoms furthest from the geometric center (on the 
periphery of the 3D conformation of the molecule) have higher R3m values, suggesting these 
attributes conform to R3m>0.65, which corresponds to API which are dispersable in PVPva. 
Multiple linear regression of R3m against simpler, more intuitive descriptors and properties 
showed a relationship with MW and molecular density, which further supports these conclusions. 
The size and shape of API molecules is believed to be important to the kinetics of ASD formation. 
The relative location of heavy atoms is expected to increase the likelihood of non-covalent 
interactions with the polymer, since the atoms heavier than carbon in the API library considered 
are more electronegative. Heavy atoms which are far from the geometric center of the molecule, 
and close to each other in Euclidean space, are more likely to result in a larger R3m value, and 
also increase the likelihood of an increased dipole moment in that molecule. This is expected to 
increase the likelihood of non-covalent interactions (i.e., dipole-dipole interactions), and thereby 
impact thermodynamic parameters such as the enthalpy of mixing. The formation of ASDs is a 
complex phenomenon that involves thermodynamics and kinetics. As a result, individual 
parameters are generally insufficient to capture sufficient information for the prediction of ASD 
formation. In contrast, R3m is more useful despite also being a single parameter because it contains 
more information as a result of its derivation from several matrices which contain physically and 
chemically relevant data.  
 An important premise for the interpretability of R3m with respect to geometry is that it is 
able to capture three-dimensional (3D) information about the API. However, this assumes that the 
predicted conformation used for the calculation of R3m which has been used up to this point 
reasonably matches the ‘true’ conformation of the API during co-solidification. If this assumption 
is invalid, the conclusion that R3m contains useful geometric information is weakened. The next 
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chapter will investigate the validity of this premise, and continue to advance the interpretability of 
R3m.  
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Chapter 6. The Impact of API Three-Dimensional 
Conformation on R3m 
6.1. Introduction 
 As described in Chapter 4, R3m was found to correctly predict the formation of ASDs for 
a 15 member library of API (Figure 38) prepared using the melt-quench method at 2 concentrations 
(Figure 39).48, 174 A decision boundary of R3m equal to 0.65 was identified as being 100% 
predictive for ASD formation in PVPva by the melt-quench method, where molecules having 
R3m>0.65 all formed persistent ASDs in the polymer, as confirmed using a suite of analytical 
characterization techniques. Additionally, Chapter 5 showed that R3m contains information about 
the size and shape of a molecule, the number and relative positions of API atoms in 3D space (with 
increasing significance for molecules containing heavier peripheral atoms), and topological 
connectivity. R3m is useful because it is derived from multiple matrices which contain physical 
and chemical data which is relevant to the complexity of ASD formation. Ultimately, the utility of 
the R3m descriptor is based, in part, on its ability to capture relevant three-dimensional (3D) 
information about the API. However, this assumes that the predicted conformation used for the 
calculation of R3m reasonably matches the ‘true’ conformation of the API during co-solidification. 
In order to support or refute the argument that the R3m descriptor is useful because of the 
geometric information it contains, it is necessary to investigate the impact of 3D conformation of 
the resulting value of R3m, and to investigate if the predicted 3D conformation is representative 
of the amorphous form.  
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Figure 38: Molecular structures of API in the M/Q compound library with R3m values given 
parenthetically.  
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Figure 39: Modeling of dichotomous classifications of API dispersability in PVPva for co-
solidified mixtures prepared by melt-quenching against the molecular descriptor R3m. Separation 
is observed in the melt quench models, where all API having R3m > 0.65 were dispersable in 
PVPva.48, 174 Reproduced here from Figure 25a, for convenience. 
 
 Until this point, the calculation of R3m resulted in a single number determined using the 
lone conformation obtained from the crystal structure for each molecule, or from a predicted 
conformation.  Predictions of dispersability in PVPva using R3m, however, would ideally capture 
information about the distribution of conformations that is possible for a molecule in its amorphous 
state.  To further understand the validity of the R3m dispersability model it is necessary to 
investigate whether the values used to build the original model are representative of the 
conformational distributions expected for amorphous API as dispersions form. This chapter 
considers the hypothesis that the predicted 3D conformation used to calculate R3m is sufficiently 
representative of the geometry of an API in its dispersed state (approximated herein by the 
amorphous conformation of the API alone). Specifically, the values of R3m determined from 
predicted conformations are expected to fall within the distributions of R3m values calculated from 
conformations expected in the amorphous state.  As such, the decision boundary concerning 
dispersability will remain unchanged, and therefore, no changes in the original classifications of 
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dispersability for library molecules is expected. To address this hypothesis, the overall impact of 
3D conformation on the value of R3m will be investigated. Next, molecular dynamic simulations 
will be used to obtain a reasonable distribution of conformations expected for the amorphous forms 
for each library API molecule. Distributions of R3m will be evaluated to see if they contain the 
original value (calculated from the conformation in the crystal structure). Finally, the model for 
the prediction of ASD formation will be updated to include these distributions in R3m which result 
from the variation in 3D conformations for each API. Inclusion of this conformational information 
is expected to improve future predictions, particularly for API which fall near the established 
decision boundary.  
 
6.2. Experimental Section 
 
6.2.1. Preparation of Co-solidified Mixtures 
 The preparation of co-solidified mixtures has been previously described in Chapter 4 (see 
section 4.2.2). Briefly, the melt-quench method involves dry blending the polymer and API at a 
specific weight ratio and transferring to a crucible, where the mixture is then heated to 10°C above 
the melting point of the API for approximately 30 minutes with intermittent stirring. The molten 
mass is then quenched by immersion of the crucible in ice water under dry N2 purge to minimize 
exposure to water condensation and plasticization. The resulting solids were stored overnight in a 
desiccator containing P2O5 and characterized the next day using powder X-ray diffraction (PXRD), 
differential scanning calorimetry (DSC), and hot-stage polarized light microscopy. Additional 
details concerning the categorization of dispersability can be found in Chapter 4. Dispersion 
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behavior was regressed against a database of molecular descriptors, from which R3m was the only 
one that correctly separated the library according to dispersability in PVPva (Figure 2).  Although 
co-solidified mixtures were also prepared using a solvent evaporation method in the cited 
reference, this chapter will focus on the melt-quench data to eliminate the potentially confounding 
presence of organic solvent in those mixtures.  
 
6.2.2. Crystal Structure Data  
 To explore the variation in R3m between experimental and predicted conformations 
beyond the original library shown in Figure 38, 80 individual molecules were identified, consisting 
of primarily BCS class II API. Crystal structure files were obtained from the Cambridge 
Crystallographic Data Centre (CCDC)156 in order to compare predicted 3D structures to 
experimental (crystal) data. A total of 130 CCDC files were used, comprised of 50 polymorphic 
forms of 33 of the 80 API. The CCDC reference codes for these files can be found in Table 20 in 
the Appendix. For cases where multiple crystal structure files existed for a single polymorph, the 
file with the lowest reported R-factor was selected. 
 
6.2.3. Molecular Dynamics  
 Molecular Dynamics (MD) simulations were performed using Materials Studio175 to 
sample multiple 3D structural conformations in the amorphous form. The COMPASS II force field 
was applied for all of the simulations described since it has been parameterized for drug-like 
molecules, includes functional groups of interest, and has been optimized using experimental 
data.182 The MD process is illustrated in Figure 40. First, the API structure was drawn and its 
geometry optimized using the Forcite module. The Conformers module was then applied using the 
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systematic grid scan method to identify the conformation of lowest total energy (Figure 40a). This 
was performed to ensure the initial structure for MD simulations was not sterically trapped in an 
unlikely conformation. Next, the amorphous structure was built using the Amorphous Cell module, 
where 40 molecules derived from the previously identified lowest energy conformation of the API 
were placed into a virtual box with cubic dimensions and a density of 1 g/cm3. The construction 
of the amorphous cell was replicated for a total of 10 cells, and the 3 cells having the lowest total 
energy following geometry optimization were selected for subsequent MD simulations (Figure 
40b). Finally, MD simulations were conducted using the Forcite module for a total of 500 ps using 
the NPT ensemble to permit the cell volume to fluctuate (Figure 40c). The virtual temperature was 
held at 298 K using the Nosé-Hoover thermostat, and the virtual pressure was held at 1 atm using 
the Berendsen barostat. The amorphous density for each API was determined by taking the average 
of the density over the final 300 ps of the simulation. 3D molecule conformations were extracted 
from 7 frames equally spaced throughout the final 300 ps of the simulation (illustrated by red boxes 
in Figure 40c). Individual molecular conformations were then extracted and R3m was calculated 
for each conformation (Figure 40e), resulting in a total of 840 conformations for each API. A larger 
cell was constructed using 200 API molecules to confirm that the size of the amorphous cell did 
not have a significant impact on the calculated R3m distribution, nor the predicted amorphous 
density. No significant change in the resulting distribution of R3m values was observed (see Figure 
74 in the Appendix), so an amorphous cell containing 40 molecules was used for all future studies 
to save on computational time.  
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Figure 40: Example molecular dynamics simulation. (a) The conformer tool is used to identify the 
lowest energy conformation (black dashed line). (b) This conformation is used to construct 10 
amorphous cells. The 3 with the lowest energy (indicated in orange) are selected for MD 
simulations. (c) The MD simulation using the NPT ensemble. Multiple frames are selected after 
equilibration (indicated by the red boxes). (d) The selected frames are saved and coordinates are 
extracted using MATLAB to calculate R3m values for each individual molecule. (e) Some 
example conformations from a single MD frame.  
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6.2.4. Extraction of Conformations from MD Simulations 
and Calculation of R3m 
 The extraction of the 3D molecule conformations from the Materials Studio MD simulation 
was performed using MATLAB. Seven frames per simulation were saved as .xsd files. Relevant 
data from these files, such as the atom types, atom coordinates, connectivity, etc. were extracted 
using in-house MATLAB code. The coordinates of each molecule were then centered and the R3m 
descriptor was calculated for each conformation using another in-house MATLAB function. The 
MATLAB functions for this process can be obtained via the links provided in Table 21 in the 
Appendix.  
 
6.3. Results & Discussion 
 R3m belongs to the geometry, topology, and atom weights assembly (GETAWAY) class 
of descriptors. The calculation of the R-GETAWAY class of molecular descriptors is described in 
more detail elsewhere.35, 51 The R3m equation is given in Equation (18),35 and reproduced below 
(equation (24)) for convenience.  
(24)         R3m = ∑ ∑
√hii∙hjj
rij
∙ mi ∙ mj ∙ δ(3; dij) i>j
A−1
i=1  
Here, A is the number of atoms in the molecule, m is the atomic mass normalized to carbon, i and 
j refer to 2 separate atoms, rij is the Euclidean distance between atoms, hii and hjj are the leverages, 
and δ(k:dij) is a delta-Dirac function, where k is the topological distance. For R3m, the topological 
distance (k) is equal to 3, and the weighting is the atomic mass relative to carbon. The terms, which 
are used to calculate R3m, are calculated using several matrices. The first is the 3×A molecular 
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matrix, which contains the atomic coordinates. The geometry matrix is an A×A symmetric matrix 
containing the Euclidean distance between each atom in the molecule. The molecular influence 
matrix is an A×A matrix calculated in the same manner as the leverage matrix for linear 
regression,51 and the diagonal of this matrix contains the leverage values used in Equation (24) 
(i.e., hii, hjj).  
 The matrices comprising Equation (24) are all impacted to some extent by the 3D 
conformation of a molecule. Changing the conformation of a molecule will result in a change to 
the values of an API’s molecular matrix, and subsequently, its geometry matrix. While the 
Euclidean distance of atoms having a topological distance of 1 (i.e., atoms connected by a covalent 
bond) will remain essentially unchanged due to the consistency of these bond lengths, the 
Euclidean distances of atoms, which are separated at larger topological distances, will vary due to 
conformational differences resulting from altered torsion and bond angles. Likewise, leverage 
values, which are a measure of the distance of atoms from the geometric center of a molecule, will 
also change owing to potentially significant changes in the location of the geometric center caused 
by changes in torsion angles. It is evident, then, that changes in 3D conformation will likely result 
in changes to R3m. However, the extent and significance of these changes remains unclear. It was, 
therefore, necessary to first investigate whether conformational changes could result in any 
significant changes to R3m, and by extension, have a potential impact on future predictions of 
ASD formation in PVPva made by the R3m model. 
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6.3.1. Investigating the Potential Impact of 3D 
Conformation 
 The 3D coordinate system of the API impacts the magnitude of the R3m value owing to 
changes in both geometric distances and leverage values. It is, therefore, important to consider the 
source of the coordinates. Ideally, the coordinates used to calculate R3m should be representative 
of the API conformation in an ASD so that the model can capture realistic information regarding 
molecular size and shape, and the potential to interact with the polymer. Using inaccurate 3D 
coordinates would make arguments about relationships between R3m and physical properties more 
tenuous. As a result, 3D coordinate predictions were investigated and compared with experimental 
data and with molecular dynamics simulations.  
 
6.3.1.1. CORINA vs. crystal structure data 
 The 3D conformations of the 15 library API shown in Figure 38 were predicted using the 
COoRdINAtes (CORINA) algorithm.178 CORINA sets bond angles and lengths based on the types 
of atoms, hybridization states, and types of bonds.  Additionally, atom positions are adjusted to 
avoid non-bonded atom overlap, and a pseudo-force-field is applied to minimize the sum of 
stretching, bending, out-of-plane, and torsional energies.178  While it is possible to calculate R3m 
using experimentally obtained coordinates (e.g., crystal structure data), the model was built using 
1D data (simplified molecular input line entry specification (SMILES) files) in order to make the 
model more generally applicable. For example, in the event that a new chemical entity does not 
have a solved crystal structure, the model could still be applied. However, it is important to 
consider the performance of the CORINA model in comparison to the physical state of interest, 
since a reasonable 3D conformation is believed to be integral to the model.  
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 Given the abundance of structural information available in the CCDC, an initial 
comparison of predictions relevant to the solid state began with crystalline conformations for the 
molecules being investigated. The CORINA algorithm has been previously shown to make good 
predictions of molecular conformation in crystals,178 and a more recent study with a larger dataset 
of 2,443 small organic molecules showed an average root mean square deviation of 0.95 Å between 
actual and predicted conformations.183 However, it remained unclear how the value of R3m 
between experimental and predicted structures would vary. To address this question a dataset of 
primarily BCS class II crystalline structures were assembled (see Table 20 in the Appendix for a 
list of API and their respective CCDC reference codes). The R3m descriptor was calculated using 
both the reported crystallographic structures and for CORINA-predicted structures. In cases for 
which crystal structures for polymorphic forms of API were available (33 API, for a total of 50 
polymorphs), the R3m value was determined using these coordinates as well. Inclusion of 
polymorphs allowed for the assessment of 3D conformational variability within individual API.  
Histograms of the average absolute difference between calculated R3m values are shown in Figure 
41a and b, where Figure 41a is a compilation of 80 different API structures, and Figure 41b 
includes a total of 130 API (50 of which are polymorphs of 33 of the original 80 structures). A low 
average absolute difference between R3m values is observed, with a majority of the API having a 
difference in R3m of ≤0.05 between CORINA and CCDC 3D coordinates. Specifically, a 
difference in R3m≤0.05 was observed for 68% of the 130 structures (API and polymorphs) while 
86% had a difference in R3m≤0.1. Figure 41c shows a linear regression fit for the 80 individual 
API, and Figure 41d shows a similar regression including the polymorphs (130 API total). The 
slopes of the lines are 0.91 and 1.04, respectively.  
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Figure 41: Histograms of the average absolute difference between R3m values calculated using 
CORINA and R3m calculated using crystal structures obtained from the CCDC. (a) 80 API, and 
(b) 130 API, which included 50 polymorphic forms of the original 80 compounds. Linear 
relationship between (c) R3m values for 80 API calculated using 3D structures from CCDC vs. 
the CORINA algorithm, and (d) R3m values for 80 API (blue diamonds) and 50 polymorphic 
forms for a total of 130 API (orange circles). The orange regression line reflects the fit for all 130 
API. Points indicated by the red box show R3m values calculated for the different polymorphs of 
aripiprazole. 
  
 While the difference in R3m between CORINA predictions and experimentally determined 
3D conformations was generally negligible, there were some notable exceptions. One such 
example is aripiprazole, for which the largest difference between CCDC and CORINA R3m values 
was observed (ΔR3m = 0.28). The aripiprazole polymorphs are indicated by the red box in Figure 
41d. Figure 42 shows a comparison of the 3D coordinates from CCDC crystal structures for the 
aripiprazole polymorphs having the largest difference in R3m value. The observed difference in 
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R3m is the result of a significant change in the torsion angle of the linear butyl carbon chain in 
aripiprazole. Polymorph I has a dihedral angle of 174.7°, while polymorph VII has a dihedral angle 
of 58.34°. This change in dihedral angle causes a shift in the geometric center of the molecule, and 
results in changes to the leverage values. This change will also result in changes in specific atomic 
positions, and therefore, changes in the Euclidean distances between atoms.   
 
 
Figure 42: (a) Molecular structure of aripiprazole. (b) A comparison of the CCDC structures 
obtained for 2 aripiprazole polymorphs, where the dichlorophenyl groups are overlaid on the left. 
The change in 3D coordinates results in a relatively significant difference in R3m values 
(aripiprazole I (CCDC ID: MELFIT01,184 orange) R3m = 0.951, aripiprazole VII (CCDC ID: 
MELFIT07,185 teal) R3m =1.204).  
 
 While in certain cases, larger differences in R3m were observed, the average absolute 
difference in R3m for all 180 conformations was 0.06.  Nevertheless, it is evident that the potential 
variation in R3m is important to consider. It is possible that a calculated R3m value may deviate 
significantly from the ‘true’ R3m value, where the ‘true’ value would be representative of the 
distribution of real 3D conformations of the API in the environment of interest. When used in the 
extant R3m model for predicting ASD formation in PVPva, variations in R3m owing to 
conformation may potentially affect the accuracy of the model, since dispersion behavior is 
predicted based on a boundary value of R3m = 0.65. In certain cases, particularly for API having 
an R3m close to 0.65, conformational changes could potentially cause the calculated R3m value 
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to fall on either side of this boundary, resulting in different dispersability predictions. As a result, 
the calculation of R3m should be based on a realistic conformation so that accurate predictions can 
be made.  
 Calculated values for R3m may also vary depending on the environment of the API. For 
example, if the 3D conformation of an API in a solvent system is significantly different, there may 
be a difference in the ‘true’ R3m value. Accounting for these types of variabilities may help to 
improve predictions of dispersability in the future. This potential route for model improvement has 
driven the investigation described below. In previous work, differences in dispersability were 
observed between melt and solvent preparation methods.174 Understanding API conformational 
changes that result from changes in the environment surrounding the API may also lead to better 
predictions of ASD formation, and is a topic of future research.  
 
6.3.2. Simulation of Amorphous 3-D Conformations using 
Molecular Dynamics 
 While the CORINA algorithm appears to adequately predict the crystalline structure of 
most API (ΔR3m<0.1 for 86%), it remained unclear if the crystalline conformation was sufficiently 
representative of the API in its amorphous state. Ideally, since the value of R3m is being used to 
predict the formation of ASDs in PVPva, the calculated R3m should be representative of the 
conformations of the API that are most likely in the amorphous state. The conformations of each 
API in the amorphous form will likely adopt a distribution of possibilities relative to the crystalline 
form owing to the increased entropy, volume, and free energy. Correspondingly, a wide 
distribution of R3m values is possible for each API depending on how much each matrix is 
influenced by molecular conformations. By determining the breadth of R3m distributions for each 
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API in our library, it is possible to establish a sense of the possible variation relative to the original 
R3m values used to build the dispersion prediction model, and comment on the likelihood of 
misclassified dispersion behavior. The width of these distributions may significantly impact the 
model decision boundary, and subsequently, future predictions.  
 Since experimental data for the 3D conformations likely in the amorphous form are not 
available, molecular dynamics (MD) simulations were applied to predict structures more 
representative of the amorphous form, as described in section 6.2.3. A 500 ps simulation was run 
in triplicate for each API. Individual simulation frames were extracted after the system appeared 
to reach equilibrium (after 200 ps). The individual 3D coordinates from the molecules in these 
frames were extracted using MATLAB to obtain a sampling of possible 3D conformations, and 
the values for R3m were calculated for each. Links to relevant MATLAB code can be found in 
Table 21 in the Appendix. In total, R3m values for 840 conformations were calculated for each 
API, and resulted in a distribution of possible R3m values for molecules in the amorphous state.  
 It is important to note that while MD simulations may yield a result, its usefulness will 
depend on the assumptions and parameters applied to obtain it. It is necessary to consider the 
limitations of the computation and to compare results with other physical models, where available, 
to ensure that each output is meaningful.186 For this reason, the amorphous density as determined 
by MD simulations was compared with the experimental amorphous density values, where 
available. The corresponding MD amorphous densities, experimental values, and crystallographic 
densities for each API are given in Table 9.  
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Table 9: Predicted and actual (where available) amorphous densities for library API. 
Experimentally determined densities were obtained from the literature. 
API R3m 
Actual 
Amorphous 
Density (g/cm3) 
Predicted 
Amorphous 
Density (g/cm3) 
Actual 
Crystalline 
Density (g/cm3) 
CCDC 
Refcode156 
Propranolol 0.342 N/A 1.08 1.164 IMITON187 
Cimetidine 0.403 N/A 1.20 1.312 CIMETD188 
Melatonin 0.407 N/A 1.16 1.276 MELATN01189 
Terfenadine 0.561 N/A 1.04 N/A N/A 
Cloperastine 0.562 N/A 1.11 N/A N/A 
Nifedipine 0.568 1.20
a
 1.23 1.382 BICCIZ03
190 
Quinidine 0.593 N/A 1.14 1.234 BOMDUC191 
Sulfanilamide 0.595 N/A 1.44 1.514 SULAMD03192 
Tolbutamide 0.687 N/A 1.21 1.252 ZZZPUS18193 
Indomethacin 0.737 1.34
b
 1.29 1.401 INDMET03
194 
Ketoconazole 0.814 1.30
c
 1.30 1.4 KCONAZ
195 
Itraconazole 0.872 1.30
d
 1.26 1.36 TEHZIP
196 
Chlorpropamide 0.927 N/A 1.36 1.45 BEDMIG10197 
Felodipine 0.964 1.28
a
 1.26 1.451 DONTIJ
198 
Bicalutamide 1.001 N/A 1.43 1.554 JAYCES199 
a – Marsac, et. al.85 
b – Tong, et. al.200 
c – Van den Mooter et. al.6 
d – Six et. al.201 
 
 As shown, experimentally determined amorphous densities were available in the literature 
for nifedipine, indomethacin, ketoconazole, itraconazole, and felodipine. For these 5 API, the 
difference between the experimental and MD predicted amorphous densities was less than 4%, 
and, as expected for amorphous solids, always lower than the corresponding crystallographic 
density obtained from CCDC files. Similarity between predicted and experimental amorphous 
density increased confidence that the results of the MD simulations were meaningful. 
 Figure 43 shows a box-and-whisker plot for the R3m values that were calculated by 
sampling structures from the MD simulations. The boxes indicate the upper and lower quartile of 
the R3m distribution for each API, and whiskers indicate the edges of a normal distribution. Red 
crosses indicate outliers from the normal distribution, the red horizontal line within the boxes 
indicates the median, and the center of the black diamonds indicates the mean. The original R3m 
values, which were determined using the CORINA predicted 3D structure, are shown by the blue 
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dashed horizontal lines. The dotted black horizontal line indicates the original R3m boundary of 
0.65, where molecules having R3m greater than this value were confirmed to be dispersable in 
PVPva.  
 
 
Figure 43: A box-and-whisker plot of the R3m values calculated from MD simulations (840 R3m 
values for each API). The red line toward the center of the box is the median, the box shows the 
interquartile range, and the whiskers indicate the interquartile range multiplied by 1.5. Values 
outside of this range have the red ‘+’ symbol, indicating values that fall outside of a normal 
distribution. The black diamonds indicate the mean, and the blue dashed lines indicate the R3m 
values calculated from SMILES files and the CORINA algorithm. The horizontal black dotted line 
indicates the original R3m decision boundary, and the horizontal black dot-dashed line indicates 
the boundary updated using MD simulation results (R3m=0.632, see Figure 45). The green boxes 
indicate API which were experimentally observed to successfully form ASDs using the melt 
quench method, while those API in red indicate compounds which failed to form ASDs. 
 
The median R3m values determined using MD simulations were generally similar to CORINA 
predicted values originally used to build the dispersability model. The average absolute difference 
between CORINA and both the mean and median MD determined R3m values was 0.03. The 
largest difference between median MD determined R3m and the corresponding R3m values 
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calculated using CORINA was observed for cimetidine, which had an absolute difference of 0.11. 
The variability observed for cimetidine is specifically a result of the variation in Euclidean distance 
between the intramolecular sulfur and the two intramolecular nitrogen atoms, which are separated 
from it at a topological distance of 3 (see Figure 38). The flexibility of the chain that extends from 
the imidazole group, and the resulting impact on the Euclidean distance between these heavier 
atoms, has more impact on the value of R3m. As the sulfur and nitrogen atoms approach each other 
in 3D space, the R3m value is expected to increase.  
 In general, the R3m value from CORINA predicted conformations fall within the 
distributions or R3m values determined by MD simulations. Only propranolol fell outside this 
distribution (see Figure 43). This was the result of a linear 3D conformation predicted by the 
CORINA algorithm, as shown in Figure 44b. The blue propranolol molecule shown in Figure 44b 
and Figure 44c corresponds to the CORINA conformation. The red molecule in Figure 44b was 
pulled from the MD simulation and had an R3m value matching the MD median value. The green 
molecule in Figure 44c was also extracted from the MD simulation based on its similarity to the 
CORINA calculated R3m value (difference in R3m = 0.0014). A linear conformation is less 
commonly observed in the MD simulation due to the impact of the surrounding environment. A 
rotation about the O8, C7, C6, C5 dihedral is more common, and results in an increase in R3m 
relative to that calculated for a linear conformation predicted by CORINA due to the shift in the 
geometric center of the molecule, and subsequent change in leverage values. 
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Figure 44: Propranolol conformations and their effect on R3m. (a) Propranolol with atoms labeled. 
Propranolol molecules in blue correspond to the CORINA calculated conformation ((b) and (c)). 
(b) The propranolol molecule in red was extracted from MD simulations and has an R3m value 
equal to the median. (c) The green propranolol molecule shows a conformation from the MD 
simulation having an R3m value most similar to the CORINA conformation (difference in R3m = 
0.0014). 
  
 The result is an increased confidence that R3m values determined using the predicted 3D 
conformation from the CORINA algorithm are sufficiently representative of the amorphous form. 
The R3m values applied to build the original dispersability model all fall reasonably close to the 
median values calculated using conformations obtained from the MD simulations, where the 
largest absolute difference between median MD R3m and CORINA R3m values was 0.11. This 
indicates that the R3m values used to build the original model captured relevant and more realistic 
structural information for the API molecules relative to how they might appear during ASD 
formation with PVPva. This increased confidence that the conformation is representative of the 
amorphous form strengthens the idea that R3m captures meaningful physicochemical properties. 
In contrast, if the model had been originally built using descriptor values that were not sufficiently 
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representative of the amorphous form, the failure to capture the ‘true’ 3-D conformation would 
significantly weaken arguments that size and shape information captured were relevant to the 
formation of ASDs. Ultimately, the MD determined R3m values do not significantly affect the 
model, and the resulting predictions are unchanged. However, it is important to note that variations 
in conformation can have a significant impact on the R3m value, and, therefore, could potentially 
impact predictions for molecules subject to large conformational differences. Inclusion of this 
conformational variability is likely to improve future predictions (see section 6.3.3). Applying the 
median R3m value for future predictions may also help to improve future predictions by capturing 
the R3m value of the energetically preferred conformation. A bar plot comparing R3m values 
calculated from CORINA generated structures, structures obtained from the CCDC, and MD 
simulation structures are shown in the Table 20 of the Appendix. 
 
6.3.3. Updated R3m Model 
 As discussed in the previous sections, the original dispersability model was built using 
individual R3m values for each API based on a single predicted 3D conformation generated by the 
CORINA algorithm. However, the conformation of an API in the amorphous form will likely have 
a wider distribution of possible conformations relative to the crystalline form due to the increased 
entropy, volume, and free energy, and therefore, a distribution of possible R3m values. Wide 
distributions of R3m may significantly impact the model decision boundary, and subsequently, 
future predictions. Therefore, since a large number of potential conformations have been extracted 
from MD simulations, and their respective R3m values were calculated, these data were modeled 
against experimental observations using logistic regression. The resulting logistic regression 
model is shown in Figure 45.  
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Figure 45: Logistic regression model using the expanded MD dataset. This model contains 12,600 
data points for R3m (jittered to more clearly show the amount of data). Red circles correspond to 
API which failed to form an ASD in PVPva by melt-quenching, while green circles correspond to 
API which were observed to successfully form an ASD in PVPva by melt-quenching. The blue 
line shows the logistic curve. This expanded model resulted in an updated boundary value of 0.632. 
The equation for the regression line and the standard errors of the coefficients are given.  
 
The value of R3m at the model boundary was of particular interest, since this boundary will be 
applied for future predictions of ASD formation in PVPva. The updated model resulted in a shift 
in the R3m decision boundary from approximately 0.65 to 0.632. This change is illustrated by the 
horizontal dotted and dot-dash lines in Figure 43, respectively, and the updated model is shown in 
Figure 45. When this updated boundary is compared to the individual R3m values determined from 
CORINA 3D conformation prediction of SMILES files, the predictions regarding dispersability in 
PVPva remain unchanged relative to the original model. This is because the updated boundary still 
falls within the gap on the R3m axis where complete separation of the data occurred. All API 
having R3m values below 0.6 failed to form ASDs, while those having R3m above 0.68 
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successfully formed ASDs in PVPva. This complete separation results in large standard errors for 
the coefficients in logistic regression,121 and ultimately, it was unnecessary and inappropriate to 
apply logistic regression to the completely separated data.202 Instead, this boundary (R3m=0.65) 
was defined as the mid-point between the values at the edge of each phenomenological category.  
 It is important to note that the conformational flexibility of the molecules at the decision 
boundary resulted in some of the calculated R3m distributions having values at their extremities 
that crossed the updated threshold value. For example, cimetidine, nifedipine, and quinidine have 
a few simulated conformations whose R3m was greater than 0.632. Additionally, tolbutamide and 
indomethacin have some simulated conformations whose R3m fell below 0.632. Molecules that 
have R3m values that cross the updated boundary may help to explain some of the 
misclassifications observed in the solvent evaporation data described in Chapter 4. For example, 
at 15% w/w drug loading, nifedipine was found to successfully disperse in PVPva despite an 
R3m<0.65, while tolbutamide, at 75% drug loading regularly failed to disperse in PVPva when 
co-solidified mixtures were prepared by solvent evaporation, despite an R3m>0.65. These 
misclassifications by the model, combined with the distribution of R3m values that cross the 
decision boundary, warrant further future investigation regarding the API conformation in the 
presence of solvent. If these API have sufficiently different preferred 3D conformations in the 
presence of methanol, this could help to explain deviations from the R3m model, and ultimately 
improve the model performance. 
 In the original R3m model there was uncertainty for future predictions at the decision 
boundary because of the gap between R3m values near the boundary (0.595 for sulfanilamide and 
0.687 for tolbutamide). This gap led to the selection of a boundary value of 0.65 (their mean), but 
predictions for new API having values between 0.595 and 0.687 would not be supported by data 
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in the model. Inclusion of the R3m data from conformational information has resulted in a better-
defined decision boundary and permits the application of logistic regression. Although the updated 
boundary (R3m=0.632) is based on a larger dataset of 3D conformations, the categorization of 
dispersion behavior for each API using the original model remains unchanged. The similarity 
between the models further supports the conclusion that the R3m descriptor is able to capture 
relevant 3D information about the API. Incorporation of these additional data into the model has 
resulted in improved confidence in the model boundary by ensuring that the model incorporates 
conformational flexibility. As a result, future predictions will likely improve, particularly for API 
with R3m values near the model boundary.   
 
6.4. Conclusions 
 The 3D conformation of an API molecule has an impact on its R3m value, especially if 
shape changes influence matrices used to calculate this molecular descriptor. Comparisons 
between 3D conformations obtained using the CORINA algorithm, crystal structure data, and MD 
simulations showed that the resulting variations in R3m was generally low for each API. A large 
majority (86%) of an expanded dataset of API had a difference in R3m≤0.1, with a maximum 
difference in R3m equal to 0.28. The average absolute difference between CORINA and both the 
mean and median MD R3m values was 0.03, and the largest difference between median MD R3m 
and CORINA R3m values was 0.11. Ultimately, these results support the hypothesis that predicted 
3D conformation originally used to calculate R3m is sufficiently representative of the geometry of 
an API in its amorphous conformation as it forms an ASD in PVPva. However, the potential for 
large conformational changes to impact the R3m value should not be ignored, since these large 
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variations, although less common, can have significant impact on predictions of ASD formation, 
particularly if the calculated R3m value lies near the model boundary.  
 Ultimately, this study further supports the idea that R3m captures relevant 3D conformation 
information about the API. The incorporation of additional conformational variability into the 
model has improved confidence in the model boundary. Inclusion of conformational flexibility 
will capture a more realistic distribution of R3m values, and subsequently, will improve future 
predictions.  
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Chapter 7. Investigating the Relationship Between 
R3m & Solubility of API in PVPva 
7.1. Introduction 
The previous chapters have shown that R3m continues to be useful for the prediction of 
ASD formation for the polymer PVPva, and provides additional details regarding the 
physicochemical interpretation of R3m. However, while R3m has been shown to be useful for an 
extant API library, the extent to which R3m captures thermodynamic and/or kinetic factors 
remains unclear. The purpose of the research described in this chapter is to investigate whether the 
molecular descriptor R3m is specifically related to thermodynamic factors that are known to be 
important to ASD formation. Specifically, the solubility of an API in a polymer carrier is expected 
to be an important factor for dispersability. If an API is soluble in the polymer at a concentration 
and temperature of interest, the resulting mixture will be thermodynamically stable, and will not 
phase separate or crystallize. In this case, the successful formation of an ASD is not 
thermodynamically inhibited. However, as the concentration of an API increases beyond the 
saturation solubility, the system will be thermodynamically driven to crystallize, and the likelihood 
of successfully forming an ASD will decrease. Therefore, the solubility is important for ASD 
formation because it gives a measure of the thermodynamic driving force for phase separation and 
recrystallization.  Figure 46 (reproduced from Figure 1 in section 1.2.2.3 for convenience) shows 
a phase diagram for API-polymer mixing. Of particular interest in the present chapter is the 
boundary representing crystalline API-polymer solubility, which describes thermodynamically 
stable mixtures. Progressing in the positive y-direction from this solubility curve results in 
increasing levels of supersaturation, and therefore, increasing the thermodynamic drive to phase 
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separate and crystallize. The solubility of crystalline API in polymer is expected to be a useful 
measure of the relative thermodynamic driving force for phase separation and recrystallization, 
and therefore, give an indication of the likelihood of successful ASD formation. This important 
boundary in the phase diagram can be experimentally estimated, and this chapter will focus on the 
determination of the crystalline API-polymer solubility.  
 
 
Figure 46: Theoretical figure illustrating both drug-polymer solubility and miscibility. (Adapted 
from the Journal of Pharmaceutical Sciences, Vol 99(7), F. Qian, J. Huang, M. A. Hussain., Drug–
Polymer Solubility and Miscibility: Stability Consideration and Practical Challenges in 
Amorphous Solid Dispersion Development, Pages No. 2941-2947, Copyright 2010, with 
permission from Elsevier).4 Zones I and II indicate thermodynamically stable mixtures, Zones III 
and IV indicate meta-stable zones, and Zones V and VI are unstable zones where recrystallization 
is certain within a timeframe dictated by the molecular mobility of mixtures. Of particular interest 
to this chapter is the red solid line representing crystalline API-polymer solubility. Reproduced 
from Figure 1 for convenience. 
 
It is important to note that determination of API solubility in a polymer is non-trivial. 
Methods for measuring both miscibility and solubility of API in polymers have been reported in 
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the literature.  For the purposes of this chapter, both were reviewed and reported here for 
completeness (Table 10). Currently, there is no generally accepted method for such measurements. 
Since it is not possible to measure solid-solid solubility, the solubility of API in polymer is usually 
determined by extrapolation from data obtained when the polymer is in a liquid-like state, or by 
performing measurements using polymer liquid analogues. Each of these methods is, therefore, 
subject to its own assumptions, whose validity, especially for the temperature range of interest 
must be considered before selecting a method. A number of these methods and their associated 
experimental assumptions are described in Table 10. Since the focus of the chapter is on solubility, 
those methods appropriate for measuring solubility were considered, and the dissolution end-point 
method203 was selected.
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Table 10: Comparison of methods for the determination of API solubility in polymer. 
Method Description Assumptions 
Method 
Ref. 
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The API and polymer are sieved to ensure a small particle size, then 
geometrically mixed at the appropriate weight %. The mixture is 
analyzed by differential scanning calorimetry (DSC) at a slow ramp 
rate to identify the melting point depression. This value can be related 
to the interaction parameter (χ) via the application of the Flory-
Huggins theory and, thereby, related to miscibility.  
• Small, controlled particle size (e.g. Marsac et al30 used 45-75 
μm).  
• Molecular mixing occurs during the timescale of the DSC 
experiment. 
• 100% Crystalline API.92  
• Application of Flory-Huggins lattice theory is acceptable. 
o A single lattice is suitable to characterize both solvent and 
solute.84 
o The solution configuration is random.84 
• Extrapolation of Flory-Huggins theory is reliable. 
• API is thermally stable over the temperature range of the DSC 
experiment. 
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t API and polymer are weighed in the appropriate weight fractions and 
cryomilled to reduce particle size and, thereby, increase close contact 
between particles. The resulting solid is analyzed by DSC at a slow 
ramp rate to identify the dissolution endpoint (a.k.a. melting point 
depression). The process is repeated at multiple concentrations to 
create a plot of the log solubility vs. 1/T. The data can be extrapolated 
to lower temperatures using the Van’t Hoff equation (solubility) or by 
applying Flory-Huggins theory (miscibility).  
• Comminution of particles increases potential for inter-
particulate close contact. 
• Molecular mixing occurs during the timescale of the DSC 
experiment. 
• API not fully amorphous, since this would result in no 
detectable dissolution. 
• API is thermally stable. 
• Selected extrapolation method can be reliably applied to the 
temperature of interest. 
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API and polymer are cryomilled to reduce particle size and achieve 
close contact. The resulting solid is then analyzed by DSC, where the 
sample is annealed at a specific temperature for 4-10 h. During 
annealing, the sample is expected to reach equilibrium. The sample is 
then heated through Tm to determine if any crystals remain. Remaining 
crystals would indicate that the annealing temperature was too low to 
achieve complete dissolution. The process is repeated to isolate the 
appropriate temperature that corresponds with the solubility at the 
selected concentration. The process is repeated for multiple 
concentrations. The resulting data can be fit to the Flory-Huggins 
model to obtain χ to estimate miscibility. 
• API does not degrade during annealing (4-10 h) 
• Annealing time is sufficient to allow the sample to reach 
equilibrium. 
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Table 10 (continued) 
Method Description Assumptions Method 
Ref. 
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API and polymer are co-milled to generate a supersaturated system. A 
subsample of the resulting mixture is annealed in the DSC above Tg 
to allow de-mixing to the equilibrium solubility. The resulting mixture 
is then cooled and scanned to identify the Tg corresponding to the 
solubility at the annealed temperature. The Gordon-Taylor equation is 
then used to determine the equilibrium solubility from the 
experimentally determined Tg. Finally, the data can be extrapolate to 
other temperatures using Flory-Huggins theory to estimate 
miscibility. 
• API recrystallization is faster than dissolution. 
• Supersaturated systems can be obtained by co-milling 
• Phase separation is complete during annealing. 
• No deviations from the Gordon-Taylor relationship 
• API does not degrade during annealing (≥2 h). 
• No significant changes to the sample occur post-annealing 
(i.e., during cooling and heating to determine the Tg). M
ah
ie
u
 e
t 
a
l.
9
3
 
L
iq
u
id
 P
o
ly
m
er
 a
n
a
lo
g
u
e
 
Excess crystalline API is added to a temperature-controlled vessel 
containing the liquid polymer analogue. The mixture is stirred for 
sufficient time to ensure equilibrium has been reached (e.g., >24 h). 
The resulting liquid is then decanted, centrifuged, and filtered to 
remove solid particles. The solubility of the API in the liquid polymer 
analogue is then determined by UV or HPLC. The activity coefficient 
can then be determined using the experimentally obtained solubility 
and the free energy difference between the amorphous and crystalline 
forms of the API.  The activity coefficient can then be compared to 
the Flory-Huggins interaction parameter using the appropriate 
equation (see Marsac et al85), and used to estimate miscibility.  
• The polymer of interest has a low molecular weight liquid 
analogue available.  
• The mixture is permitted to reach equilibrium before analysis. 
• Measured thermodynamics of the API indicates compatibility 
with the polymerized version of the polymer. 
• API mixes with the polymer analogue with ideal entropy of 
mixing. 
• Interactions between the polymer liquid analogue and API are 
identical to polymer-API interactions. 
• The determined activity coefficient of the API at the solubility 
limit of the analogue is the same at the solubility limit of the 
API in polymer.  
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 Polymer solutions of known concentrations are prepared by dissolving 
the polymer in an inert solvent. An excess of crystalline API is then 
added to the solution and mixed for 1 week to ensure equilibrium is 
reached. The samples were then filtered and analyzed by HPLC. The 
polymer concentration is varied and the method is repeated to generate 
a linear fit of API solubility vs. polymer concentration, where the y-
intercept is the solubility of the drug in the solvent with no polymer. 
The slope of the resulting line is used to estimate the API-polymer 
solubility in the solid state.  
• The solvent is inert. Specifically, the interactions between API 
and polymer in the dissolved state are similar to the 
interactions in their solid state. Also, the solvent should not 
impact the structure of the API and polymer. 
o If the solvent is not inert, the resulting curve is expected 
to be non-linear. 
• The API is stable in solution. 
• The polymer is sufficiently soluble in the selected solvent. 
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Table 10 (continued) 
Method Description Assumptions Method 
Ref. 
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Mixtures of polymer and API of a known concentration are annealed 
at different temperatures to allow dissolution of API into the polymer. 
The API concentration should be high enough to ensure API crystals 
remain post annealing. The resulting mixture is then analyzed by DSC 
to obtain the melting enthalpy of the remaining crystalline phase. The 
process is repeated at multiple concentrations to generate a plot of 
enthalpy of melting vs. dissolved mass fraction. The data are linearly 
extrapolated to zero enthalpy to determine the solubility at that 
temperature. The process is repeated for multiple annealing 
temperatures to determine the solubilities at the respective 
temperatures. 
• Assumes the presence of one polymorph, since the presence of 
multiple polymorphs would impact the resulting enthalpy. 
• API does not degrade during annealing (10 h) 
• Annealing time is sufficient to allow the sample to reach 
equilibrium 
o Rate of mixing may significantly decrease with increase 
in polymer concentration  
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For this work, the dissolution endpoint (Tend) method described by Tao et al
203 was selected 
for the determination of API solubility in PVPva, primarily because quantitative data could be 
obtained relatively fast, while also avoiding long annealing times at high temperatures which could 
result in chemical degradation of API and/or polymer. For example, the annealing method requires 
holding drug-polymer mixtures at elevated temperatures for 10 h or longer. Thermogravimetric 
analyses of library API have shown weight loss in some cases during 30 min isothermal holds 
above their respective Tm (e.g., chlorpropamide). Although these weight losses were minor (<2%), 
extended annealing times are expected to result in more significant degradation. Additionally, API 
degradation can also result in melting point depression due to the subsequent presence of 
impurities and/or the reduction in the weight fraction of the compound of interest. This would 
further complicate results, particularly for the thermal methods described in Table 10.  
Ultimately, methods requiring stability of the API at elevated temperatures for extended 
durations were excluded because it was unlikely that they could be applied for all of the drugs in 
the existing library and, therefore, would complicate direct comparisons between API. In addition, 
the application of cryomilling for the dissolution endpoint method will result in reduced particle 
size, increased particle-particle contact, and subsequent reduction in the extent of diffusion 
necessary to accomplish API-polymer mixing. This is expected to reduce the effect of mixing 
kinetics on experimental data. Initial screening studies for this method showed good repeatability 
(i.e., low variability between replicates of differential scanning calorimetry (DSC) measurements) 
and reproducibility (i.e., low variability between cryomilled batches).   
For the Tend method, mixtures of API and polymer were evaluated using DSC to identify 
temperatures ranging between Tg and Tm corresponding to the solubility of API in PVPva. By 
varying the concentrations of the binary mixtures, the relationship between temperature and 
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solubility was estimated. The reduction in the Tm for an API in these mixtures is a result of the 
reduced chemical potential due to the presence of the polymer, which causes a significant decrease 
in the entropy of the mixture relative to the pure API.30  If cohesive interactions between the API 
and polymer are more numerous and/or stronger than their individual adhesive interactions, the 
change in enthalpy will also contribute to a decrease in the chemical potential.30  Therefore, the 
Tend can be used to experimentally determine the solubility of the API in polymer.  
 
7.2. Materials & Methods 
Five API were selected from the extant library, which spanned the range of R3m values. 
These included cimetidine (R3m = 0.403), nifedipine (R3m = 0.568), indomethacin (R3m = 
0.737), ketoconazole (R3m = 0.814), and chlorpropamide (R3m = 0.927). Ketoconazole (65277-
42-1) was purchased from Spectrum Chemicals (Gardena, CA). Chlorpropamide (94-20-2) was 
purchased from MP Biomedicals (Solon, OH). Indomethacin (53-86-1) was purchased from 
Sigma-Aldrich (St. Louis, MO). Cimetidine (51481-61-9) and nifedipine (21829-25-4) were 
purchased from TCI Chemicals (Tokyo, Japan). PVPva was obtained from BASF (25086-89-9, 
Kollidon VA 64 Fine). 
 
7.2.1. Cryomilling 
API and PVPva were weighed and transferred directly into polycarbonate cryomilling 
tubes containing a steel rod. The target total weight ranged from 0.75-1.00 g to permit efficient 
grinding and sufficient sample size for analysis. Closed tubes were placed into a SPEX SamplePrep 
6770 cryogenic impact mill, and the milling chamber was pre-cooled with liquid N2 for a minimum 
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of 2 min. Milling occurred at a frequency of 10 Hz in cycles consisting of 2 min of active milling 
followed by 2 min of cool-down. Reported milling durations refer to the total active milling time, 
exclusive of cooling periods. The milling chamber was periodically replenished with liquid N2 to 
ensure complete tube immersion and rapid removal of heat generated during milling.  
The total milling time ranged from 4 to 30 min, and at least 3 different cryomilling 
durations were performed for each sample.  Samples were determined to have been sufficiently 
cryomilled when no significant changes (ΔTend ≲ 0.5 °C) were observed in the measurement of 
end-point dissolution. Immediately after milling, the sample tubes were transferred to a desiccator 
containing P2O5 and allowed to equilibrate to room temperature before opening to minimize water 
vapor condensation. Once at ambient temperature, powders were transferred to scintillation vials 
and stored in the desiccator until needed for thermal analysis.  
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Figure 47: Experimental setup for dissolution end-point experiments. Cryomilling was performed 
for multiple durations and an optimal duration was identified using both PXRD and DSC. PXRD 
was used to qualitatively confirm that crystals remain. DSC was used to measure Tend. The optimal 
cryomilling duration was identified by comparison of changes in Tend (ΔTend  ≲ 0.5 °C). The 
optimal milling duration was then replicated to obtain n = 5-9 measurements of Tend. 
 
7.2.2. Differential Scanning Calorimetry (DSC) 
A model Q100 DSC (TA instruments, New Castle, DE) was used for these experiments. 
The instrument was calibrated using o-terphenyl, In, and Sn (three-point temperature calibration) 
and In was used for the enthalpy calibration.  N2 was used as the purge gas during all experiments, 
at a constant purge rate of 50 mL/min. Milled samples were weighed (3-7 mg) into Al hermetic 
pans with pin-holed lids, which were subsequently crimped. Samples were subjected to a 1 °C/min 
heating ramp through the melting point of the API. It is important to note that the dissolution 
endpoint (Tend) method, as described by Tao et al.,
203 involved determining Tend at a number of 
DSC ramp rates and extrapolating to zero-heating rate. However, since the ultimate goal of this 
work was to obtain a rank-order of solubility for comparison with R3m values for library API, a 
ramp rate of 1 °C/min was selected to balance sufficient in situ mixing with experiment duration. 
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Additionally, the validity of the extrapolation to zero-heating rate has not been confirmed,92 while 
a heating rate of 1 °C/min was previously applied by Marsac et al.85 for the determination of 
melting point depression using DSC.  
Samples from each cryomilling experiment were analyzed for Tend in duplicate, at a 
minimum. Once the cryomilling duration was selected for an API, then samples for Tend 
experiments were replicated and analyzed in triplicate (n=5-9). The Tend value for mixtures was 
determined as the intersection of a tangent line drawn from the baseline after the drug had 
completed dissolution in the polymer, and a tangent line drawn from before the inflection point of 
the endotherm as it approached the baseline, where peak inflection was identified using the first 
derivative of heat flow with respect to temperature.  
 
 
7.2.3. Powder X-ray Diffraction (PXRD) 
Cryomilled powders were back-filled into stainless steel sample holders having a sample 
well depth of 2.4 mm and diameter of 16 mm. Diffraction data were collected using an X’Pert Pro 
MPD system (PANalytical B.V., Almelo, Netherlands) in Bragg-Brentano geometry, equipped 
with a Cu anode (λ = 1.5406° Å), 10 mm beam mask, 0.04 soller slits, 2° divergence slit, Ni Kβ 
filter, and X’Celerator™ detector. The operating voltage and amperage were set to 45 kV and 40 
mA, respectively. Samples were rotated at 7.5 rpm during data collection to minimize effects of 
preferred orientation. Irradiation time was set to 76.24 s per step with an angular step size of 0.017° 
2θ over a range of 4.5 to 60° 2θ. PXRD data were used to qualitatively verify the presence of 
crystallinity in the sample. This was done to ensure that milling did not reduce sample crystallinity 
to the extent that a melting endotherm was either undetectable or too small to reliably identify Tend 
in subsequent DSC experiments, which would prevent determination of the dissolution endpoint. 
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Correspondingly, cryomilling was controlled to facilitate simultaneous mixing and particle size 
reduction of the API and polymer, while maintaining crystallinity at least detectable by PXRD 
(<10% crystallinity206). Additionally, PXRD data were used to monitor induction of solid-state 
conversions to different crystalline polymorphs, which was observed for chlorpropamide, where 
milling induced a partial conversion from the alpha (low-temperature stable) to epsilon (high-
temperature stable) enantiotrope. In the case of chlorpropamide, the percent solubility reported 
corresponds to the high-temperature epsilon polymorph, since conversion to the high-temperature 
form occurs over the low ramp rate applied in DSC. 
 
7.3. Results & Discussion 
7.3.1.  Solubility Parameter 
The initial indication that a relationship between solubility and R3m may exist was inferred 
from an observed relationship between R3m and the Hansen partial solubility parameters. Data for 
these parameters were collected from the literature for 10 of the 15 library API87 and PVPva, the 
values for which are shown in Table 11 .  
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Table 11: Solubility parameter data for select library API. 
 
Plots of the Hansen partial solubility parameters are shown in Figure 48a, b, and c. In Figure 48c, 
the API that successfully dispersed are closest to the PVPva value for the Hansen partial solubility 
parameter for hydrogen bonding (δh), as indicated by the green shaded area. All compounds with 
R3m <0.65 failed to disperse in PVPva.  This corresponded with the same compounds having a 
difference in δh relative to PVPva greater than approximately 1 (J/cm3)1/2. Those API outside this 
box, and therefore, having a greater difference in δh, failed to form an ASD in PVPva by melt 
quenching.  
 
Compound δd δp δh δt δv Δδ R3m 
Experimental 
Observation 
(melt-quench) 
Cimetidine 19.38 10.87 10.77 24.69 22.22 1.14 0.403 0 
Nifedipine 19.6 5.84 8.59 22.19 20.45 5.43 0.568 0 
Propranolol 19.52 3.35 11.04 22.72 19.81 7.92 0.342 0 
Quinidine 20.72 5.37 11.97 24.52 21.40 6.40 0.593 0 
Sulfanilamide 20.87 9.61 14.19 27 22.98 5.05 0.595 0 
Chlorpropamide 20.7 8.04 9.78 24.31 22.21 3.44 0.927 1 
Indomethacin 22.19 5.97 9.42 24.84 22.98 5.97 0.737 1 
Itraconazole 21.66 10.94 10.64 26.5 24.27 2.62 0.872 1 
Ketoconazole 21.55 9.63 10.2 25.72 23.60 2.82 0.814 1 
Tolbutamide 19.53 6.97 9.13 22.61 20.74 4.23 0.687 1 
PVPva 19.23 11.15 9.67 24.37 22.23 N/A N/A N/A 
All API Hansen partial solubility parameters were obtained from Thakral et al.87  
PVPva Hansen partial solubility parameters were obtained from Kitak et al.207 
0 = Failed to Disperse, 1 = Successfully Dispersed 
δd, δv,  δh: Hansen partial solubility parameters (dispersion, polar, hydrogen-bond, respectively),  
δv = volume dependent solubility parameter, δt = Hildebrand total solubility parameter  
Solubility Parameter units: (J/cm3)1/2 
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Figure 48: The relationship between the Hansen Partial Solubility Parameters and R3m. (a) The 
dispersion Hansen partial solubility parameter, (b) the polar Hansen partial solubility parameter, 
(c) the hydrogen-bond Hansen partial solubility parameter, and (d) the 3-D solubility parameter, 
where the Euclidean distance between PVPva and the selected drugs is determined (0 is PVPva). 
 
Additionally, there appeared to be a potential inverse correlation between R3m and the 3D 
solubility parameter (Δδ), as seen in Figure 48d. The 3D solubility parameter is the Euclidean 
distance between all three partial solubility parameters and the values for PVPva (Equation (25)).  
 
 (25)         Δδ =  √((δdAPI − δdpolymer)
2
+ (δpAPI − δppolymer)
2
+ (δhAPI − δhpolymer)
2
)       
 
While the observed potential relationship between the Hansen partial hydrogen bonding 
solubility parameter and R3m was promising, it is important to note that the application of 
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solubility parameters for the prediction of solubility and miscibility has several limitations (see 
Chapter 2, section 2.2.3. ). To further investigate the potential relationship between R3m and 
solubility, the dissolution end point method was applied for a select number of API which spanned 
the range of R3m.  
 
7.3.2. Dissolution End-Point (Tend) Method 
The ultimate goal of this research was to relate the solubility of API in PVPva to temperatures 
of interest in order to assess the relationship between solubility and the molecular descriptor R3m. 
It was hypothesized that if a correlation was found between the descriptor and experimentally 
determined solubility of API in PVPva, this could indicate that R3m captures useful 
thermodynamic information. This could help to explain why R3m appears to be particularly useful 
for predicting ASD formation with this specific polymer.   
Representative experimental results for the determination of the optimal milling duration and 
the dissolution end-point is shown in Figure 49 and Figure 50 . The temperature at which the 
extrapolated solubility curve intersects with the Tg of the API-polymer mixture was of interest. 
This temperature is expected to be useful since it is the temperature corresponding to the 
equilibrium solubility at which thermodynamic forces are theoretically overcome by kinetics 
owing to the significant change in molecular mobility. The solubility of the API in polymer at 
room temperature is also of interest because this is the temperature at which the co-solidified 
mixtures were stored and characterized. However, extrapolation to room temperature is tenuous 
due to the significant change in mobility that is expected for all of the drugs examined as part of 
our library. At Tg, the mobility is expected to change significantly, which will subsequently shift 
the factors important to ASD formation from thermodynamics to kinetics. Specifically, below Tg, 
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thermodynamics will no longer be as important due to the reduced mobility of the system. Even if 
the solidified mixture is thermodynamically driven to phase separate at these lower temperatures, 
the reduced mobility will significantly extend the timescale of phase separation. This significant 
increase in the impact of kinetics below Tg is expected to result in increased uncertainty in 
solubility predictions as the extrapolation continues significantly below the glass transition 
temperature.  
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Figure 49: Example data collected during optimization of cryomilling duration. Ketoconazole: PVPva 50:50% w/w. (a) PXRD data, (b) 
DSC data, (c) a bar plot of replicate Tend measurements at different milling durations. No significant changes in the experimentally 
determined dissolution end point are observed after 16 minutes of cryomilling. 
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Figure 50: Example data collected during optimization of cryomilling duration. Indomethacin: PVPva 50:50% w/w. (a) PXRD data, (b) 
DSC data, (c) a bar plot of replicate Tend measurements at different milling durations. The optimal milling duration was identified as 12 
minutes in this case. After 12 minutes, the endotherm became more difficult to analyze, and at 24 minutes of milling the endotherm was 
essentially absent, and therefore Tend could not be determined. 
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A limitation of the dissolution end-point method is the increased kinetic inhibition to 
mixing as the temperature of interest approaches the Tg of the polymer. It is assumed that mixing 
will occur on the timescale of the experiment, however, polymer viscosity will limit mixing near 
its Tg. As a result, the range of temperatures over which Tend data can be collected is limited by the 
viscosity of the polymer. In order to determine the solubility at the temperatures of interest, it is, 
therefore, necessary to extrapolate the data. In this study, the extrapolation was performed using a 
linear fit of the natural log of the mole fraction solubility of the API (ln) vs. the inverse of the 
dissolution end-point temperature (i.e., a van’t Hoff plot).  
At its Tm, the API will be in equilibrium between its crystalline and liquid states. The 
presence of an impurity (polymer) will result in a change in entropy and enthalpy impacting the 
chemical potential of the API relative to the pure state. This shifts the API solid-liquid equilibrium 
and subsequently depresses the observed melting point. Experimental observations of melting 
point depression can be used to reveal the specific relationship between API mole fraction and 
temperature (Equation (26)), where a plot of the natural log of mole fraction solubility (X) vs. the 
reciprocal temperature (1/T) is expected to yield a linear relationship.  
 
(26)             ln(X) = −
ΔHmix
RT
+
ΔSmix
R
 
 
A linear fit of this relationship can then be applied to extrapolate to temperatures for which 
experimental data cannot be obtained owing to kinetic factors, which inhibit API-polymer mixing 
(e.g., those approaching the Tg).  
 The experimental results for the 5 API of interest are given in Figure 51, below, where a 
van’t Hoff plot and a linear fit of data is applied. In general, the fit was good (R2 > 0.94 for all API 
modeled). The slope and intercept obtained from linear fits was used to extrapolate the solubility 
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to lower temperatures. Figure 52 shows the application of the van’t Hoff fit, and the subsequent 
extrapolation to lower temperature.  
 
 
Figure 51: Experimental data for the determination of API solubility in PVPva at different 
temperature using the Van’t Hoff equation. API plotted as triangles are those API which failed to 
disperse in PVPva by melt-quenching, while circles indicate API that successfully formed ASDs 
by melt-quenching.  
 
 210 
 
Figure 52: Experimental data for the determination of API solubility in PVPva at different 
temperatures. The dotted lines show the Van’t Hoff extrapolation to lower temperature.  Triangles 
are used for API which had previously been show to fail to form an ASD in PVPva by melt-
quenching, while circles indicate API that had successfully formed an ASD in PVPva. Plots of the 
predicted Tg for each API determined using the Couchman-Karasz equation are shown as solid 
and dot-dash lines. 
 
 The van’t Hoff extrapolation and the predicted Tg values were then used to determine the 
percent solubility at the temperature of interest. This is illustrated in Figure 76 in the appendix. 
Figure 53 shows the percent weight solubility of the specified drug in PVPva as determined by 
extrapolation at the predicted Tg. Drug loadings are indicated as circles for 15% w/w API and 
squares for 75% w/w API preparations. Points above the blue and red lines indicate supersaturation 
at 15% and 75% w/w API drug loading, respectively. The difference in solubility between these 
concentrations is a result of the change in predicted Tg caused by changes in the concentration of 
drug present. For example, the predicted solubility for all preparations at 75% w/w drug loading 
is lower because the Tg of the API, which is the primary ingredient in these mixtures, will plasticize 
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the mixture, resulting in a lower predicted Tg. This results in the solubility curve being extrapolated 
to a greater extent to the identified lower temperature, and, therefore, a lower solubility relative to 
the respective 15:85% w/w API:polymer mixtures. As noted previously, the extrapolated solubility 
at the predicted Tg is of interest because this is the temperature at which the impact of 
thermodynamics is expected to be overcome by kinetic effects as the mixture solidifies.  
 
 
Figure 53: Weight percent solubility at the predicted glass transition temperature for 15% (circles) 
and 75% (squares) drug loading vs. R3m. The horizontal blue and red lines are included to 
reference the drug loading of interest (15 and 75% API). The vertical dashed line shows the 
previously established R3m boundary (R3m = 0.65).  
 
It was posited that, if the R3m value for an API correlated with that drug’s solubility in 
PVPva, then it was expected that API having R3m values below 0.65 (cimetidine and nifedipine) 
would have lower solubility in PVPva relative to the API with R3m > 0.65 (indomethacin, 
ketoconazole, and chlorpropamide). This pattern was observed for 4/5 API investigated, with 
ketoconazole being the exception. Cimetidine and nifedipine both had lower solubilities in PVPva 
at the mixed Tg, relative to indomethacin and chlorpropamide.  Correspondingly, the driving force 
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to recrystallize as they cooled during quenching should be greater for cimetidine and nifedipine, 
which was consistent with the observation that 24 h after preparation these samples had evidence 
of crystallization, and were categorized as not dispersable in PVPva.  In contrast, the indomethacin 
and chlorpropamide both were more soluble in PVPva at the mixed Tg, suggesting that during 
preparation, the driving force for recrystallization should be lower than for cimetidine and 
nifedipine.  Again, this was consistent with the categorization of indomethacin and chlorpropamide 
as dispersable in PVPva, given persistence as an ASD without evidence of recrystallization at the 
time of characterization.   
Taken together, these data might suggest that compounds having R3m<0.65 (not 
dispersable in PVPva) should have poorer solubility in the polymer relative to compounds having 
R3m>0.65. Instead, ketoconazole, stands as an exception, having the lowest solubility in PVPva 
among the 5 compounds studied, and according to the results, was supersaturated at Tg even at the 
lower 15% drug loading. This was unexpected because ketoconazole was observed to successfully 
form an ASD in PVPva by melt-quenching at both 15% and 75% drug loadings, and had an R3m 
= 0.814. Currently, it is hypothesized that the large molecular weight and overall size of 
ketoconazole molecules relative to the other compounds tested may have contributed to a lower 
molecular mobility and diffusivity in the PVPva matrix. Given experimental controls to facilitate 
mixing of molten ketoconazole and PVPva above the melting temperature of the drug, the 
contributions of its relative size and mass likely help to kinetically inhibit crystallization as the 
mixture is cooled. Despite having the poorest solubility in the polymer, these observations are still 
consistent with the categorization of ketoconazole as “dispersable” in PVPva, as all its preparations 
persisted as an ASD, without evidence of recrystallization within 24 h, at the time of initial 
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characterization. This premise is the focus of future research, in which the solubility of other API 
in the library will be investigated to determine if this trend is general.  
Following a comparison of trends in R3m magnitude, dispersability observations, and 
solubility in PVPva, it appears that solubility of drug in polymer alone could not fully explain the 
successful formation of ASDs, and serve as a more physically intuitive surrogate for predictions 
using R3m. This result supports the distinction between dispersability and solubility, where kinetic 
factors such as the contribution of molecular mobility to nucleation in the solid state are also 
expected to contribute to persistence as an ASD, and categorizations as dispersable. The 
ketoconazole exception to the trends with respect to API solubility in PVPva and dispersability 
predictions suggest that, as a complex molecular descriptor, R3m may better encapsulate the 
physicochemical information (potentially both thermodynamic and kinetic) important for ASD 
formation in this specific polymer, which solubility (a strictly thermodynamic quantity) alone is 
unable to capture. Future work will focus on the expansion of the solubility dataset for the API 
library, as well as the determination of miscibility of the library API in PVPva by determination 
of the Flory-Huggins interaction parameter.  
 
7.4. Conclusions 
The results described in this chapter confirm that solubility alone cannot fully explain the 
successful formation of ASDs. This supports the idea that dispersability and solubility are distinct. 
While solubility is a thermodynamic quantity, dispersability is expected to be impacted by both 
thermodynamic and kinetic factors. The relationship between R3m and dispersability in PVPva 
indicate that the complexity of R3m is more useful for the prediction of ASD formation than 
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solubility due to its ability to better capture physicochemical information that is important for ASD 
formation. 
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Chapter 8.  Summary 
 The central hypothesis of this work has been that there exists a combination of materials 
properties that correlates with the probability that an ASD will form in PVPva. Since molecular 
descriptors are mathematical representations of properties of a molecule, it was hypothesized that 
they can be successfully applied to predict the formation of amorphous solid dispersions. The 
research described in the preceding chapters has supported this hypothesis, and points toward the 
application of R3m as a useful tool for formulation development. Successful future development 
of ASDs is dependent on continued research to better understand the applicability of these 
predictive methods, as replacements for the experimental trial-and-error methods of the past. 
Ultimately, methods that can rapidly direct scientists toward formulations having greater 
probability of success will prove beneficial to both pharmaceutical development and human health.  
 R3m was shown to have statistically significant performance for the prediction of 
dispersability of a library of up to 18 API in PVPva, prepared at two different concentrations, using 
two different preparation methods. Dispersability predictions using the R3m model were 100% 
accurate for dispersions prepared by melt-quenching. All API having an R3m > 0.65 were 
dispersable in PVPva, at concentrations of both 15% w/w and 75% w/w, while API having an R3m 
< 0.65 failed to disperse in this polymer. R3m predictions were less accurate for dispersions 
prepared using a solvent-evaporation method, however, the prediction accuracy remained high and 
models showed statistical significance (p-value < 0.05). A fixed R3m boundary of 0.65 resulted in 
an overall prediction accuracy of 87.5%. These data suggest that R3m is useful for the prediction 
of ASD formation, and prompted an investigation into the meaning of R3m in order to improve 
model interpretability, and to advance scientific understanding of the formation of ASDs.  
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 The subsequent investigation into the physicochemical interpretation of R3m concluded 
that the descriptor contains information about the size and shape of an API molecule, the number 
and relative positions of intramolecular atoms in 3D space (with increasing significance for heavier 
atoms), and increasing topological connectivity which indicates increased branching. In general, 
large molecules, having increased topological connectivity (reflective of increased branching), 
molecules having more heavy atoms (higher molecular density), and with heavy atoms furthest 
from the geometric center (on the periphery of the 3D conformation of the molecule) have higher 
R3m values, suggesting these attributes conform to R3m>0.65, which corresponds to API which 
are dispersable in PVPva. This interpretation of the descriptor was further supported by multiple 
linear regression of R3m against simpler, more intuitive descriptors and properties. A moderate 
correlation was observed between MW, molecular density, and R3m. The size and shape of API 
molecules is believed to be important to the kinetics of ASD formation. The relative location of 
heavy atoms is expected to increase the likelihood of non-covalent interactions with the polymer, 
since the atoms heavier than carbon in the API library considered are more electronegative. Heavy 
atoms which are far from the geometric center of the molecule, and close to each other in Euclidean 
space, are more likely to result in a larger R3m value, and also increase the likelihood of an 
increased dipole moment in that molecule. This is expected to increase the likelihood of non-
covalent interactions (i.e., dipole-dipole interactions), and thereby impact thermodynamic 
parameters such as the enthalpy of mixing. The formation of ASDs is a complex phenomenon that 
involves thermodynamics and kinetics. As a result, individual parameters are generally insufficient 
to capture sufficient information for the prediction of ASD formation. In contrast, R3m is more 
useful despite also being a single parameter because it contains more information as a result of its 
derivation from several matrices which contain physically and chemically relevant data. 
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 Ultimately, the argument that R3m captured useful geometric information about the API 
was further supported via comparisons between 3D conformations obtained using the CORINA 
algorithm, crystal structure data, and MD simulations. Results showed that the variations in R3m 
between these conformations was generally low for each API. A large majority (86%) of an 
expanded dataset of API had a difference in R3m≤0.1, with a maximum difference in R3m equal 
to 0.28. The average absolute difference between CORINA and both the mean and median MD 
R3m values was 0.03, and the largest difference between median MD R3m and CORINA R3m 
values was 0.11. Ultimately, these results showed that the predicted 3D conformation originally 
used to calculate R3m is sufficiently representative of the geometry of an API in its amorphous 
conformation as it forms an ASD in PVPva. However, the potential for large conformational 
changes to impact the R3m value should not be ignored, since these large variations, although less 
common, can have significant impact on predictions of ASD formation, particularly if the 
calculated R3m value lies near the model boundary. Ultimately, this study further supported the 
idea that R3m captures relevant 3D information about the API. The incorporation of additional 
conformational variability into the model has improved confidence in the model boundary, and 
inclusion of this variability helped to capture a more realistic distribution of R3m values, and will 
likely improve future predictions.  
 The successful formation of an ASD is dependent on both thermodynamic and kinetic 
factors. Solubility is an important aspect of ASD formation because it gives a measure of the 
thermodynamic driving force for phase separation and recrystallization. Attempts to correlate R3m 
with solubility were unsuccessful, suggesting that solubility alone cannot fully explain the 
successful formation of ASDs. This supports the idea that dispersability and solubility are distinct. 
While solubility is a thermodynamic quantity, dispersability is expected to be impacted by both 
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thermodynamic and kinetic factors. The relationship between R3m and dispersability in PVPva 
indicate that the complexity of R3m may better encapsulate physicochemical information 
important for ASD formation which solubility alone is unable to capture. 
 Ultimately, the application of the R3m model may help to speed formulation development 
for ASDs containing PVPva. This model also points toward the potential application of molecular 
descriptors in similar models for other polymers. This work builds toward a future research goal 
of building a formulation development tool for ASDs. Such a tool (envisioned in Figure 2) could 
be used to rapidly identify an appropriate polymer for a new chemical entity with minimal 
experimentation, and thereby aid ASD development by reducing experimental burden, time to 
market, and development costs.  
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Figure 54: Evidence of Terfenadine polymorphs. DSC method adapted from Leitǎo et al.154 
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Figure 55: Tolbutamide polymorphs. (a) Tolbutamide was received as the Form I polymorph, as 
evident when comparing the experimental PXRD pattern with the reference pattern (CSD-
ZZZPUS02).155, 156 (b) After several months of storage, Tolbutamide appears to recrystallize as the 
Form II polymorph, as shown by comparison of the experimental PXRD pattern to the reference 
pattern (CSD-ZZZPUS15).156, 208 
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Table 12: Results Summary – Melt Quench 75:25% w/w (API: PVPva). The final inferences are 
made based on observations made from the suite of analytical techniques. 
Melt Quench 75:25 %w/w 
API DSC 
PXRD 
Diffraction 
Peaks (API) 
PDF Combined Inference 
 Propranolol HCl Not definitive Yes N/A Failed to Disperse 
 Melatonin Not definitive No Phase Separated Failed to Disperse 
 Cimetidine Not definitive No Phase Separated Failed to Disperse 
 Terfenadine Not definitive Yes (1/3) Phase Separated  Failed to Disperse 
 Cloperastine HCl Not definitive Yes N/A Failed to Disperse 
 Nifedipine Miscible Yes (2/3) Phase Separated Failed to Disperse 
 Sulfanilamide Immiscible Yes N/A Failed to Disperse 
 Quinidine Immiscible No Phase Separated Failed to Disperse 
 Tolbutamide Miscible No Dispersed Dispersed 
 Indomethacin Miscible No Dispersed Dispersed 
 Felodipine Miscible No Dispersed Dispersed 
Itraconazole Miscible No N/A Dispersed 
 Ketoconazole Not definitive No Dispersed Dispersed 
 Chlorpropamide Miscible No Dispersed Dispersed 
 Bicalutamide Not definitive No Dispersed Dispersed 
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability. 
 
 
Table 13:  Results Summary – Melt Quench 15:85% w/w (API: PVPva). The final inferences are 
made based on observations made from the suite of analytical techniques. 
Melt Quench 15:85 %w/w 
API DSC 
HSM  
(birefringence) 
PXRD 
Diffraction 
Y/N (API) 
PDF 
Combined 
Inference 
 Propranolol HCl Partially Miscible ND N N/A Failed to Disperse 
 Cimetidine Partially Miscible Trace N Dispersed Failed to Disperse 
 Melatonin Partially Miscible ND N Phase Separated Failed to Disperse 
 Terfenadine Partially Miscible ND N Dispersed Failed to Disperse 
 Cloperastine HCl Partially Miscible Trace N Dispersed Failed to Disperse 
 Nifedipine Partially Miscible ND N Dispersed Failed to Disperse 
 Quinidine Partially Miscible Trace N N/A Failed to Disperse 
 Sulfanilamide Partially Miscible Trace N N/A Failed to Disperse 
 Tolbutamide Miscible ND N Dispersed Dispersed 
 Indomethacin Miscible ND N Dispersed Dispersed 
 Ketoconazole Miscible ND N Dispersed Dispersed 
 Itraconazole Miscible ND N Dispersed Dispersed 
 Chlorpropamide Miscible ND N Dispersed Dispersed 
 Felodipine Miscible ND N Dispersed Dispersed 
 Bicalutamide Miscible ND N Dispersed Dispersed 
ND: None Detected. 
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability. 
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Table 14: Results Summary – Solvent Evaporation 75:25% w/w (API: PVPva). The final 
inferences are made based on observations made from the suite of analytical techniques. 
Solvent Evaporation 75:25 %w/w 
API DSC 
HSM  
(birefringence) 
PXRD 
Diffraction Y/N 
(API) 
PDF 
Combined 
Inference 
 Propranolol HCl Immiscible Yes Yes N/A Failed to Disperse 
 Cimetidine Partially Misc. None Detected No Dispersed Failed to Disperse 
 Melatonin Partially Misc. Yes (minor)  Yes (2/2, minor) N/A Failed to Disperse 
 ABT-102 Immiscible Yes Yes N/A Failed to Disperse 
 Terfenadine Miscible None Detected No Dispersed Dispersed 
 Cloperastine HCl Immiscible Yes Yes N/A Failed to Disperse 
 Nifedipine Miscible (2/3) Yes Yes N/A Failed to Disperse 
 Quinidine Immiscible Yes Yes N/A Failed to Disperse 
 Sulfanilamide Immiscible Yes Yes N/A Failed to Disperse 
 ABT-072 Partially Misc. Yes (minor)  No N/A Failed to Disperse 
 Tolbutamide Partially Misc. Yes (2/3) No (2/3) N/A Failed to Disperse 
 Indomethacin Miscible None Detected No Dispersed Dispersed 
 Ketoconazole Miscible None Detected No Dispersed Dispersed 
 Chlorpropamide Miscible None Detected No Dispersed Dispersed 
 Felodipine Miscible None Detected No Dispersed Dispersed 
 Bicalutamide Miscible None Detected No Dispersed Dispersed 
ND: None Detected. 
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability. 
Note: Itraconazole and ABT-348 had insufficient solubility in methanol for preparation at this concentration. 
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Table 15: Results Summary – Solvent Evaporation 15:85% w/w (API:PVPva). The final inferences 
are made based on observations made from the suite of analytical techniques. 
Solvent Evaporation 15:85 %w/w 
API DSC 
HSM  
(birefringence) 
PXRD 
Diffraction 
Y/N (API) 
PDF 
Combined 
Inference 
Propranolol HCl Immiscible ND No N/A Failed to Disperse 
Cimetidine Immiscible ND No Dispersed Failed to Disperse 
Melatonin Immiscible ND No Dispersed Failed to Disperse 
ABT-102 Miscible ND No N/A Dispersed 
Terfenadine Miscible ND No Dispersed Dispersed 
Cloperastine HCl Immiscible ND No Dispersed Failed to Disperse 
Nifedipine Miscible ND No Dispersed Dispersed 
Quinidine Immiscible Yes (2/3) Yes (2/3) N/A Failed to Disperse 
Sulfanilamide Immiscible ND No N/A Failed to Disperse 
ABT-072 Miscible ND No N/A Dispersed 
Tolbutamide Miscible ND No Dispersed Dispersed 
ABT-348 † Immiscible Yes Yes (3/3) N/A Failed to Disperse 
Indomethacin Miscible ND No Dispersed Dispersed 
Itraconazole † Immiscible Yes (1/3) No Phase Separated Failed to Disperse 
Ketoconazole Miscible ND No Dispersed Dispersed 
Chlorpropamide Miscible ND No Dispersed Dispersed 
Felodpine Miscible ND No Dispersed Dispersed 
Bicalutamide Miscible ND No Dispersed Dispersed 
ND: None Detected. 
N/A: Not applicable. Amorphous API could not be prepared with sufficient physical stability. 
     † Lowest Solubility in MeOH. 
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Table 16: (a) Solubility rankings were assigned based on the classifications proposed in USP 34. 
(b) Solubility rankings are shown for the library compounds. ABT-348 and Itraconazole had the 
lowest solubility in methanol. 
(a)   
Description Category 
Approx. Volume (ml) of Solvent  
Needed to Dissolve 1g of Solute 
Very Soluble 1 Less than 1 
Freely Soluble 2 1 to 10 
Soluble 3 10 to 30 
Sparingly Soluble 4 30 to 100 
Slightly Soluble 5 100 to 1000 
Very Slightly Soluble 6 1000 to 10,000 
Practically Insoluble 7 Greater than 10,000 
(b) 
API Solubility Group Category 
Terfenadine  Very Soluble 1 
Quinidine  Very Soluble 1 
Indomethacin  Very Soluble 1 
Propranolol HCl  Freely Soluble 2 
Cimetidine  Freely Soluble 2 
Tolbutamide  Freely Soluble 2 
Melatonin  Soluble 3 
Cloperastine HCl  Soluble 3 
Felodipine  Soluble 3 
Ketoconazole  Soluble 3 
Chlorpropamide  Soluble 3 
ABT-102  Sparingly Soluble 4 
Nifedipine  Sparingly Soluble 4 
Sulfanilamide  Sparingly Soluble 4 
ABT-072  Slightly Soluble 5 
Bicalutamide  Slightly Soluble 5 
ABT-348  Very Slightly Soluble 6 
Itraconazole  Very Slightly Soluble 6 
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Table 17: Modeling statistics for solvent evaporation R3m models. The abbreviation LR refers to 
the likelihood ratio. Removing the most poorly soluble compounds (Itraconazole and ABT-348) 
resulted in an increased likelihood ratio, and therefore, lower p-value. However, removal of these 
compounds from the model is inadvisable due to the potential for bias.  
Method Regression Equation LR (χ²) Misclassification Rate 
SE (15:85) logit P(Y) = -3.96 + 6.48(R3m) 4.65* 27.8% (n = 18) 
SE (75:25) logit P(Y) = -12.47 + 18.16(R3m) 12.36‡ 6.3% (n=16) 
SE (15:85) - exclusions logit P(Y) = -10.99 + 19.59(R3m) 10.11† 18.8% (n = 16) 
* p-value < 0.05 
†
 p-value < 0.005 
‡
 p-value < 0.0005 
 
 
 
Table 18: Statistical assessment of solvent evaporation models with solubility rank as an additional 
covariate. The drop in deviance tests indicated that adding solubility rank had no statistically 
significant improvement over R3m alone. 
Method Regression Equation LR 
(χ²) 
Misclassification 
Rate 
Drop in 
Deviance (χ²) 
SE (15:85) logit P(Y) = -3.49 - 0.458(SolubilityRank) + 
8.102(R3m) 
6.2* 22.2% (n = 18) 1.56 
SE (75:25) logit P(Y) = -12.61 - 1.68(SolubilityRank) + 
23.64(R3m) 
15.01† 6.3% (n=16) 2.65 
*p-value < 0.05 
†p-value < 0.001 
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Figure 56: Multiple logistic regression model of 15% w/w API in PVPva with R3m and solubility 
ranking as covariates. (a) A 3-D plot showing the logistic regression surface that results from 
inclusion of solubility ranking as a covariate. (b) Comparison of univariate (R3m only) and 
multivariate (R3m and solubility ranking) model statistics. AUC (ROC) = area under the receiver 
operating characteristic curve. 
 
 
 
Figure 57: Multiple logistic regression model of 75% w/w API in PVPva with R3m and solubility 
ranking as covariates. (a) A 3-D plot showing the logistic regression surface that results from 
inclusion of solubility ranking as a covariate. (b) Comparison of univariate (R3m only) and 
multivariate (R3m and solubility ranking) model statistics. AUC (ROC) = area under the receiver 
operating characteristic curve. 
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Figure 58: Modeling of dichotomous classifications of API dispersability in PVPva for co-
solidified mixtures prepared by (a) melt quenching and (b) solvent evaporation, against the 
molecular descriptor R3m. Separation is observed in the melt quench models; all API having R3m 
> 0.65 were dispersable in PVPva. Logistic regression was used to model solvent evaporation 
behavior. Labels have been added to compounds having: variations between preparation methods, 
outcomes which vary with concentration, and/or relatively low solubility in methanol. See section 
4 (discussion) for additional details.
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Table 19: List of all 176 drugs used for multiple linear regression of molecular descriptors. Library API are indicated in bold. 
ABT-072 ABT-102 ABT-348 aceclofenac acetaminophen acetazolamide acyclovir 
agomelatine albendazole allopurinol alprazolam amitriptyline amoxicillin aripiprazole 
aspirin atorvastin azathioprine azithromycin benidipine bicalutamide bisacodyl 
cabergoline caffeine candesartan cilexetil carbemazepine carvedilol cefdinir cefditoren 
cefixime cefotiam cefpodoxime cefuroxime axetil celecoxib chloroquine chlorpromazine 
chlorpropamide cilostazol cimetidine ciprofloxacin clarithromycin clofazimine clomipramine 
cloperastine clopidogrel clozapine curcumin dapsone dexamethasone diazepam 
diclofenac diloxanide diovan duloxetine ebastine efavirenz epalrestat 
eprosartan erythromycin esomeprazole ethyl icosapentate ezetimibe famotidine felodipine 
fenofibrate flurbiprofen fluvoxamine folic acid furosemide gefitinib glibenclamide 
gliclazide glimepiride glipizide griseofulvin haloperidol hydrochlorothiazide hydroxyzine 
ibuprofen imatinib imipramine indapamide indinavir indomethacin irbesartan 
isotretinoin itraconazole ketoconazole ketoprofen lamotrigine levodopa linezolid 
lisdexamfetamine lopinavir loratadine lorazepam lovastatin manidipine mebendazole 
medroxyprogesterone melatonin meloxicam menatretrenone mesalamine metaxalone methylphenidate 
metoclopramide metronidazole modafinil mosapride mycophenolate mofetil nabumetone nalidixic acid 
naproxen nelfinavir nevirapine nicergoline niclosamide nifedipine nilvadipine 
nimesulide nitrofurantoin olanzapine orlistat oxcarbazepine oxycodone phenacetin 
phenobarbital phenytoin pioglitazone pranlukast praziquantel pregabalin propranolol 
propylthiouracil pyrantel pyrimethamine quetiapine quinidine raloxifene ramelteon 
rebamipide retinol risperidone ritonavir rofecoxib rosuvastatin salbutamol 
salmeterol serotonin simvastatin spironolactone sulfadiazine sulfamethoxazole sulfanilamide 
sulfasalazine sulpiride sultamicillin tacrine tacrolimus tamoxifen telmisartan 
teprenone terfenadine theophylline ticlopidine tocopherol nicotinate tolbutamide tosufloxacin 
triflusal trimethoprim ursodeoxycholic acid valproic acid valsartan verapamil warfarin 
zaltoprofen       
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Figure 59: Bicalutamide. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 60: Chlorpropamide. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 61: Cimetidine. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 62: Cloperastine. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 63: Felodipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices 
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix, 
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution 
to R3m, (h) bar plot of leverages. 
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Figure 64: Indomethacin. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 65: Itraconazole. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 66: Ketoconazole. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 67: Melatonin. (a) 2D structure with atom numbers labeled. Visual representation (matrices 
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix, 
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution 
to R3m, (h) bar plot of leverages. 
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Figure 68: Nifedipine. (a) 2D structure with atom numbers labeled. Visual representation (matrices 
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix, 
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution 
to R3m, (h) bar plot of leverages. 
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Figure 69: Propranolol. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 70: Quinidine. (a) 2D structure with atom numbers labeled. Visual representation (matrices 
and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) topology matrix, 
(d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, (g) contribution 
to R3m, (h) bar plot of leverages. 
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Figure 71: Sulfanilamide. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 72: Terfenadine. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Figure 73: Tolbutamide. (a) 2D structure with atom numbers labeled. Visual representation 
(matrices and bar plots) of data relevant to the calculation of R3m: (b) molecular matrix, (c) 
topology matrix, (d) geometry matrix, (e) influence/distance matrix, (f) bar plot of weighted mass, 
(g) contribution to R3m, (h) bar plot of leverages. 
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Table 20: List of all 80 API used to examine the relationship between R3m calculated by CORINA generated 3D structures and 3D 
structures obtained from the CCDC. CCDC refcodes are given in parentheses.  
acyclovir (MECWIC, MECWIC03) diclofenac (MISBEW) indinavir (DIJWOJ) 
phenobarbital (PHBARB07, 08, 09, 
11, 12, 13) 
acetaminophen (HXACAN12) diloxanide (DEMDIJ) linezolid (TIYQAU01, 02) praziquantel (TELCEU) 
agomelatine (WENOW, 01, 02) efavirenz (AJEYAQ02, 03, 04) lorazepam (BEQGIN) pyrimethamine (MUFMAB01) 
albendazole (BOGFUZ, SUTWIO) epalrestat (ZIPKOA01, 02, 03) lovastatin (CPHAZO01) raloxifene (SAQYIR) 
allopurinol (ALOPUR) eprosartan (SUJXUR) medroxyprogesterone (MACXPR10) rebamipide (ILUPEM) 
alprazolam (MENMIB, MENMIB01) erythromycin (QIFKEX, 01) metaloxone (AXOGAW, 01) risperidone (WASTEP, 01) 
amitriptyline (YOVZEO) ezetimibe (QUWYIR01) metoclopramide (AMBZCL) ritonavir (YIGPIO02, 03) 
aripiprazole (MELFIT, 01, 03, 04, 
06, 07, 08, 09) 
famotidine (FOGVIG06, 07) metronidazole (MINMET02) rofecoxib (CAXMUJ) 
aspirin (ACSALA14,  20) fenofibrate (TADLIU01, 02) mosapride (ZEHSEK) salbutamol (BHHPHE) 
cabergoline (SUPBEK, 01, 03) furosemide (FURSEM13, 14, 16) mycophenolate (WAJYUC) simvastatin (EJEQAL, 01, 02) 
caffeine (NIWFEED03, 04) gefitinib (FARRUM02, 03) nabutemone (XOCUI03, 04) spironolactone (ATPRCL01, 10) 
carvedilol (GIVJUQ, 01, 02) gilbenclamide (DUNXAL01) nalidixic (NALIDX01) sulfadiazine (SULDAZ07) 
celecoxib (DIBBUL) gliclazide (SUVGUL) naproxen (COYRUD13) 
sulfamethoxazole (SLFNMB05, 06, 
07, 08) 
clarithromycin (NAVSUY01, 02) glimepiride  (TOHBUN01, 02) nevirapine (PABHIJ01) sulpiride (PYMSBZ11) 
clofazimine (DAKXUI, 01, 02, 03) glipizide (SAXFED) niclosamide (HEBFUR01) telmisartan (XUYHOO, 01) 
clozapine (FUQMOU01) griseofulvin (GRISFL10, 11) nimesulide (WINWOL, 02) theophylline (BAPLOT05, 06) 
curcumin (BINMEQ08, 09) haloperidol (HALDOL02) nitrofurantoin (LABJON01, 02) trimethoprim (AMXBPM12, 13) 
dapsone (DAPSUO05, 12, 15) hydrochlorothiazide (BANPAK) olanzapine (UNOGIN02, 03, 04) valsartan (KIPLIG) 
dexamethasone (DEXMET11) ibuprofen (IBPRAC19) oxcarbazepine (CANDUR01, 02) verapamil (CURHOM) 
diazepam (DIZPAM11) imipramine (IMIPRC) phenacetin (PYRAZB21) warfarin (BEFZES) 
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Figure 74: The impact of the size of the amorphous cell on the results of molecular dynamics 
calculations. (a) An amorphous cell containing 40 ketoconazole molecules, (b) an amorphous cell 
containing 200 ketoconazole molecules, (c) the resulting distributions of R3m after a molecular 
dynamics simulation. The blue bars are for the 200 molecule simulation, resulting in 1400 R3m 
values, while the orange bars are for the simulations containing 40 molecules (3 replicates for a 
total of 840 R3m values).  
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Figure 75: A comparison of R3m values calculated from 3-D conformations generated from the 
CORINA algorithm, obtained from crystal structure data, and generated by molecular dynamic 
simulations. R3m values calculated using CORINA and CCDC structures fall within the range of 
values determined using molecular dynamics. 
 
 
Table 21: Relevant MATLAB functions 
MATLAB Function Name Purpose Link 
R3mCalculate Calculate the value of R3m from an .sdf file https://www.mathworks.com/matlabcent
ral/fileexchange/69891-r3mcalculate  
GetAtomCoords Extract the 3D molecule conformations from 
Materials Studio .xsd files 
https://www.mathworks.com/matlabcent
ral/fileexchange/70004-getatomcoords  
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Figure 76: A plot of predicted % solubility vs. Temperature. The solid lines correspond to the van’t 
Hoff extrapolation. The dotted lines correspond to the Couchman-Karasz predicted Tg values. The 
gray dotted lines illustrate the determination of the solubility at the temperature of interest. The 
predicted glass transition temperature corresponding to the concentration of the prepared 
dispersion was used to identify the relevant % solubility. These values were then used for the plot 
shown in Figure 53. 
 
 
